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1.1 Prostate Cancer Epidemiology 
Prostate cancer is the second most commonly diagnosed cancer and the 5th cause of cancer 
death worldwide (1). In the US it is the most diagnosed cancer for men, accounting for 26% 
of all cancers diagnosed and 9% of all cancer deaths in men (2). In 2015 in the US, an 
estimated 220,800 men were diagnosed from prostate cancer and about 27,540 men died 
from prostate cancer (2).  
 
The highest incidence rates of prostate cancer are found in Australia/New Zealand, 
Northern America, Western and Northern Europe (3). In particular, Caribbean men, and 
African-Americans are at the highest risk of both prostate cancer detection and mortality (3, 
4).  
 
The incidence in these regions, and in particular the US, increased substantially in the early 
nineties due to the introduction of the Prostate Specific Antigen (PSA) test (Figure 1). On 
the other hand, prostate cancer mortality has experienced a downwards trend, possibly due 
to improvements in treatment and prostate cancer screening (5, Figure 2). 
 
Figure 1: Age-adjusted prostate cancer incidence rates, per 100,000 men, for the US general 
population and African-Americans, in the period 1975-2012. 
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Figure 2: Age-adjusted prostate cancer mortality rates, per 100,000 men, for US general 
population and African-Americans, in the period 1975-2012. 
 
 
 
 
1.2 Prostate Cancer Screening 
PSA is a protein produced in the prostate gland. The PSA-test consists of a simple blood 
test which gives the value of PSA in the blood. The higher the value is, the higher is the 
probability of cancer to be present, though an elevated PSA value could also be due to other 
causes. Usually, a PSA threshold of 3 or 4 is used for a positive screening test.  After an 
elevated PSA, the patient will be referred for a prostate biopsy, and this will determine if 
the patient has cancer, and what is the severity of the disease. (6) 
 
In the US in 2013, about 31% of men older than 50 years of age reported to have had a 
PSA-test in the last year. In practice, screening is performed in an inefficient way. For 
instance, while between 2008 and 2013, there was a significant decrease in the screening 
rate for men older than 75, which are unlikely to benefit from screening, however this rate 
is still higher than for men aged between 50 and 74 (Figure 3 and ref.7). 
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Figure 3: Usage of PSA-based screening in the US. * 
 
 
* Based on (7). Some numbers are extrapolated from the published figure.  
 
1.3 Evidence on the benefits of screening 
 
The two biggest randomized clinical trials on prostate cancer screening were the ERSPC 
(European Randomized study of Screening for Prostate Cancer) (8) and the PLCO 
(Prostate, Lung, Colorectal and Ovarian cancer screening trial) (9). Other trials include the 
Norrkoping, Stockholm and Quebec studies, but a literature review concluded that they 
have a high risk of bias (10). Additionally, there is an ongoing trial on prostate cancer 
screening in the UK, CAP/ProtecT, which was originally designed as a trial for treatment of 
prostate cancer. This trial did not report any results yet about the efficacy of screening (11).  
 
1.3.1 ERSPC trial 
The ERSPC trial included 182,160 men, aged between 50 and 74, starting in 1994, in 
Belgium, Finland, France, Italy, The Netherlands, Spain, Sweden and Switzerland. The 
biggest centres in the study are Finland and the Netherlands. Men in the screening arm 
received PSA testing every 4 years (in Sweden every two years) between ages 50 and 74 
(core age group 55-69), followed by prostate biopsy if the PSA value was 3 ng/ml or higher 
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in most centres. Men in the control arm received usual care. The latest report from the trial 
at 13 years follow-up showed a prostate cancer mortality reduction of 21% (8).  
 
1.3.2 PLCO trial 
 
The PLCO included 76,685 men aged between 55 and 74, in ten centres in the US, enrolled 
between 1993 and 2001. The screening arm applied annual PSA-testing during 6 years and 
digital rectal examination (DRE) for 4 years. It was recommended for men to undergo 
prostate biopsy if PSA ≥ 4 ng/ml. The latest report from the trial at 13 years of follow-up 
showed no mortality reduction due to prostate cancer screening (9). There were several 
reasons for this, namely the high degree of screening in the control arm (about 52%) and 
the low observed biopsy compliance (about 40%). (12, 13)  
 
1.4 The harms of screening 
While the blood draw for the PSA test is harmless, the subsequent prostate biopsy is not 
without harm. Several studies report a small risk of infection, and an increase in the risk of 
hospitalization compared to a control population (14-16). After screen-detection, a major 
concern is overdiagnosis and overtreatment. Overdiagnosis consists of the detection of 
cancer that would not have become clinically detected in absence of screening. If an 
overdiagnosed person is treated then we define the person as overtreated.  
 
Main treatments for prostate cancer include surgery (radical prostatectomy) and radiation 
therapy. Radical prostatectomy results in the removal of the prostate gland. Radiation 
therapy directly kills cancer cells by using high-energy rays (17). Treatment for prostate 
cancer has major secondary effects, which are detrimental for the quality of life of the 
patient. A significant proportion of men treated by radical prostatectomy or radiation 
therapy report incontinence, impotence and bowel problems (18, 19). 
 
Overdiagnosis is difficult to measure in a clinical trial. Ideally, we would need to follow all 
patients from randomization to death, to compute the true estimate of overdiagnosis, 
however we would need to wait decades for this. Estimates of overdiagnosis in prostate 
cancer can vary considerably depending on the method used or even between 
microsimulation models. For instance, three simulation models estimated a range for 
overdiagnosis between 23% and 42% of screen detected men (20). Another study using the 
excess incidence method, suggested that 60% of screen-detected men may be 
overdiagnosed (21).  
 
In practice, these estimates are also difficult to translate from the population level to an 
individual patient. The probability that an individual benefits from screening and treatment 
can vary substantially depending on the individual person’s characteristics. Namely, 
I n t r o d u c t i o n  | 15 
 
 
overdiagnosis is highly age-dependent, with the majority of overdiagnosis cases occurring 
in men older than 60 (22-24). However, even within the same age group there could be 
large differences. For instance, Wever et al (24) estimated that for screen-detected men in 
the age group 65-69, the probability of overdiagnosis ranges from 9% to 50%, depending 
on disease stage at detection. 
 
1.5 Active Surveillance 
Active surveillance (AS) consists of the monitoring of men diagnosed with prostate cancer, 
but not yet treated, with PSA tests or repeat biopsies. The benefit of AS consists in the delay 
or avoidance of radical treatment, with the goal of helping patients to keep their pre-
diagnosis quality of life. What is still unclear is whether the benefits of avoiding treatment 
outweigh the risk that a patient misses his cure by delaying radical treatment. 
 
There are multiple AS cohorts designed to study the safety of this approach: Prostate 
Cancer Research International Active Surveillance (PRIAS) (25), UCSF cohort (26), Johns 
Hopkins (JH) (27) or the Toronto cohort (28) among others (29, 30). However, with the 
exception of the Toronto cohort, their median follow-up times are shorter than 5 years. So 
far, the results seem favorable, with few prostate cancer deaths and metastatic cases 
reported in their latest publications (25-28, 30), but there is a lack of long term results. 
 
Most AS cohorts contain only one AS protocol. Usually, low-risk patients (stage <T2a and 
Gleason Score 6 or lower) are selected (30). While in some cohorts follow-up biopsies 
occur yearly (JH (27)), in others biopsy occurs up to every 3 years after the first year 
(PRIAS (25)). It is not yet clear whether AS is safe for intermediate risk patients. While in 
the UCSF cohort (26) it was found that the 4-year treatment-free survival (TFS) did not 
significantly differ between low and intermediate risk men, intermediate risk patients had 
significantly worse outcomes in the Toronto cohort (28).  There are also differences 
regarding the criteria for referral to treatment. While in most cohorts grade and/or volume 
progression is the main criteria for referral to treatment (30), PSA velocity also plays a role 
in the Toronto cohort (28).  
 
The usage of modelling to evaluate the lifetime outcomes of AS is necessary. Namely, there 
is a lack of long term results, since prostate cancer has a long lead time and its effects may 
be felt only years later and there are multiple ways of performing Active Surveillance, 
namely, different selection criteria or different time intervals between follow-up biopsies.  
 
The current consensus is to offer AS for low-risk men, or at least to mention the option of 
AS to low-risk men (31). The uptake of Active Surveillance has been changing rapidly (32). 
For instance, in the CapSURE cohort, the usage of AS increased from less than 10% in 
2010, to about 40% in 2013 (Figure 4, ref. 32). Across community practices in Michigan 
about half of the low-risk men receive AS (33).  
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Figure 4: Usage of Active Surveillance under low-risk men in the CapSURE cohort.*  
 
 
* Based on (32). Including Watchful Waiting, particularly before 2000. 
 
1.6 MISCAN: A microsimulation model for cancer 
screening 
Here I give a brief description of the MISCAN model. For more technical details the reader 
is invited to read Chapter 12, Model Appendix. MISCAN (Microsimulation Screening 
Analysis) is a microsimulation semi-Markov model, where durations and transition 
probabilities to the next health state are dependent on current state, and where individual 
life histories are simulated.  A man may develop prostate cancer depending on a probability 
of onset. If the person develops prostate cancer, then the time of onset is modelled based on 
a piecewise constant cumulative hazard, which depends on the particular age group. Each 
pre-clinical health state denotes a combination of T-stage, Gleason Score and absence or 
presence of metastasis. In each of these states, a person may become clinically diagnosed or 
screen-detected.  
 
The screening module consists of a single joint sensitivity, which denotes sensitivity for 
PSA detection, biopsy compliance and biopsy sensitivity (See Chapters 3-5, Model 
Appendix). This was modified in Chapter 2, where we model PSA growth explicitly, and 
we separated biopsy sensitivity and biopsy compliance (See Chapters 2, 6-9, Model 
Appendix).  
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After detection, a patient is assigned to either radical prostatectomy (RP), radiation therapy 
(RT) or AS. The post-detection survival consists of three components, an effect of screening 
dependent on disease stage at detection (in Chapters 6-9, this changed to a continuous effect 
of screening depending on lead-time), an effect of treatment based on (34, 35) and a 
baseline survival, based on SEER data from the pre-PSA era.   
 
For the European model, onset, transition probabilities and durations are calibrated to 
ERSPC data. For the US model, we calibrate the joint sensitivity of screening or PSA 
growth and an extra hazard of clinical diagnosis to SEER incidence data and using a 
generator which simulates an opportunistic screening schedule based on (36). Some of the 
PSA growth model parameters are based on literature (37), while others were freed to 
calibrate both to ERSPC’s PSA distribution per age group and SEER incidence. The effect 
of screening is modelled as a cure probability which is calibrated to observed prostate 
cancer mortality reduction in the ERSPC (8).  
 
1.7 Data 
 
We populate the natural history model of MISCAN primarily with ERSPC data described 
above. In chapter 2, it was also used to model PSA growth. In order to adapt the model to a 
US population setting, the model was additionally calibrated to Surveillance, Epidemiology, 
and End Results (SEER) incidence data. SEER registry collects data on incidence and 
survival of multiple cancers throughout the US. It currently covers about 28% of the US 
Population (38).  
 
In the Active Surveillance module of MISCAN, probabilities of referral to treatment given 
progression were calibrated to data from the Johns Hopkins cohort (27). It is a single arm 
observational study, where the main outcomes are overall and prostate specific survival.  
The Johns Hopkins cohort started recruiting men in 1995, and in the latest report it includes 
1298 very low risk (Gleason 6, T1c and lower) and low-risk (Gleason 6, stage T2a or 
lower) men. Main criteria for referral to radical treatment included biopsy reclassification, 
either by volume or gleason progression. We used treatment free-survival as the target 
dataset for the calibration. Additionally, biopsy compliance during AS is based on observed 
biopsy compliance during the PRIAS study (25).  
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1.8  Aims and Research Questions in this thesis  
 
1.8.1 Aim I: Screening 
 
In the first part of this thesis we will use this microsimulation model to project the effects of 
multiple screening policies in the population. A limitation of using clinical trials to inform 
screening policies is that given the multitude of possible strategies to implement screening, 
no trial would have enough power to detect what is the most efficient screening policy. In 
most studies in this aim, we will try to find the set of screening policies that have the best 
balance between harms and benefits, usually by studying the trade-off between prostate 
cancer mortality reduction/life years gained and overdiagnosis or the trade-off between 
costs and QALYs gained.  
 
Research Question 1: “Can we find a set of screening policies that significantly reduce the 
amount of overdiagnosis, while keeping most of the prostate cancer mortality reduction?”  
 
Research Question 2: “Can prostate cancer screening be cost-effective?” 
 
Research Question 3: “What is the influence of comorbid conditions in the harms and 
benefits of cancer screening?” 
 
In the research question 4, we will try to explain disparities in prostate cancer incidence 
between African-Americans and the general US population. 
 
Research Question 4: “Why is the prostate cancer incidence higher in African-Americans 
than in the general US population?”  
 
1.8.2 Aim II: Active Surveillance 
 
While the results of Active Surveillance seem promising, with few cases of prostate cancer 
mortality or metastasis, there is a lack of observed lifetime outcomes. Additionally, given 
the number of possible avenues for selecting and following men during AS, the use of 
modelling to evaluate the outcomes of AS protocols is necessary. 
 
In the second part of this thesis we added a module to MISCAN to simulate several Active 
Surveillance protocols. We validated this module with Johns Hopkins data, and projected 
several combinations of Active Surveillance Protocols and screening policies.  
 
As in Aim 1, our goal is to find the set of policies with the best balance of harms and 
benefits. We will do this from several viewpoints, namely, by estimating the reduction in 
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overtreatment due to AS and extra prostate cancer mortality or at its costs and effects 
compared to immediate treatment.   
 
Research Question 5: “What is the prostate cancer mortality increase and overdiagnosis 
reduction associated with Active Surveillance, in comparison with Immediate Radical 
Treatment?” 
 
Research Question 6: “Do personal characteristics matter when choosing between 
immediate radical treatment and active surveillance in an older age group (65+)?” 
 
Research Question 7: “Is Active Surveillance more cost-effective than Immediate Radical 
Treatment?” 
 
Research Question 8: “When should Active Surveillance for prostate cancer stop if no 
progression is detected?” 
 
1.8.3 Aim III: Parameter Uncertainty in MISCAN  
 
Results obtained with microsimulation models are subject to uncertainty. In this aim, we 
will investigate the effect of parameter uncertainty, that is, uncertainty in the outcomes due 
to uncertainty in parameter estimates, in overdiagnosis estimates. Since this task can be 
computationally intensive, we will perform this while trying to minimize the running time 
of MISCAN needed to obtain a confidence interval for the outcomes.  
 
Research Question 9: “Can we evaluate parameter uncertainty in MISCAN in a more 
efficient manner?” 
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Abstract 
 
While the benefit of prostate specific antigen (PSA) based 
screening is uncertain, a significant proportion of screen-detected 
cases is overdiagnosed. In order to make screening worthwhile, it 
is necessary to find policies that minimize overdiagnosis, without 
significantly increasing prostate cancer mortality (PCM).  
 
Using a microsimulation model (MISCAN) we project the 
outcomes of 83 screening policies in the US population, with 
different start and stop ages, screening frequencies, strategies 
where the PSA value changes the screening frequency, and 
strategies in which the PSA threshold (PSAt) increases with age.  
 
In the base case strategy, yearly screening 50-74 with a PSAt of 3, 
the lifetime risk of PCM and overdiagnosis equals respectively, 
2.4% and 3.8%.  
 
The policies that reduce overdiagnosis the most (for maximum 
PCM  increases relative to basecase of 1%, 3% and 5%, 
respectively) are with a PSAt of 3, (1) yearly screening 50-74 
where, if PSA  <1 at age 65 or older, frequency becomes 4 years, 
with 3.6% (5.9% reduction),  (2) 2-year screening 50-72, with 2.9% 
(24.3% reduction) and (3) yearly screening 50-70 (PSAt of 4 after 
age 66), with 2.2% (43.4% reduction).  
 
Stopping screening at age 70 is a reasonable way to reduce the 
harms and keep the benefit. Decreasing the stopping age has a 
larger effect on overdiagnosis reduction than reducing the screen 
frequency. Screening policies where the frequency of screening 
depends on PSA result or in which the PSAt changes with age did 
not substantially improve the balance of harms and benefits 
relative to simple yearly screening. 
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Introduction 
 
There is not yet a consensus about the magnitude of the net benefit of early 
detection of prostate cancer, since the two largest prostate cancer screening 
randomized controlled trials found conflicting results. In the Prostate, Lung, 
Colorectal and Ovarian (PLCO) screening trial, after 13 years of follow-up, it was 
found that annual PSA screening does not reduce prostate cancer mortality.1 On the 
other hand, the European Randomized Study of Screening for Prostate Cancer 
(ERPSC) trial, after a 11-year follow-up and with mainly a 4-year screening 
interval, found a 20% prostate cancer mortality (PCM) reduction in comparison 
with no screening.2 
 
Current guidelines in the US for prostate cancer screening reflect the lack of 
consensus, on what is the best trade-off between harms and benefits: the U.S. 
Preventive Services Task Force (USPSTF) recommended in 2012, against PSA 
screening, while the American Urological Association (AUA) advised in 2013 that 
men should be screened between the ages 55 and 69. 3  Even within the 
organizations that are favourable to screening, different screening algorithms are 
proposed.4  
 
In general, screening could result in some lives saved, with many overdiagnosed 
cases. Overdiagnosis is the detection of cancer, where in the absence of screening, 
the cancers would have never been detected. There is a small chance of 
complications due to biopsy after an elevated PSA5. However there are significant 
side effects associated with treatment that have a negative effect in the quality of 
life 6. Overdiagnosis estimates can vary considerably depending on the methods and 
populations used 7, with number needed to detect to prevent one prostate cancer 
death between 5 and 48, and proportion of overdiagnosis in screen-detected cases 
varying between 22 and 67% 7-8.   
   
In order to make PSA screening worthwhile, given the uncertainty surrounding the 
magnitude of the benefit of screening, and the estimates suggesting that a 
significant proportion of screen-detected cases is overdiagnosed, there is a clear 
need to find screening policies with a better balance of harms and benefits.  We aim 
to find the combination of start-stop age, screening frequency and prostate-specific 
antigen threshold for biopsy referral (PSAt) that minimizes overdiagnosis for 
several thresholds of limited PCM increase compared to screening yearly with a 
PSAt of 3 between ages 50 and 74. 
 
Previously several studies 6,9 found that stopping screening at an earlier age than 70 
is more cost-effective than screening until age 74.  Others 10-11 found that strategies 
where frequency is determined by PSA result or where a higher PSAt for older are 
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used could have a better balance of harms and benefits. 
 
We add to Gulati et al 11 by evaluating more combinations of frequencies and 
stopping ages, and strategies in which the PSAt increases for older age groups. A 
promising new way of performing prostate cancer screening is to risk stratify men 
based on PSA level at a certain age 12,13. Men with a lower PSA would then be 
screened less frequently. What is still unclear is whether this set of policies is 
effectively better than simple screening algorithms, and therefore we also compare 
the harms and benefits of several ways of doing PSA-based risk stratification.  
 
Few people advocate screening beyond age 75. However, Berghdal et al.14 noticed 
that after 10 years of stopping screening in the ERSPCtrial the incidence of high 
risk cancers in the screening group closely resembles the control (no screen) group. 
Therefore we also quantify the harms and benefits of screening for these older men.   
 
Methods 
 
Simulation Model 
 
Microsimulation Screening Analysis (MISCAN) is a microsimulation model, which 
simulates individual life-histories. A detailed description is available in 
http://cisnet.cancer.gov/prostate/profiles.html . Each health state denotes a different 
disease, detection and treatment phase. There are three detection phases, preclinical, 
clinical and screen detected. We model 18 disease stages, consisting of the 
combination of 3 stages (T1, T2, T3), 3 grades (which correspond to Gleason Score 
2-6, 7 and > 7) and whether or not the cancer is metastasized. In each of these 
disease stages, an individual can progress to a higher disease state, be clinically or 
screen detected, or can die.   
 
The transition probabilities and durations, including the transitions between 
different stages, grades and duration until metastasized cancer are calibrated to 
ERSPC data. The durations between different disease states and between disease 
states and clinical detection are modelled as Weibull distributions with its 
parameters depending on T-stage and Gleason Score 15-16.  Relative to our ERSPC 
model, there is an extra hazard of clinical detection, which implies an earlier time of 
clinical diagnosis in the US 17.   
 
After detection, the person is assigned to either watchful waiting, radical 
prostatectomy (RP) or radiation therapy (RT) with equal chance. A baseline prostate 
cancer survival curve is assigned, based on SEER data (1983-1986) from the pre-
PSA era. The effect of treatment is introduced with a lower hazard ratio for PCM  
(0.62 for RP and 0.70 for RT) based on Etzioni et al 18.  Additionally there is a cure 
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rate based on the mortality reduction observed in the ERSPC trial and dependent on 
whether Gleason Score is lower or equal than 7 (0.42) or higher than 7 (0.23) 19. 
 
A new feature in MISCAN, is the PSA growth generator. It resembles Inoue et al. 20 
, but with some important modifications (Model Appendix, Chapter 11). The PSA 
growth parameters together with biopsy sensitivities are calibrated to SEER  
incidence data from 1990 to 2002 and to the PSA distribution of the first round of 
the ERSPC screening trial, except the correlation between errors in the PSA growth 
equation, which was calibrated to ERSPC data from different screening rounds to 
predict the probability that PSA< 1 about age 60 and PSA > 3 two screening rounds 
later. 
 
The simulated population of ten million is based on the lifetables of Mariotto et 
al.21. US screening patterns are imposed, based on the screening generator of  
Mariotto et al. 21. Additionally we assume 100% biopsy compliance and  90% 
screen attendance in the basecase analyses.  
 
Up to the year 2012, we reproduce the screening patterns in the US population. 
Afterwards a screening policy is implemented. We accept new cohorts of men aged 
50, between 2012 and 2022. Additionally, men opportunistically screened prior to 
2012 and not yet diagnosed are also screened. This allows us to incorporate the 
effect of current screening practices in our projections. 
 
The main outcomes are the lifetime risk of prostate cancer mortality (PCM) and 
overdiagnosis. Here we define overdiagnosis as a person who is screen-detected 
with prostate cancer, but would not be diagnosed in the absence of screening and 
dies from other causes.  
 
Screening Policies 
 
The base case screening strategy is yearly PSA testing between ages 50 and 74 with 
a PSAt of 3. We compute combinations of screening policies with starting ages 50, 
54, 58 and 62, and stop ages 62, 66, 68, 70, 72 and 74. The frequencies used are 
yearly, 2-year and 4-year. In addition, we investigated yearly screening until age 80 
(Table 1). 
 
Vickers et al.12  and Roobol et al.13 suggest that using PSA to do risk stratification 
might help to improve outcomes of standard screening policies. Therefore, for a set 
of yearly screening policies, we compute the effects of changing the screening 
frequency based on the PSA value at a certain age (60, 65 and 70). Additionally, we 
also study whether using a higher PSAt for older age groups, might help to improve 
the harms and benefits trade-off.   
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 Table 1: List of screening policies by age, frequency, PSA threshold and PSA value or 
age dependent condition. 
Policy 
Start/Stop 
Age  Frequencies PSAt* Condition 
Basecase 
    1 50-74 yearly 3 
 Varying Start/Stop Age and Screen Frequencies  
2 50-62 2-,4-year, yearly 3 
 3 50-66 2-,4-year, yearly 3 
 4 50-68 2-year, yearly 3 
 5 50-70 2-,4-year, yearly 3 
 6 50-72 2-year, yearly 3 
 7 50-74 2-,4-year 3  
8 54-62 2-,4-year, yearly 3 
 9 54-66 2-,4-year, yearly 3 
 10 54-68 2-year, yearly 3 
 11 54-70 2-,4-year, yearly 3 
 12 54-72 2-year, yearly 3 
 13 54-74 2-,4-year, yearly 3 
 14 58-66 2-,4-year, yearly 3 
 15 58-68 2-year, yearly 3 
 16 58-70 2-,4-year, yearly 3 
 17 58-72 2-year, yearly 3 
18 58-74 2-,4-year, yearly 3  
19 62-70 2-,4-year, yearly 3  
20 62-74 2-,4-year, yearly 3  
Higher PSAt by age  
21 50-70/72/74 Yearly 4  
22 50-70/72/74 Yearly 3 if  66 ≤ age < 70,  then PSAt = 4, if age ≥ 
70 then PSAt = 5 
23 50-70/72/74 Yearly 4 if  66 ≤ age < 70,  then PSAt = 5, if age ≥ 
70 then PSAt = 7 
Screen Frequency and Stop Age dependent on PSA result  (PSA based risk stratification) 
24 50-74 yearly 3 if age ≥ 60 and PSA < 1 then Stop 
25 50-74 yearly 3 if age ≥ 60 and PSA < 1 then frequency is 
8-year 
26 50-74 yearly 3 if age ≥ 60 and PSA < 1 then frequency is 
4-year 
27 50-74 yearly 3 if age ≥ 60 and PSA < 1 then frequency is 
2-year 
28 50-74 yearly 3 if age ≥ 65 and PSA < 1 then Stop 
29 50-74 yearly 3 if age ≥ 65 and PSA < 1 then frequency is 
4-year 
30 50-74 yearly 3 if age ≥ 65 and PSA < 1 then frequency is 
2-year 
31 50-74 yearly 3 if age ≥ 70 and PSA < 1 then Stop 
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Screening Men Older than 75 
32 50-76/78/80 yearly 3 
 33 50-76/78/80 yearly 3 if age ≥ 70 then PSAt = 4 
34 50-76/78/80 yearly 3 
if  66 ≤ age < 70, then PSAt = 4, if age ≥ 
70 then PSAt = 5 
35 50-76/78/80 yearly 4 
if  66 ≤ age < 70, then PSAt = 5, if age ≥ 
70 then PSAt = 7 
AUA 2013 guideline based policies  
36 55-69 yearly 4 
 37 55-69 2-year, yearly 3 
      
 
Finally, we investigate strategies based on the 2013 AUA guideline. This guideline 
recommends to screen men between ages 55 and 69. As the recommended PSAt and 
screening frequency is not clear, we run this policy for PSAt’s 3 and 4 ng/ml, yearly 
and every 2 years.3 
 
We perform sensitivity analyses by running several scenarios for some of the best 
policies (PCM increase thresholds: -3%, 0%, 3% and 6%). We run four scenarios 
assuming a reduced screening efficacy: a screening attendance of 70% and 50%, a 
decrease of 20% in biopsy sensitivity and a 41% biopsy compliance combined with 
a 85% attendance as observed in the PLCO trial 22. We also vary the parameters that 
determine PSA growth by 20%, to get a range of possible screening outcomes. 
 
Results 
 
Model Validation 
 
In Model Appendix Figure 2, we compare the predicted incidence by MISCAN 
compared to the observed incidence in the US SEER data between 1975 and 2009. 
The model reproduces the peak in prostate cancer incidence due to the introduction 
of PSA testing, but with slight overprediction. Beyond the calibration period, the 
predicted incidence is close to the observed incidence rate. 
 
In Model Appendix Table 3, the PSA distribution projected by MISCAN is close to 
the PSA distribution observed in the 1st round of the ERSPC trial. The maximum 
difference between predicted and observed is about 6 percentual points (For more 
details see Model Appendix PSA Growth Generator Section). 
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Model Projections 
 
In table 2, we show the outcomes of the reference strategy compared to stop 
screening in 2012. In the reference strategy the lifetime risk of prostate cancer 
detection is 14.0%. The lifetime risk of metastasis and PCM is, respectively, 0.7% 
and 2.4%, while if we stop screening after 2012, it becomes respectively, 1.7% and 
2.8%. The PCM reduction due to screening is 19.4%, and the lifetime risk of 
overdiagnosis is 3.8% corresponding to 43.8% of the screen-detected cases.   
 
 
Table 2: Basecase screening policy compared with stopping screening 2012. 
 
 
Lifetime Risk % 50-74,1y, PSAt=3 Stop Screening 2012 
Prostate Cancer Mortality 2.4 2.8 
Metastasis 0.7 1.7 
Overdiagnosis 3.8 0 
Detection 14.0 9.7 
Performance 
 
 
PCM Benefit % 19.4 - 
Number Needed to Screen 162 - 
Number Needed to Treat 15 - 
Overdiagnosis (% of  Screen Detected) 43.8 - 
Metastasis  ( % of Detected) 4.7 17.8 
* In the absence of screening (also prior to 2012) the lifetime risk of PCM is 3.0%.   
# PSAt stands for prostate-specific antigen threshold for biopsy referral. 
 
 
In table 3 we show the lifetime risk of overdiagnosis and PCM, divided by several 
thresholds of PCM increase, due to reduced screening intensity, and ordered by 
overdiagnosis reduction. Increasing the start age of screening from 50 to 54, 58 and 
62 has little effect on overdiagnosis. Starting screening at age 54 seems to be the 
best age of these four, as starting earlier has little effect on PCM (0.2% increase 
from age 50), while starting later increases PCM (0.8% for age 58 and 2.2% for age 
62, in Table 3). 
 
Decreasing the stop age from 74 to an earlier age gives a profound effect. With 
yearly screening, stopping at 72, 70 or 68 reduces the lifetime risk of overdiagnosis, 
respectively, from 3.8% to 3.1% (18.0% reduction), 2.5% (34.0% reduction) and 
2.0% (48.3% reduction). Correspondingly, PCM increases, due to less intensive 
screening, from 2.4% to 2.4% (1.6% increase), 2.5% (3.2% increase) and 2.5% 
(5.1% increase) only. Stopping screening at an earlier age than 68 can reduce 
overdiagnosis by more than 60%, but then PCM increases more than 6% in 
comparison with screening until age 74 (Table 3). 
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Keeping the stop age fixed, a reduction in the screening frequency from yearly to 
every 2 years or 4 years substantially reduces the amount of overdiagnosis (Table 
3). However, in most cases, the effect of decreasing the stop age is more powerful 
than reducing the screen frequency. For instance, consider the policy where screen 
every two years between ages 50 and 72. The PCM increases from 2.4% to 2.5% 
(3.0% increase) and overdiagnosis decreases from 3.8% to 2.9% (24.3% reduction), 
while screening yearly between 50 and 70 increases PCM slightly more to 2.5% 
(3.2% reduction) but reduces overdiagnosis to 2.5% (34.0% reduction). Also see 
PCM increase thresholds 2%, 4%, 5% and 7% in Table 3.   
 
Compared to the reference strategy, the three AUA inspired strategies (55-69 yearly 
with PSAt of 3 and PSAt of  4,  2-year with a PSAt of 3, respectively) reduce 
overdiagnosis from 3.8% to 2.2% (41.0% reduction), 1.9% (50.4% reduction) and 
2.1% (45.3% reduction). PCM increases, respectively, from 2.4% to 2.5% (4.4% 
increase), 2.5% (6.3% reduction) and 2.5% (5.4% increase) (Table 3). 
 
We also projected outcomes for policies where the frequency of screening changes 
according to the PSA value (Table 1). Stopping screening at ages 60 or 65 if the 
PSA is smaller than 1, reduces overdiagnosis from 3.8% to 2.8% (27.6% reduction) 
and 3.2% (17.1% reduction) but PCM increases from 2.4% to 2.5%  (3.6% increase) 
and 2.4% (1.9% increase), respectively. This is a lower overdiagnosis reduction than 
other policies with similar PCM levels (Table 3). 
 
A possible way to reduce overdiagnosis is to increase the PSAt (Table 1). The 
combination where we screen from age 50 with a PSAt of 3, increase to 4 after age 
66, and 5 after age 70 has similar harms and benefits trade-off, as simple yearly 
screening strategy (Table 3).  By contrast, most screening policies with an initial 
PSAt of 4 have a lower overdiagnosis reduction compared to other screening 
policies with similar PCM levels (See PCM increase thresholds 3%, 5%, 6% and 
7% in Table 3). 
 
Screening until age 76 or 80 decreases PCM from 2.4% to 2.3% (1.4% reduction) 
and 2.3% (3.6% reduction), respectively, and less metastasized cases. But this 
comes at a price of an overdiagnosis increase from 3.8% to 4.6% (20% increase) 
and 6.3% (64.6% increase), respectively (Table 3). 
 
The policies that reduce overdiagnosis the most, for maximum PCM  increases of 
1%, 2%, 3%, 4% and 5% are, respectively, yearly screening 50-74 where, if PSA <1  
at age 65 or older, screening frequency changes to 4 years, yearly screening 50-72, 
2-year screening 50-72, yearly screening 50-70 (all with a PSAt of 3) and yearly 
screening 50-70 with a PSAt of 3 for men younger than 66 and PSAt of 4 for men 
older than 66 (Figure 1 and Table 3). 
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Table 4: Selected screening policies by PCM increase threshold, due to less intensive 
screening, relative to basecase (50-74, 1y, PSAt=3) and ordered by overdiagnosis 
reduction.  
Maximu
m 
PCM 
Increase 
Threshol
d 
Screening Policy      
 
Probability 
Overdx                   
( - Overdx % ) 
Probability  
PCM                   
(+ PCM %) 
0% 50-74, 1y, PSAt = 3 3.80 (0.0) 2.38 (0.0) 
1% 50-74, 1y, PSAt = 3,  if age > 65, PSAt < 1 
then  freq. = 4y 
3.58 (5.9) 2.39 (0.7) 
 58-74, 1y, PSAt = 3 3.81 (-0.1) 2.38 (0.8)  
 54-74, 1y, PSAt = 3 3.81 (-0.2) 2.40 (0.2)  
2% 50-72, 1y, PSAt = 3 3.12 (18.0) 2.41 (1.6) 
 50-74, 1y, PSAt = 3, if age > 65, PSAt < 1 
then stop 
3.15 (17.1) 2.42 (1.9) 
 50-74, 2y, PSAt = 3 3.51 (7.6) 2.41 (1.6) 
3% 50-72, 2y, PSAt = 3 2.88 (24.3) 2.45 (3.0) 
 50-74, 1y, PSAt = 3, if 66 ≤ age < 70 then 
PSAt = 4, if age ≥ 70 then PSAt = 5 
3.10 (18.6) 2.43 (2.2) 
 50-74, 1y, PSAt = 4 3.31 (12.8) 2.44 (2.6) 
 62-74, 1y, PSAt = 3 3.76 (1.1) 2.43 (2.2) 
4% 50-70, 1y, PSAt = 3 2.51 (34.0) 2.46 (3.2) 
 50-74, 1y, PSAt = 3, if age > 60, PSAt < 1 
then stop 
2.75 (27.6) 2.47 (3.6) 
 50-74, 4y, PSAt = 3 3.07 (19.4) 2.47 (3.8) 
5% 50-70, 1y, PSAt = 3, if age > 66 then PSAt 
= 4 
2.15 (43.4) 2.49 (4.5) 
 55-69, 1y, PSAt = 3 2.24 (41.0) 2.48 (4.4) 
 50-70, 2y, PSAt = 3 2.31 (39.2) 2.49 (4.5) 
 50-74, 1y, PSAt = 4, 66  ≤  age < 70 then 
PSAt = 5, if age  ≥  70 then PSAt = 7 
2.61 (31.2) 2.49 (4.6) 
6% 50-68, 1y, PSAt = 3 1.97 (48.3) 2.50 (5.1) 
 55-69, 2y, PSAt = 3 2.08 (45.3) 2.51 (5.4) 
 50-70, 1y, PSAt = 4 2.13 (43.9) 2.51 (5.5) 
7% 50-66, 1y, PSAt = 3 1.48 (61.1) 2.55 (6.9) 
 50-70, 1y, PSAt = 4, 66  ≤  age < 70 then 
PSAt = 5, if age  ≥  70 then PSAt = 7 
1.84 (51.6) 2.54 (6.4) 
 55-69, 1y, PSAt = 4 1.88 (50.4) 2.54 (6.3) 
 50-70, 4y, PSAt = 3 1.99 (47.5) 2.53 (6.3) 
17% Stop Screening 2012 0.00 (100.0) 2.83 (16.2) 
Screening Men Older than 75   
-1% 50-76, 1y, PSAt = 3 4.56 (-20.0) 2.34  (-1.4) 
-3% 50-80, 1y, PSAt = 3 6.26 (-64.6) 2.30 (-3.6) 
# All other screening policies are shown in Online Supplement tables 3 (by screening 
frequency and start stop age)  and 4 (PSA based risk stratification,  PSAt dependent 
on age, screening men older than 75). 
## Reduction (-) or increase (+), in percentage,  relative to basecase (50-74, PSAt=3, 
yearly screening). Screening policies are ordered by overdiagnosis reduction. 
* PSAt stands for prostate-specific antigen threshold for biopsy referral, Overdx for 
Overdiagnosis, PCM for prostate cancer mortality.  
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Figure 2: The screening policies that reduce the overdiagnosis the most, for each 
prostate cancer mortality (PCM) threshold.  
 
  
*All policies with a PSA threshold for biopsy referral of 3, unless stated otherwise. 
The numbers between brackets are relative to the basecase screening policy (50-74, 
1y, PSAt=3).  
# PSAt stands for prostate-specific antigen threshold for biopsy referral, Overdx for 
Overdiagnosis, PCM for prostate cancer mortality. 
 
 
Sensitivity Analyses  
 
Varying the PSA growth parameters by 20%, lowering the sensitivity or the 
attendance does not seem to have a major impact in the results, resulting in the 
worst case in a slightly lower screening benefit.  However, if we apply together the 
biopsy compliance and attendance observed in the PLCO trial, there is a significant 
reduction in screening benefit.  The lifetime risk of PCM for 50-74 yearly screening 
at a PSAt of 3  is about 2.5%, which is close to stopping screening at age 68, under 
our initial assumption of 100% biopsy compliance. On the other hand, the risk of 
overdiagnosis is about 2.9% stopping at 74, with PLCO compliance compared to 
2.0%  with 68 as stop age and with 100% biopsy compliance. (Supplementary 
Information Table 3 and 4). 
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50-74, 1yBasecase
50-74, 1y, if PSA > 1 and age > 65 then freq = 4y(0.7%, 5.9%)
50-72, 1y(1.6%, 18.0%)
50-70, 1y(3.2%, 34.0%)
50-70, 1y, if age > 66 then PSAt=4(4.5%, 43.4%)
50-72, 2y(3.0%, 24.3%)
50-68, 1y(5.1%, 48.3%)
50-66, 1y(6.9%, 61.1%)
(Increase PCM %, Decrease Overdx %)
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Discussion 
 
For the reference strategy of screening yearly between 50 and 74 with a PSAt of 3,  
we predict a lifetime risk of PCM of 2.4% (19.4% PCM reduction due to screening) 
and a corresponding 3.8% lifetime risk of overdiagnosis (43.8% of screen-detected 
cases).  
 
Overdiagnosis estimates can diverge considerably, depending on the methods and 
population used 7-8. Based on ERSPC, Welch et al.23 estimated 60% of screen-
detected cases are overdiagnosed, while Draisma et al 17, used 3 simulation models 
and estimated a range  between 23 and 42%. Gulati et al.11 found a lifetime risk of 
overdiagnosis and PCM of 3.3% and 2.2%, respectively, for a similar strategy of 
yearly screening between 50 and 74 with PSAt 4, which compares to 3.3% and 
2.4%, in our model. Wu et al 24 estimated a 3.4% lifetime risk of overdiagnosis in 
Finland, for men screened between 55 and 67 every 4 years.   
 
Ranking screening policies by harms and benefits is a difficult task. Usually we 
cannot reduce PCM without increasing overdiagnosis. Additionally, the weighting 
of harms and benefits is highly subjective. However, one could intuitively say, that 
if a screening strategy causes a small decrease in the benefit and a large decrease in 
the harms, one would prefer such a policy. Following this principle and according to 
our model’s predictions, it seems hard to justify screening for prostate cancer in 
average men older than 70.  Namely, we predict that if one screens yearly from age 
50 to 70, overdiagnosis reduces from 3.8% to 2.5% (34.0% reduction) and PCM 
from 2.4% to 2.5% (3.2% increase), compared to screening until 74.   
 
It should be stressed however, that this conclusion is dependent on the particular 
individual’s health and life expectancy.  Additionally, our model represents an 
“ideal” screening environment, which contrasts with the 41% biopsy compliance 
observed in PLCO, and that more accurately represents the US reality 22. Screening 
yearly, with the biopsy compliance as in the PLCO between ages 50 and 74 gives a 
similar PCM level, as if we would have 100% biopsy compliance and stop at age 
68. The overdiagnosis level of the latter though, is much lower, suggesting there 
could be a large efficiency gain by screening less, but enforcing a significantly 
higher biopsy compliance. In practice though, biopsy compliance is likely not 
random as in MISCAN. It could be dependent on life expectancy or variables which 
are also predictors of the severity of the disease like PSA value. 
 
If we compare policies with similar levels of PCM, it seems that the effect of 
decreasing the stopping age on overdiagnosis reduction is larger than reducing the 
screening frequency or increasing the initial PSAt to 4. This can seem somewhat 
counterintuitive, as prostate cancer is a slow growing disease, but one should also 
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notice that the probability of overdiagnosis is highly age dependent 25-27. 
 
We also evaluated screening policies inspired by the 2013 AUA guideline. We find 
that screening between 55 and 69 is a reasonable way to go forward, as with later 
ages overdiagnosis increases substantially, and there is a very small difference in 
mortality between starting screening at age 50 and age 54.  However, our 
predictions are more favourable for yearly screening with a PSA threshold for 
biopsy referral of 3, than screening every two years or with a PSAt of 4.   
 
PSA based risk stratification reduces overdiagnosis. However, it seems that for a 
similar PCM increase, the overdiagnosis reduction is smaller than the effect of 
decreasing the stopping age. This could be the case since few men with PSA smaller 
than 1 at age 60 will develop the disease in our model. This is in accordance with 
the ERSPC trial, where the probability of having a PSA lower than 1 at age 60 and a 
PSA higher than 3, in the next two rounds is only 2.3% (Online Supplement Table 
2). A limitation of these analyses is that we did not vary the stop age. Also other 
ways of doing PSA based risk stratification could be considered. 
 
Screening men older than 75 saves some lives, but each additional year of screening 
adds a large number of overdiagnosed cases, about 20% for additional 2 yearly 
screening rounds, and it is therefore undesirable, at least for a person with average 
life expectancy. 
 
Due to the high number of parameters in MISCAN it is not possible to do a 
(probabilistic) sensitivity analysis including all parameters and assumptions used to 
construct the model could have an influence in the projections. For instance, the 
results from Gulati et al.11 do not differ much from our own, but we verify that for 
similar screening strategies, the overdiagnosis level is similar but PCM is lower, 
thus their model is slightly more favourable to screening.  
 
In this study we also did not model Active Surveillance (AS). This type of treatment 
can reduce the harms of screening, namely by delaying and in some cases avoiding 
the side-effects associated with radical treatment. On the other hand, its long term 
effects still needs to be investigated as most current AS observational cohorts have a 
small follow-up 28. Referring screened men to AS who are at low and perhaps 
intermediate risk could greatly reduce the harms of screening. The inclusion of 
quality of life and costs associated with each disease state can potentially change the 
relationship between harms and benefits. For instance, Heijnsdijk et al.6 found that 
adding quality of life estimates reduced the benefit of screening by 23%. 
Extrapolating that result to this study could mean that stopping screening earlier 
would be preferred. Also introducing costs could potentially favour stopping 
screening earlier. 
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In general we should screen men with a life expectancy higher than the expected 
duration from onset of the disease to a state where the prostate cancer is not curable. 
In most cases the patient’s health status will give an idea about the life expectancy, 
but since the onset of the disease is not observed and there is considerable variation 
in its duration, it remains a difficult task, to predict which men may benefit of 
screening.  
 
Our results support the view that screening men older than 70 yearly and 
indiscriminately can lead to a large increase of overdiagnosis. However, depending 
on the maximum tolerated level of PCM, earlier stopping ages could be considered.  
Additionally, we find that screening at lower frequencies than yearly and newly 
proposed screening protocols in which the frequency depends on PSA result 12,13 or 
where the PSAt  increases with age, do not seem to improve much on simple yearly 
screening.
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Supplementary Material  
 
Additional Outcomes 
 
Table 1: Screening policies per start-stop age and screening frequency, with PSAt of 3 
Reduction (-) or increase (+), in percentage,  relative to basecase (50-74, PSAt=3, 
yearly screening) 
Yearly Screening  
Strategy Age Freq. PSAt - Overdx % + PCM % + Mx % 
Stop 
Screen 
2012 
- - - 100.0 16.2 62.2 
1 50-74 Yearly 3 0.0 0.0 0.0 
2 50-62 Yearly 3 80.8 10.5 50.8 
1y 50-66 Yearly 3 61.1 6.9 39.9 
1y 50-68 Yearly 3 48.3 5.1 32.6 
1y 50-70 Yearly 3 34.0 3.2 23.3 
1y 50-72 Yearly 3 18.0 1.6 12.6 
1y 54-62 Yearly 3 80.7 10.7 51.0 
1y 54-66 Yearly 3 60.9 7.1 40.1 
1y 54-68 Yearly 3 48.1 5.3 32.8 
1y 54-70 Yearly 3 33.8 3.5 23.7 
1y 54-72 Yearly 3 17.8 1.8 12.9 
1y 54-74 Yearly 3 -0.2 0.2 0.7 
1y 58-66 Yearly 3 61.2 7.6 40.8 
1y 58-68 Yearly 3 48.3 5.8 33.7 
1y 58-70 Yearly 3 34.0 4.0 24.9 
1y 58-72 Yearly 3 17.9 2.4 14.5 
1y 58-74 Yearly 3 -0.1 0.8 2.8 
1y 62-70 Yearly 3 35.2 5.3 28.1 
1y 62-74 Yearly 3 1.1 2.2 8.1 
1y 55-69 Yearly 3 41.0 4.4 28.6 
 
Screening Every 2 years 
Strategy Age Frequency PSAt - Overdx % + PCM % + Mx % 
2 50-62 2-year 3 82.6 11.1 51.8 
3 50-66 2-year 3 64.5 7.8 42.0 
4 50-68 2-year 3 52.6 6.2 35.3 
5 50-70 2-year 3 39.2 4.5 27.2 
6 50-72 2-year 3 24.3 3.0 17.7 
7 50-74 2-year 3 7.6 1.6 7.1 
8 54-62 2-year 3 82.2 11.1 51.8 
9 54-66 2-year 3 63.9 7.9 41.9 
10 54-68 2-year 3 51.9 6.2 35.3 
11 54-70 2-year 3 38.6 4.6 27.2 
12 54-72 2-year 3 23.6 3.0 17.8 
13 54-74 2-year 3 6.7 1.6 7.2 
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14 58-66 2-year 3 63.7 8.1 42.3 
15 58-68 2-year 3 51.6 6.4 35.8 
16 58-70 2-year 3 38.2 4.8 27.8 
17 58-72 2-year 3 23.2 3.3 18.7 
18 58-74 2-year 3 6.2 1.9 8.4 
19 62-70 2-year 3 38.8 6.1 30.5 
20 62-74 2-year 3 6.8 3.3 12.7 
37 55-69 2-year 3 50.4 6.3 34.6 
  
  
   
Screening Every 4 years 
Strategy Age Frequency PSAt - Overdx % + PCM % + Mx % 
2 50-62 4-year 3 85.2 11.9 53.3 
3 50-66 4-year 3 69.6 9.1 45.2 
5 50-70 4-year 3 47.5 6.3 33.5 
7 50-74 4-year 3 19.4 3.8 18.1 
8 54-62 4-year 3 84.3 11.8 52.9 
9 54-66 4-year 3 68.3 9.0 44.7 
11 54-70 4-year 3 45.9 6.2 32.7 
13 54-74 4-year 3 17.6 3.8 17.4 
14 58-66 4-year 3 67.3 9.1 44.6 
16 58-70 4-year 3 44.7 6.5 32.7 
18 58-74 4-year 3 16.1 4.1 17.7 
19 62-70 4-year 3 44.4 7.3 34.1 
20 62-74 4-year 3 15.6 4.9 20.2 
* PSAt stands for prostate-specific antigen threshold for biopsy referral, Overdx for 
Overdiagnosis, PCM for prostate cancer mortality and Mx for Metastasis. 
** See Appendix Table 9 for all 2 and 4-year runs and the note on Cohort Effects. 
*** In italic, screening policies based on the 2013 AUA guideline. 
 
 
 
 
Table 2: Higher PSAt per age, PSA based risk stratification and Screening men older 
than 75 
Reduction (-) or increase (+), in percentage,  relative to basecase (50-74, PSAt=3, 
yearly screening) 
Higher PSAt’s per age  
Strategy Age Freq. PSAt - Overdx % + PCM % + Mx % 
21 50-70 Yearly 4 43.9 5.5 30.3 
21 50-72 Yearly 4 29.3 4.0 21.7 
21 50-74 Yearly 4 12.8 2.6 11.7 
22 50-70 Yearly 3* 43.4 4.5 28.9 
22 50-72 Yearly 3* 33.4 3.5 22.9 
22 50-74 Yearly 3* 18.6 2.2 14.0 
23 50-70 Yearly 4* 51.6 6.4 34.1 
23 50-72 Yearly 4* 44.1 5.7 30.3 
23 50-74 Yearly 4* 31.2 4.6 23.4 
36 55-69 Yearly 4** 45.3 5.4 31.5 
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*In this policy the PSAt depends on age: 
 22: if 66 ≤  age < 70,  then PSAt = 4, if age ≥ 70 then PSAt = 5. 
 23: if 66 ≤  age < 70,  then PSAt = 5, if age ≥ 70 then PSAt = 7. 
** 36: screening policy based on the 2013 AUA guideline. 
 
  PSA based risk stratification (Screen Frequency and Stop Age dependent on PSA 
result) 
Initial Screening Strategy: 50-74, 1y, PSAt=3 
Strategy: PSA based condition - Overdx % + PCM % + Mx % 
24: If PSA<1 from age 60 then stop screening. 27.6 3.6 26.2 
25: If PSA<1 from age 60 then 8 year frequency. 18.0 2.3 17.2 
26: If PSA<1 from age 60 then 4 year frequency. 9.4 1.3 9.3 
27: If PSA<1 from age 60 then 2 year frequency. 3.5 0.5 3.5 
28: If PSA<1 from age 65 then stop screening. 17.1 1.9 15.7 
29: If PSA<1 from age 65 then 4 year frequency. 5.9 0.7 5.6 
30: If PSA<1 from age 65 then 2 year frequency. 3.6 0.4 3.2 
31: If PSA<1 from age 70 then stop screening. 2.9 0.3 2.3 
 
Screening Men Older than 75 
Strategy Age Freq. PSAt - Overdx % + PCM % + Mx % 
32 50-76 Yearly 3 -20.0 -1.4 -13.8 
32 50-78 Yearly 3 -41.9 -2.6 -27.9 
32 50-80 Yearly 3 -64.6 -3.6 -39.7 
33 50-76 Yearly 3* -5.3 1.4 1.3 
33 50-78 Yearly 3* -25.3 0.3 -9.2 
33 50-80 Yearly 3* -46.3 -0.5 -17.9 
34 50-76 Yearly 3* 1.9 1.1 4.6 
34 50-78 Yearly 3* -16.6 0.1 -4.9 
34 50-80 Yearly 3* -36.1 -0.7 -13.2 
35 50-76 Yearly 4* 16.4 3.6 16.2 
35 50-78 Yearly 4* -0.1 2.8 9.0 
35 50-80 Yearly 4* -17.7 2.1 3.0 
*In this policy the PSAt depends on age: 
 33: if age ≥ 70, then PSAt = 4. 
 34: if 66 ≤  age < 70,  then PSAt = 4, if age ≥ 70 then PSAt = 5. 
 35: if 66 ≤  age < 70,  then PSAt = 5, if age ≥ 70 then PSAt = 7. 
#  PSAt stands for prostate-specific antigen threshold for biopsy referral, Overdx for 
Overdiagnosis, PCM for prostate cancer mortality and Mx for Metastasis. 
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Sensitivity Analyses 
 
Table 3: Basecase screening policy (50-74, PSAt=3, yearly screen), attendance, 
biopsy compliance and sensitivity 
 Attendance 
 PLCO 
Biopsy 
Compliance  
Sensitivity PSA 
growth 
Lifetime 
Risk % 
90% 70% 50% 
 
41% 80% 
-
20% 
20% 
Overdiagnosis 3.8 3.6 3.3  2.9 3.6 3.3 4.3 
PCM 2.4 2.4 2.4  2.5 2.4 2.4 2.3 
Metastases 0.7 0.7 0.7  0.8 0.7 0.8 0.6 
Detection 14.0 16.7 16.2  13.4 16.8 13.6 14.5 
Performance 
 
       
Mortality 
Benefit % 19.4 18.8 17.6  15.3 18.6 17.3 21.4 
NNS 161.7 166.1 175.3  205.1 168.5 181.9 146.2 
NNT 15.2 15.0 14.8  15.7 15.3 15.3 15.2 
Overdiagnosis        
(% of Detected) 
43.8 43.6 43.7  40.4 43.2 42.3 45.2 
Mx (% of 
Detected) 4.7 5.5 5.0  6.2 4.9 5.6 3.8 
* Basecase 90% attendance and 100% biopsy compliance. For the PLCO biopsy 
compliance, all the sensitivities were multiplied 0.41 and with an attendance of 85%, 
as observed on the PLCO trial ref. For the sensitivities, all sensitivity parameters 
were multiplied by 0.8.  For the “PSA growth”,  parameters b1i  and b2i , described in 
table 6, are multiplied by 0.8 or 1.2.  
** PCM stands for prostate cancer mortality, NNS stands for number needed to 
screen to save one life, NNT for number needed to treat to save one life and Mx for 
Metastasis. 
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Table 4:  Sensitivity Analyses 
Reduction (-) or increase (+), in percentage,  relative to basecase (50-74, PSAt=3, 
yearly screen) 
Different screening efficacy assumptions 
 Age, Frequency - Overdx % + PCM % + Mx % 
Attendance 50%    
50-68, yearly 49.5 4.6 29.4 
50-72, 2-year 31.6 3.9 21.5 
50-80, yearly -66.5 -3.2 -33.6 
Attendance 70%   
50-68, yearly 48.8 4.9 31.4 
50-72, 2-year 27.3 3.5 19.4 
50-80, yearly -65.4 -3.5 -37.6 
PLCO Biopsy Compliance and Attendance  
50-68, yearly 54.6 4.2 26.9 
50-72, 2-year 39.7 4.2 23.2 
50-80, yearly -72.4 -3.0 -29.4 
      Biopsy Sensitivity*80% 
50-68, yearly 49.3 4.9 31.7 
50-72, 2-year 27.3 3.3 19.4 
50-80, yearly -65.9 -3.5 -37.9 
  Varying PSA growth parameters * 
  
 Age, Frequency - Overdx % +  PCM % + Mx % 
-20%    
50-68, yearly 49.8 4.4 27.7 
50-72, 2-year 25.8 2.5 15.4 
50-80, yearly -64.7 -3.0 -28.6 
+20%    
50-68, yearly 47.2 5.7 37.6 
50-72, 2-year 24.1 3.3 21.2 
50-80, yearly -63.7 -4.2 -51.7 
* PSA growth equation parameters b1i  and b2i , described in table 6, are multiplied by 
0.8 or 1.2 . 
# Policies selected based on the best screening policies for maximum mortality 
increase thresholds     -3%, 0%, 3% and 6% . All Policies with a PSAt of 3. 
# # Overdx stands for Overdiagnosis, PCM for prostate cancer mortality and Mx for 
Metastasis. 
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Abstract 
 
Background: The results of the ERSPC trial showed a 
statistically significant 29% prostate cancer mortality reduction 
for the men screened in the intervention arm and a 23% negative 
impact on the life-years gained due to quality of life. However, 
alternative prostate-specific antigen (PSA)-screening strategies 
for the population may exist, optimizing the effects on mortality 
reduction, quality of life, overdiagnosis and costs. 
 
Methods: Based on data of the ERSPC trial, we predicted the 
numbers of prostate cancers diagnosed, prostate cancer deaths 
averted, life-years and quality-adjusted life-years (QALY) gained 
and cost-effectiveness of 68 screening strategies starting at age 
55, with a PSA threshold of 3, using micro-simulation modeling. 
The screening strategies varied by age to stop screening and 
screening interval (1 to 14 years or once in a lifetime screens) and 
therefore number of tests.   
 
Results: Screening at short intervals of 3 years or less was more 
cost-effective than using longer intervals. Screening at ages 55-59 
with 2-year intervals had an incremental cost-effectiveness ratio 
of $73,000 per QALY gained and was considered optimal. With 
this strategy, lifetime prostate cancer mortality reduction was 
predicted as 13%, and 33% of the screen-detected cancers were 
overdiagnosed. When better quality of life for the post-treatment 
period could be achieved, an older age of 65-71 years for ending 
screening was obtained. 
 
Conclusion: Prostate cancer screening can be cost-effective, 
when it is limited to two or three screens between ages 55-59 
years. Screening above age 63 years is less cost-effective due to 
loss of QALYs because of overdiagnosis. 
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Introduction 
 
The European Randomised study of Screening for Prostate Cancer (ERSPC) has 
shown a disease-specific mortality reduction of Prostate-Specific-Antigen (PSA) 
screening for prostate cancer [1]. After eleven years of follow-up, prostate cancer 
mortality was reduced by 29% after adjustment for noncompliance. In terms of 
absolute effect, 37 cancers would need to be detected to avert one prostate cancer 
death [1]. Some of the screen-detected prostate tumors (23% to 42%) might never 
give rise to clinical symptoms and would not lead to death from prostate cancer [2].  
 
These overdetected cancers reduce quality of life and result in higher costs due to 
overtreatment [3], affecting the balance of benefits and harms as well as cost-
effectiveness of PSA testing for prostate cancer. In our recent study, we could 
demonstrate that the introduction of a screening program between the ages of 55-70 
with a four-year interval would result in a gain of 52 life-years and 41 quality-
adjusted life-years (QALYs) per 1000 men over their life span [4]. 
 
Very recently the AUA recommended shared decision-making for men age 55 to 69 
years that are considering PSA screening, but they gave no clear indication of the 
screen interval. In the ERSPC, the Swedish center used a 2-year screening intervals, 
whereas the other centers used 4-year intervals [1]. In the United States, annual 
screening is more common. There are no trials comparing different screening 
intervals and such empirical studies are highly unlikely to be conducted because of 
immense resources required.  
 
Few recent cost-effectiveness studies have been published using QALYs gained. 
Most cost-effectiveness studies for prostate cancer screening have been performed 
before large screening trial results had been published and showed very inconsistent 
results [5, 6]. 
 
The aim of present study is to assess the cost-effectiveness of prostate cancer 
screening. Based on data of the ERSPC trial various prostate cancer screening 
strategies were modeled to find the optimal screening intervals and ages. 
 
Methods 
 
The MISCAN model 
 
MISCAN, MIcrosimulation SCreening ANalysis, was used for the evaluation of 
prostate cancer screening. The MISCAN prostate cancer model was developed in 
2003 [7]. Since, the model was adjusted to explicitly model the metastatic stages, 
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treatment, survival and cure rates [8, 9].  
 
MISCAN is a stochastic model that simulates individual life histories. The natural 
history of prostate cancer starts with a transition from “no prostate cancer” into 
preclinical screen-detectable prostate cancer. Tumor development is modeled as a 
progression through 18 stages (a combination of clinical T-stage T1, T2 and T3+, 
differentiation grade Gleason sum less than 7, 7 and more than 7 and metastatic 
stage 0 or 1). In each preclinical stage, the tumor may progress into another 
preclinical stage, become screen detected or clinically diagnosed (Model Appendix 
Figure 1). For each individual, the model predicts two life histories: one in the 
absence of screening and one in the presence of screening.  
 
The cancers are divided into clinically diagnosed cancers, relevant screen-detected 
cancers and overdetected cancers (cancers that would not have become clinically 
diagnosed during a person’s life). The model parameters for the disease and the test 
sensitivity are estimated with the use of data from the Rotterdam and Göteborg 
ERSPC centers (46,000 men, age 55-69), and the Dutch National Cancer Registry 
and the model is validated with the use of incidence data of all ERSPC centers. 
Other cause mortality is modelled using the Dutch life expectancy. The model and 
validation have been described before [4].  
 
The treatment assignment in MISCAN is based on age, stage and Gleason score 
specific distribution of primary treatments (radiation therapy, radical prostatectomy 
and active surveillance) in the Rotterdam center of the ERSPC. It is assumed that 
30% of men under active surveillance receive a secondary treatment within 7 years. 
All men dying of prostate cancer as well as all men with metastases receive 
palliative treatment.   
 
Survival without treatment was modelled by using the Gleason score-specific 
survival curves for men detected with locoregional prostate cancer [10]. For distant 
disease, survival curves based on SEER data were used. The effects of treatment 
were modelled by assuming a relative risk of dying of 0.65 for radical 
prostatectomy [11] compared with watchful waiting. The same relative risk was 
assumed for radiation therapy.  
The cure rate assumption is used to calculate the survival: a proportion of the 
screen-detected men with a local regional cancer will be cured and the remaining 
are not cured and die of prostate cancer or other causes at exactly the same time as 
they would have in a situation without screening. This stage-dependent cure rate 
was estimated for a prostate cancer mortality reduction of 29% after a follow-up of 
11 years for men who attended at least one screen, corresponding to the prostate 
cancer mortality reduction of screened men in the ERSPC [1]. This resulted in cure 
rates of 0.51 for Gleason Score less than 7, 0.30 for Gleason Score 7 and 0.11 for 
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Gleason Score more than 7. 
 
Screening Protocols 
 
A cohort of 10 million men aged 55 in 2012 was simulated. Screening programs 
started in 2012, with 80% participation at each round. Screening intervals of 1, 2, 3, 
4, 6, 8, 10, 12 and 14 years, starting at age 55 were simulated as well as a once in a 
lifetime screens. The age at which screening was stopped was varied between 55 
and 75. The corresponding costs and effects were calculated until the year 2060 
when all men in the cohort had died. 
 
Costs  
 
The unit costs of screening, diagnoses, primary treatment, follow-up and palliative 
care were obtained from literature [3]. The costs were calculated in dollars by using 
the purchase power parity for health [12]. Indirect costs were not included. The 
number of screening visits, diagnoses, prostate cancer deaths, treatments and life-
years were predicted by the MISCAN model. To take into account biopsies with a 
negative result, the total number of biopsies was calculated by using the number of  
screen detected cancers and a mean positive predictive value of 22.7% of a biopsy 
in the screen arm of the ERSPC [13] and by using the number of clinically detected 
cancers and the positive predictive value of 35.8% of a biopsy in the control arm 
[14]. 
 
Quality of Life 
 
QALYs were calculated by using utility estimates, values between 0 (death or worst 
imaginable health) and 1 (full health), representing patient desirability of a 
particular health state. Utility estimates and durations of all phases in screening, 
diagnoses and treatment of prostate cancer were obtained from literature (Table 1) 
[4]. The loss in QALYs was calculated by multiplying the loss in utility with the 
duration of the phase in Table 1 and the number of men in a phase obtained from 
MISCAN. For example when 800 men are screened once, they lose 800 x 0.01 x 
1/52 year = 0.15 QALYs due to the screening itself.    
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Table 1. Costs, utility estimates and durations of the various phases in screening, 
diagnosis and treatment, obtained from previous studies [3, 4]* 
 
Intervention Unit costs 
($) 
Health state Utility 
estimates 
(range) 
Duration 
Screening 39 Screening 
Attendance 
0.99 (0.99-1) 1 week 
Invitation 3.2    
Blood Sample 15.5    
PSA determination 20.3    
     
Diagnosis 277 Diagnostic Phase 0.90 (0.87-0.94) 3 weeks 
Biopsy 150 Diagnosis 0.80 (0.75-0.85) 1 month 
PA-Research 54    
GP-Consulting 73    
     
Primary Therapy and 
Follow-up 
    
Staging 326    
RP 19,235 RP (< 2 mo) 0.67 (0.56-0.9) 2 months 
RT 23,110 RP (> 2 mo) 0.77 (0.70-0.91) 10 months 
AS 2,588    
19 PSA tests 680 RT (< 2 mo) 0.73 (0.71-0.91) 2 months 
10 DRE 800 RT (> 2 mo) 0.78 (0.61-0.88) 10 months 
4 biopsies 1108 AS 0.97 (0.85-1.00) Max. 7 years 
Follow-up 245 One year after 
treatment 
0.95 (0.93-1.00) 9 years 
     
Advanced Disease     
Palliative Therapy 20,000 Palliative therapy 0.60 (0.24-0.86) 30 months 
  Terminal illness 0.40 (0.24-0.40) 6 months 
     
* AS denotes Active Surveillance, RT denotes Radiation Therapy and RP denotes 
Radical Prostatectomy.  
 
Cost-Effectiveness 
 
For all screening scenarios, the costs and effects (number of diagnoses, deaths 
prevented, treatments, life-years and QALYs gained) were compared with a 
situation without screening. A discount of 3.5% was applied to both costs and 
effects [15]. Strategies that did not have an alternative or combination of 
alternatives that would result in more QALYs gained at the same or less net costs 
were identified as the efficient strategies. For every efficient strategy we determined 
the incremental cost-effectiveness ratio (ICER), which is calculated as the 
incremental net costs per incremental QALY gained compared with the previous 
cost-efficient strategy. The strategy with an ICER value up to a threshold of 
$100,000 per QALY gained was considered as optimal [16]. 
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Sensitivity Analysis 
 
One-way sensitivity analyses were performed by varying key model parameters. For 
the utility estimates the highest and lowest values were used (Table 1). A separate 
analysis was performed using a utility estimate of 1 for the post-recovery period 
(while retaining all the other utility estimates). The costs were varied by 20%. In 
addition, the cost-effectiveness was calculated in the absence of overdiagnosis and 
for a prostate cancer mortality reduction as a result of screening of 56% after 14 
years of follow-up, as has been found in the Göteborg trial [17].  
 
Results 
 
Effects of screening ages and interval 
 
The simulations predicted that without screening 120 per 1000 men would be 
diagnosed and 32 die from prostate cancer (Table 2). A single screen at age 55 years 
would result in 4 additional cases diagnosed and 1 prostate cancer death prevented 
(5% mortality reduction) with 18 life-years gained (17 QALYs) per 1000 men (6.6 
quality adjusted days per man).  
 
The cost-effectiveness was $31,467 / QALY gained (3.5% discounted). More 
intensive screening would increase the number of cancers detected, the mortality 
reduction, overdiagnosis, the life-years and QALYs gained as well as the costs. The 
increase in total costs was mainly due to an increase in treatment costs. The largest 
number of life-years was gained with screening at 1-year intervals at age 55-75 
years, but the cost-effectiveness was poor with $320,042 / QALY gained.  
 
For each level of costs, most life-years were gained with screening at 1- or 2-year 
intervals (Figure 2A). The largest gain in QALYs was obtained by screening at 1-
year intervals from age 55 to 63 years (Figure 1B). For the single screen options, 
most QALYs were gained by a screen at age 57 years. The strategies on the 
efficiency frontier (the most effective strategies) had 3, 2 or 1 year intervals. 
Screening at ages 55-59 years with 2-year intervals yielded an ICER closest to 
$100,000 per QALY gained and was therefore regarded as optimal (Table 3). Using 
this strategy of only 3 screens, a 13% prostate cancer mortality reduction was 
predicted with 33% of the screen-detected cancers overdiagnosed. Using this 
strategy, the annual death rate is around 25% lower between the ages 60 and 70 
when compared with no screening (Figure 3).  
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Figure 1: Life Years Gained (A) and QALYs Gained (B) against costs for several 
screening policies. 
 
A 
 
B 
 
*Net costs and (A) life-years gained or (B) quality-adjusted life-years (QALYs) gained 
(all 3.5% discounted) per 1000 men, of PSA screening strategies varying by interval 
and end age. The screens start at age 55, except for the once in a life-time screens. At 
some points in the Figure, the end ages are indicated. The efficient strategies in 
Figure 1B are connected by the efficient frontier (Eff frontier) and are presented in 
Table 3. Strategies below this line are less cost-effective. 
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Table 2. Predicted effects, costs and cost-effectiveness for various screening 
scenarios per 1000 men. Effects and costs are shown without discount. The cost-
effectiveness is calculated at 3.5% discount rate for effects as well as costs. 
Screening scenario No 
screen 
One 
screen  
at age 55 
Biennial 
Screening 
55-59 
Quadrennial 
Screening  
55-67 
Biennial 
Screening  
55-69  
Screening 
yearly      
55-75  
Screening tests - 800 2,342 2,944 5,706 13,610 
Men screened at 
least once 
- 800 935 955 989 997 
Effects       
Cancers diagnosed 120 124 132 156 169 207 
Screen detected 
cancers 
- 12 34 86 115 180 
Overdiagnosed 
cancers   
(% of screen-
detected) 
- 4 (30%) 11 (32%) 35 (41%) 49 (43%) 87 (48%) 
Prostate cancer 
deaths  
(% reduction) 
32 31 (5%) 28 (13%) 25 (24%) 23 (30%) 20 (40%) 
Life-years gained - 18 41 66 83 102 
QALYs gained - 17 36 50 61 64 
Costs x $1,000        
Screening - 32 94 118 228 542 
Diagnosis and 
treatment 
1,882 2,003 2,229 2,842 3,161 3,909 
Palliative care 649 616 568 496 452 390 
Total costs 2,531 2,652 2,890 3,456 3,841 4,842 
Cost-
effectiveness* 
      
Net costs per 
QALY gained 
(3.5% discounted) 
- 31,467 45,615 92,031 120,185 320,042 
* The costs and effects are compared with the “no screen” situation, numbers are rounded. 
 
 
Figure 2: The annual death rate per 1000 men by age in the absence of screening as 
well as in the presence of screening from age 55 to age 59 with 2 year intervals 
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Table 3. Prostate cancer mortality reduction, overdiagnosis, life-years gained and 
incremental cost-effectiveness for the most efficient screening strategies per 1000 
men. The QALYs gained and costs are 3.5% discounted.  
 
Screening 
strategy 
PCM 
reduction 
(%)* 
LY 
gained* 
Total net 
costs* 
QALY 
gained* 
Cost/ 
QALY* 
ICER*† 
in $ 
end 
age 
Freq. 
55 - 5 8.4 168,469 5.4 31,467 31,467 
57 2 9 13.4 303,936 7.9 38,563 53,593 
58 3 10 14.8 343,908 8.4 40,785 72,567 
59 2 13 18.2 452,568 9.9 45,615 72,971 
61 2 17 22.6 612,063 11.3 54,349 118,989 
61 1 18 24.9 747,784 11.8 63,263 243,031 
62 1 20 27.1 848,006 12.2 69,481 260,507 
63 1 22 29.0 948,659 12.3 76,910 776,149 
* Compared with no screening 
† The difference in costs compared with the previous least expensive strategy, 
divided by the difference in QALYs between those strategies. 
 
 
Sensitivity Analysis 
 
A sensitivity analysis showed that when all costs for screening, diagnosis and 
treatment were increased by 20%, the same strategy (age 55-59 years, 2 year 
interval) remained closest to the optimal ICER (Table 4). Stopping screening at a 
later age was only favorable when the highest utility estimates were applied, when 
the utility estimate for the post-recovery period was 1 (no loss in quality of life due 
to treatment was assumed), when no overdiagnosis would exist or when a mortality 
reduction of 56% was assumed. In those instances the upper age limit could be 65 to 
72 years. When the lowest utility estimates were used, screening at ages 55 and 57 
years showed the most favorable cost-effectiveness.  
 
Discussion 
 
Our results suggest that screening strategies with short screening intervals of at 
most 3 years are more cost-effective than those using longer intervals. Scenarios 
involving more frequent screening over a limited age range resulted in increased the 
life-years gained, without a substantial increase in the proportion of overdiagnosed 
cases. The most favorable results were obtained for screening cessation below age 
60 years. The incremental cost-effectiveness ratios of these strategies were $31,467 
to $72,971 per QALY gained, close to the commonly used $50,000 and $100,000 
thresholds [16]. 
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Table 4. The optimal strategies, with an ICER threshold of $100,000 per QALY 
gained for various assumptions in the sensitivity analysis. The QALYs gained and 
costs are 3.5% discounted. Results are presented per 1000 men. 
Assumption Screening 
strategy 
PCM 
reducti
on 
(%)* 
Total net 
costs*  
QALY
gained
* 
Cost / 
QALY
* 
ICER† 
in $ 
End 
age 
Interval 
Highest utility 
estimates 
72 1 37 1,752,950 51.4 34,122 89,967 
Lowest utility 
estimates 
57 2 9 303,936 3.1 98,346 99,913 
Utility post-
recovery period 1 
65 2 24 943,066 25.0 37,664 80,457 
Costs – 20% 61 2 17 489,651 11.3 43,479 95,192 
Costs + 20% 59 2 13 543,081 9.9 54,739 87,566 
No overdiagnosis 71 1 36 542,981 19.4 28,037 93,881 
Mortality reduction 
of 56% 
66 1 60 1168,563 46.4 25,205 66,499 
* compared with no screening, all costs in US dollars. 
† The difference in costs compared with the previous least expensive strategy, 
divided by the difference in QALYs between those strategies 
 
 
Earlier we found that men aged 55-59 years with moderate-risk prostate cancer are 
also the best candidates for immediate curative treatment at the time of screen-
detection, because they have the most favorable ratio between lead time and life-
years gained [18]. Previous studies concerning the costs or cost-effectiveness of 
prostate cancer screening have not evaluated life-years gained or QALYs gained 
[19-24] or were based on assumptions of mortality reduction due to screening, and 
did not use results of a prostate cancer screening trial to calibrate the model [25-31].  
 
These studies showed large variation in costs-effectiveness from $68 per QALY 
gained [29] to $729,000 per life-year saved [30], but the results are difficult to 
compare due to different assumptions in demographics and background risks, 
screening protocols, costs, effects of treatment and screening on mortality and 
discount rates. Two studies have used the results of the ERSPC trial to assess cost-
effectiveness of screening [6, 32]. They found that screening is not cost-effective 
with $291,817 per QALY gained and $262,758 per life year gained. Screening can 
be cost-effective when it is limited to men with 5 times the average risk [6], or when 
the number needed to treat is less than 18 [32].  
 
Most studies have shown that screening is less cost-effective at higher ages [5]. Our 
study suggests a lower age at cessation of screening of 59 to 61, whereas previous 
studies suggest stopping screening at age 70-71 [23, 26, 28, 31]. Our results can 
change with longer follow-up of the ERSPC trial, as a study in Göteborg suggest 
that 9 years after termination of screening the prostate cancer mortality in the screen 
arm caught up [33]. However, the ERSPC has now two additional years of follow-
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up, which confirms the relatively stable mortality reduction, compared with the 9 
and 11 years follow-up (Schröder et al, in press). The current model can also 
replicate the mortality reduction after 13-years. 
 
Our conclusion on short intervals may seem surprising. Apparently much of the 
overdiagnosis is already covered by 4 year interval screening, whereas a shorter 
interval can still increase the prostate cancer mortality reduction. 
 
Strong points of our study are that the model incorporates a mortality reduction as a 
result of screening based on a large prostate screening trial and that by simulating a 
cohort of men for their life-times, all costs and effects can be taken into account. 
 
However, our approach has also some limitations. Since the model is based on the 
ERSPC trial, in which the majority of men were screened from age 55, the model is 
not validated to predict results for starting screening below age 55. Several 
modeling studies have suggested that starting screening at age 40 may improve the 
cost-effectiveness, or at least lead to comparable prostate cancer mortality 
reductions with less harms [20, 22, 28]. Also, varying PSA thresholds for biopsy 
referral for different sub-groups can improve harm-benefit trade-off [20]. For 
example, higher PSA thresholds can be used for older ages, the screening interval 
may be based on baseline PSA level, co-morbidity can be taken into account, or 
other risk stratification methods can be used. We assumed a fixed effect of 
screening for the entire population. However, this effect can depend on factors such 
as family history, co-morbidity and ethnicity. 
 
Another limitation of the present study is that most of the disease specific and 
treatment parameters in the model were based on the data of the ERSPC Rotterdam 
and the Dutch Cancer Registry, and might not be directly applicable to other 
populations, especially already more intensively screened populations. Also, the 
treatments modalities and effects can change in the future. If active surveillance will 
be used more frequently, the total treatment costs will be lower, whereas an increase 
in radical prostatectomy or radiotherapy would increase the total costs. 
 
We have not included out-of-pocket costs and indirect costs, such as administrative 
costs, loss of productivity and income, traveling costs and time and financial losses 
by family members. Therefore, it is expected that the actual total costs of screening 
will be higher than predicted in this study. Also in this study cost prices are used 
whereas reimbursement rates can be higher. Using higher costs would probably not 
significantly alter the ranking of the results. 
 
The sensitivity analysis showed large differences in cost-effectiveness between the 
highest and lowest utility estimates. A substantial part of this variation is caused by 
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the utility estimate for the post-recovery period, because the duration of this health 
state (the residual life) is around 10 years for most men. Long-term adverse effects 
from treatment influence the quality of life in the post-recovery period. Quality of 
life can also be affected more at younger ages than at older ages. However, data for 
the long-term quality of life after treatment are lacking. Most adverse effects 
affecting the urinary tract and bowel are relieved after some years, but significant 
symptoms persist in many patients up to 5 years after treatment [34-37]. In our base 
model we used a utility estimate of 1 for the time period more than ten years after 
diagnosis. The use of QALYs to weigh the harms and benefits has been discussed 
before [4]. Expressing harms and benefits in the same units has been proposed as 
ideal for providing the evidence base for practice guidelines [38]. When only life 
years gained are taken into account, the cost-effectiveness is comparable to the cost-
effectiveness using the highest utility estimates, and the optimal strategy would be 
screening from age 55-70 with 1 year intervals. 
 
The AUA recommends shared decision-making for men age 55 to 69 years that are 
considering PSA screening and does not recommend routine PSA screening in men 
over age 70 years or less than a 10-15 year life expectancy [39]. AUA also 
recommend a routine screening interval of two years or more to be preferred over 
annual screening. Our analysis shows that screening over age 60 years is already 
less favorable at population level. When screening with 2 year intervals would be 
stopped at age 59 instead of 69 years, 5 deaths less will be averted but 38 less men 
will be overdiagnosed, leading to 25 QALYs gained less per 1000 men. Although 
the AUA and physicians may be reluctant to not recommending screening and 
shared decision making on the individual level for 60-69 year old men, this analysis 
provides further evidence of the benefit of going to two year screening intervals.  
 
Our results are more in favor of screening than the report of the USPSTF, 
recommending against PSA screening [40]. This evaluation was based on a small 
and inconclusively proven effect of screening, by just summing all prostate cancer 
screening trials including the PLCO trial, and substantial and well established 
harms. The PLCO trial had substantial contamination in the control arm [41], 
negatively effecting the power of the trial, and therefore we based our study on the 
ERSPC trial. 
 
In conclusion, this analysis based on the largest randomized trial on prostate cancer 
screening suggests that PSA-based screening can be cost-effective, when it is 
limited between ages 55 and 60 with intervals of 1 or 2 years. It might be more cost-
effective to screen repeatedly between age 55 and 60 with intervals of 1 or 2 years, 
than using longer intervals until older ages.  
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Abstract 
 
Background: Harms and benefits of cancer screening depend on 
age and comorbidity, yet reliable estimates are lacking. 
 
Objective: To estimate the harms and benefits of cancer 
screening by age and comorbidity to inform decisions about 
screening cessation.  
 
Design: Collaborative modeling with seven well-established 
cancer simulation models and common data on average and 
comorbidity level-specific life expectancy from SEER-Medicare.  
 
Setting: US population. 
 
Patients: US cohorts aged 66-90 years in 2010 with average 
health or one of four comorbidity levels (linked to specific 
conditions): none, mild, moderate, or severe. 
 
Intervention: Mammography, prostate-specific antigen testing, 
or fecal immunochemical testing.  
 
Measurements: Lifetime cancer deaths prevented and life-years 
gained (benefits); false-positive tests and overdiagnosed cancers 
(harms). For each comorbidity level: the age at which harms and 
benefits of screening were similar to that for individuals with 
average health undergoing screening at age 74. 
 
Results: Screening 1000 women with average life expectancy at 
age 74 for breast cancer resulted in 79-96 (range across models) 
false-positives, 0.5-0.8 overdiagnosed cancers, and 0.7-0.9 breast 
cancer deaths prevented. While absolute numbers of harms and 
benefits differed across cancer sites, the ages at which to cease 
screening were highly consistent across models and cancer sites 
when based on harm-benefit ratios comparable to screening 
average-health individuals at age 74. For individuals with no, 
mild, moderate, and severe comorbidities, screening until ages of 
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76, 74, 72, and 66, respectively, resulted in similar harms and 
benefits as for average-health individuals.  
 
Limitations: Comorbidity only influenced life expectancy. 
 
Conclusion: Comorbidity is an important determinant of harms 
and benefits of screening. Estimates of screening benefits and 
harms by comorbidity can inform discussions between providers 
and their older patients about personalizing decisions about when 
to stop cancer screening. 
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Introduction  
 
The US Preventive Services Task Force (USPSTF) in 2008 recommended against 
routine breast and colorectal cancer screening after age 74 (1, 2) because the 
average gain in life-years associated with extending screening beyond age 74 was 
felt to be small in comparison to the harms. However, since comorbidity might shift 
the balance of harms and benefits towards cessation at younger or older ages than 
74, the USPSTF and other groups recommended that screening cessation decisions 
be individualized based on health status (1-4).  
 
There are over 13 million individuals between ages 75 and 85 in the US, and this 
number is expected to increase to more than 28 million by 2050 (5). Thus, clinicians 
will be caring for a large and growing number of individuals affected by the 
uncertainty in how to assess health status and make recommendations regarding 
screening upper age limits.  
 
There is considerable heterogeneity in the health of these older individuals, yet none 
of the current guidelines provide clinicians with data to implement personalized 
approaches. Previous decision analyses looking at health benefits of different cancer 
screening cessation ages by life expectancy (6, 7) have limited clinical utility 
because they did not provide a framework for determining life expectancy.  
 
To fill this gap, we estimated the harms and benefits of breast, prostate, and 
colorectal cancer screening by age based on individual comorbidity using 7 
established, independently developed models from the Cancer Intervention and 
Surveillance Modeling Network (CISNET).  
 
Methods 
 
We used microsimulation models to estimate the harms and benefits of attending 
one more cancer screen in regularly screened cohorts aged 66-90 by comorbidity 
level. The harms and benefits for each cohort were compared to that of an average-
health cohort attending one more screen at age 74.  
 
The Models 
 
The models used for this analysis are MISCAN-Fadia (MIcrosimulation SCreening 
Analysis – Fatal diameter) and G-E model (Georgetown-Einstein) for breast cancer; 
(8, 9) MISCAN-prostate and the FHCRC (Fred Hutchinson Cancer Research 
Center) model for prostate cancer; (10, 11) and MISCAN-Colon, CRC-SPIN 
(ColoRectal Cancer Simulated Population model for Incidence and Natural history), 
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and SimCRC (Simulating ColoRectal Cancer) for colorectal cancer (12-14).  
 
Each model simulates the life histories of individuals from birth to death and tracks 
underlying disease in the presence and absence of screening. These models have 
previously been applied to inform the USPSTF recommendations for breast and 
colorectal cancer screening (15, 16) and to evaluate prostate cancer screening and 
treatment interventions (17, 18). Using multiple models per cancer site provides a 
credible range of results and serves as a sensitivity analysis on the impact of 
variations in underlying model structure and assumptions (Supplementary 
Information Table 1).  
 
Briefly, screening extends life through detection of disease at an earlier stage or a 
smaller size when it may have better survival after treatment than in the absence of 
screening. Inputs were standardized across models within cancer site, including test 
characteristics, screening and follow-up assumptions, treatment distributions, and 
cancer-specific and other-cause survival. Sources for the model inputs have been 
described in prior publications (15, 16, 19).  
 
Descriptions of each model have been published elsewhere (8-14); model profiles 
are available (http://cisnet.cancer.gov/profiles/) and additional information about the 
models is available from the authors upon request. CISNET also includes 
procedures for external collaboration for interested investigators 
(http://cisnet.cancer.gov). Selected model outputs for 74-year old individuals who 
have average health (and life expectancy) and who had been screened regularly 
prior to age 74 are provided in Table 1. 
 
Population 
 
After assuming that all individuals underwent regular screening starting at age 50 
with biennial mammography, biennial prostate-specific antigen (PSA) testing, or 
annual fecal immunochemical testing (FIT), respectively, the models begin their 
simulation for US cohorts of individuals aged 66 to 90 years old in the year 2010 
who have average risk of cancer and a specified comorbidity level (none, mild, 
moderate, or severe) and follow these individuals for their remaining lifetime. For 
reference, we also simulated cohorts aged 74 years and 76 years (75 years for 
colorectal cancer) with average health and corresponding average life expectancy. 
We assumed that comorbidity influenced non-cancer life expectancy but not cancer 
risk or progression, treatment, or cancer-specific survival.   
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Table 1. Selected clinical model outputs for 74-year old individuals who have average 
health (and life expectancy) and who had been screened regularly prior to age 74, in 
the presence and absence of screening at age 74. 
 Breast Cancer Prostate Cancer Colorectal Cancer 
 MISCAN-
Fadia 
G-E model MISCAN-
Prostate  
FHCRC 
Prostate 
MISCAN-
Colon 
CRC-
SPIN 
SimCRC 
Lifetime probability of 
developing cancer 
without screening at 
age 74 
6.9% 8.2% 7.9% 4.7% 1.9% 1.3% 1.1% 
Lifetime probability of 
developing cancer with 
screening at age 74 
7.2% 8.4% 9.8% 6.1% 1.8% 1.2% 1.0% 
Prevalence of 
undiagnosed cancer 
immediately before a 
screening at age 74 
9.3%* 1.14% 4.4% 13.3% 0.19% 0.06% 0.09% 
Prevalence of 
undiagnosed cancer 
immediately after a 
screening at age 74 
8.2%* 0.09% 1.0% 11.3% 0.06% 0.02% 0.05% 
* The large difference in undiagnosed cancers between the models reflect differences 
in modeling approach. MISCAN-Fadia includes cancers from a very small tumor size 
(0.1 mm) not yet detectable by mammography. 
MISCAN: Microsimulation Screening Analysis; Fadia: Fatal diameter; G-E: 
Georgetown-Einstein; FHCRC: Fred Hutchinson Cancer Research Center; CRC-
SPIN:ColoRectal Cancer Simulated Population model for Incidence and Natural 
history; SimCRC: Simulating ColoRectal Cancer     
 
 
Comorbidity-specific life tables 
 
Non-cancer life expectancy was derived from comorbidity scores for 16 conditions 
derived from claims from a random 5% sample of non-cancer beneficiaries 
continuously enrolled with Medicare Parts A and B from 1992 to 2005 and residing 
in the Surveillance Epidemiology, and End Results (SEER) areas (20, 21, 22). Cox 
proportional hazard methods were used to estimate non-cancer age-conditional life 
tables for each gender and age combination using comorbidity as a covariate.  
 
Comorbidity was then grouped into four levels: none, mild, moderate, and severe, 
each with its own life expectancy at a given age (Table 2). We used the weighted 
average of the comorbidity-specific life tables for the reference average-health 
cohorts.  We extrapolated beyond the 13 years of available data by assuming that 
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mortality rates converged abruptly to average US rates after that period. This is a 
conservative assumption for personalizing age of screening cessation because life 
expectancy is overestimated for those with moderate and severe comorbidity and is 
underestimated for those with no or mild comorbidities.  
 
 
Table 2 Overview of comorbidity levels, associated conditions, and life expectancies 
at ages 68, 74 and 78 years 
Comorbid
group 
% of 
popula
tion at 
age 74 
Conditions included* HR† Life 
expectancy at 
age 68 
Life 
expectancy at 
age 74 
Life 
expectancy at 
age 78 
M W M W M W 
No  69% None 1 16.6 19.3 13.1 15.1 10.7 12.4 
Mild  2% History of MI, acute 
MI, ulcer or 
rheumatologic disease 
1.01
-
1.38 
15.4 17.1 12.5 13.1 9.8 10.9 
Moderate  12% (Cardio-)vascular 
disease; paralysis; 
diabetes; or 
combinations of 
diabetes with MI, 
ulcer, or 
rheumatologic disease 
1.39
-
1.66 
14.4 16.3 11.0 12.4 8.6 9.9 
Severe  17% AIDS; COPD; mild or 
severe liver disease; 
chronic renal failure; 
dementia; congestive 
heart failure; or 
combinations of 
aforementioned 
diseases not 
categorized under 
moderate comorbidity 
≥  
1.67 
10.8 13.3 8.1 9.8 6.4 7.7 
Average 
health  
100% All 
   11.9 13.9   
HR: Hazard ratio; y year; MI myocardial infarction; AIDS Acquired Immune 
Deficiency Syndrome; COPD chronic obstructive pulmonary disease 
* Any one of the conditions listed places an individual in the associated comorbidity 
level in the first column of the table and its life expectancy at age 68, 74 or 78. 
Conditions included are those that affect life expectancy. See Appendix Table 2 for 
life expectancies at other ages. See Appendix Table 3 for ICD-09 codes for the 
conditions.  
† Hazard ratio for all-cause mortality compared to no comorbidity for the conditions 
included in each comorbidity level 
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Analysis 
 
For each cohort, we estimated the benefits and harms of screening at their current 
age. Diagnostic follow-up was based on current recommendations (breast and 
colorectal) or practice (prostate). Screening benefits were expressed as the life-years 
gained (LYG) and cancer deaths prevented (CDP) for every 1000 individuals 
screened at a given age. Harms were expressed as the false-positive tests and 
overdiagnosed cancers (i.e., cancer that would not have caused symptoms during an 
individual’s lifetime) per 1000 individuals screened.  
 
The balance between harms and benefits was expressed as the number needed to 
screen to gain one life-year (NNS/LYG). For reference, we also determined, for 
each comorbidity level, the age at which the harms and benefits of screening 
(NNS/LYG) were similar to screening the average-health population at age 74.   
 
Sensitivity Analysis 
 
We varied our method for extrapolating comorbidity-specific life tables by 
assuming that the hazard ratio between the average-health life table and the 
comorbidity-specific life table at the 13th year of observation was maintained until 
death. For colorectal cancer, we also estimated the harms and benefits of 
colonoscopy screening by age and comorbidity level.   
 
Results 
 
Screening Based on “Average” Comorbidity Level 
  
At age 74, the average life expectancy for women across all comorbidity groups is 
13.9 years. Screening 1000 women for breast cancer who have average health (and 
life expectancy) and who had been screened regularly prior to age 74 resulted in 79-
96 false-positive tests (range across models) and 0.5-0.8 overdiagnosed cancers 
(Table 3). On the benefits side, 0.7-0.9 cancer deaths would be prevented and 5.8-
7.6 life years gained (LYG), corresponding to 132-173 women that need to be 
screened at age 74 to gain one life-year.  
 
Screening 1000 women age 76 and older for breast cancer yields increased harms 
and decreased benefits. Specifically, 146-198 women needed to be screened at age 
76 to gain one life-year. The balance of harms and benefits for prostate and 
colorectal cancer screening were mostly comparable except for the rates of 
overdiagnosis, which were orders of magnitude (15-100+ times, depending on the 
model) higher for prostate cancer vs. breast or colorectal cancer screening.   
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Table 3. Benefits and harms of screening 1,000 regularly screened individuals at age 
74 or 76 (75 years for colorectal cancer) with average health, by cancer site and 
model 
Cancer site / model / 
age of screening 
Harms* Incremental benefits* Balance 
False-
positive tests 
Over-
diagnosed 
cancers 
Life-
years 
gained† 
Cancer 
deaths 
prevented 
NNS/LY
G 
NNS/CD
P 
Breast cancer 
MISCAN-Fadia 
   
74 years 79 0.8 7.6 0.9 132 1125 
76 years 77 1.0 6.9 0.9 146 1102 
G-E model    
74 years 96 0.5 5.8 0.7 173 1421 
76 years 96 0.6 5.1 0.7 198 1474 
Prostate cancer 
MISCAN-prostate 
   
74 years 116 19.7 6.6 1.2 150 830 
76 years 136 24.5 6.3 1.2 159 820 
FHCRC prostate cancer model    
74 years 242 14.5 6.1 0.8 165 1263 
76 years 268 16.2 5.1 0.7 197 1371 
Colorectal cancer 
MISCAN-Colon 
   
74 years 39 0.3 6.2 0.9 161 1118 
75 years 39 0.4 5.5 0.8 182 1218 
CRC-SPIN    
74 years 38 0.0 3.9 0.7 256 1518 
75 years 38 0.0 3.9 0.6 254 1629 
SimCRC    
74 years 38 0.1 4.9 0.8 227 1411 
75 years 38 0.1 4.3 0.7 258 1522 
* Results are per 1,000 individuals screened according to guidelines (breast and colorectal) or 
current practice (prostate) since age 50 
† One life-year gained per 1,000 individuals corresponds with 0.4 days gained per individual.  
NNS/LYG: Number needed to screen to gain 1 life-year; NNS/CDP: Number needed to screen 
to prevent 1 cancer death; MISCAN: Microsimulation Screening Analysis; Fadia: Fatal 
diameter; G-E: Georgetwon-Einstein; FHCRC: Fred Hutchinson Cancer Research Center; CRC-
SPIN:ColoRectal Cancer Simulated Population model for Incidence and Natural history; 
SimCRC: Simulating ColoRectal Cancer   
 
 
 
Screening by Comorbidity Level 
 
In individuals with no comorbidities (i.e., individuals with longer-than-average life 
expectancy), screening 1000 regularly screened women aged 74 resulted in fewer 
overdiagnosed breast cancers (0.3-0.5) and more cancer deaths prevented (0.8-1.0)  
and LYG (6.6-8.5) compared to women the same age with average health.  
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Consequently, the NNS/LYG of 117–150 was lower than that for the average-health 
population (Appendix Table 2). In fact, women with no comorbidities could be 
screened until age 76-78 and still yield a similar NNS/LYG as screening until age 
74 in the average-health population (Figures 1 and 2). The same result is obtained 
for prostate and colorectal cancer screening (Figure 1, Appendix Table 2). For the 
mild comorbidity group, screening for all three cancers at age 74 yielded similar 
harms and benefits as screening the average-health population (Figures 1 and 2, 
Appendix Table 2).  
 
In individuals with moderate comorbidity, screening at age 74 was considerably less 
favorable than in the average-health population at that age: overdiagnosed cancers 
were up to 15% higher, while cancer deaths prevented and LYG were up to 20% 
lower (Appendix Table 2). Screening those with moderate comorbidity at a median 
age of 72 (range 68-74) resulted in similar harms and benefits as screening the 
average-health population at age 74 (Figures 1 and 2, Appendix Table 2). Screening 
people with severe comorbidities for breast cancer at age 74 resulted in even more 
harms (1.3-1.9 overdiagnosed cancers) and fewer benefits (0.5-0.6 cancer deaths 
prevented; 3.5-4.5 LYG) (Appendix Table 2). In this group, screening at a median 
age of 66 (range 64–69) provided similar harms and benefits as screening the 
average-health population at age 74 (Figures 1 and 2, Appendix Table 2).    
 
Sensitivity Analysis 
 
If non-cancer mortality rates do not converge to average US rates after the 13 years 
of observed data, individuals with moderate and severe comorbidity could stop 
screening at even younger ages to have similar harms and benefits as screening the 
average-health population at age 74. ` 
 
For colonoscopy, screening to age 70 for those with no, mild, or moderate 
comorbidity provided similar harms and benefits as screening the average-health 
population at age 70 (the last colonoscopy screening age for an individual regularly 
screened since age 50); among those with severe comorbidity the balance is 
comparable at age 60 (Appendix Table 4).  
 
Discussion 
 
This is the first study to employ collaborative modeling to evaluate screening across 
three cancer sites. It systematically quantifies the balance of benefits and harms of 
screening older individuals for breast, prostate, and colorectal cancers by 
comorbidity level. The results are robust across models and cancer sites and indicate 
that comorbidity affects screening benefits and harms and decisions about ages of 
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screening cessation. These outcomes can directly inform individualized decisions 
about undergoing screening. Around 70% of the current US population aged 74 
have none of the comorbidities noted in recent analyses to influence life expectancy 
(20). Our results suggest that this group could continue to be screened until age 76 
and still have the same balance of benefits and harms expected from screening the 
average-health population until age 74.  However, the 13% of the US population 
aged 65 to 74 with severe comorbidity should stop screening at age 66 to have the 
same balance of benefits and harms as seen among average-health groups 
undergoing screening from ages 50 to 74.  
 
Our findings are consistent with and extend prior research addressing the upper age 
limits for cancer screening. For instance, Walter and Covinsky (7) found that 
screening for breast, cervical, and colorectal cancer until around age 60 for 
individuals in the lower quartile of population life expectancy has the same number 
needed to screen to prevent one cancer death as those with the median life 
expectancy at age 75. They also estimated that screening could be continued to age 
85 for those in the upper quartile of life expectancy (7). This range is consistent 
with but wider than our model projections of 66 to 76 based on number needed to 
screen per life-year gained. When we use cancer deaths prevented rather than LYG, 
our ranges were closer to those of Walter and Covinsky, although our maximal 
upper age limit was still lower since we considered individuals without 
comorbidities (70% of the population) and they used the upper quartile (25%) of 
life expectancy.  
 
A recent analysis looking at time lag to benefit after screening for breast and 
colorectal cancer suggests that screening for breast and colorectal cancer is most 
appropriate for patients with a life expectancy greater than 10 years (23). However, 
that study and others (6, 7, 24-29) provide little guidance on applying this 
framework in clinical practice, leaving it to clinical judgment to estimate life 
expectancy and individualize screening decisions. Several studies have investigated 
the relationship between comorbidity level and life expectancy (30-32) but do not 
address the question of how this relationship influences cancer screening. To date, 
only two analyses have directly related comorbidity level to cancer screening 
recommendations. One focused only on diabetes-related comorbidities and 
colorectal cancer screening (33) and one examined cardiovascular disease and 
breast screening (6). The current analysis is a multi-model collaborative analysis of 
three major cancers and includes a wider range of comorbidities than considered 
previously.  
  
There is considerable debate about the value of PSA screening. The USPSTF 
recently concluded that PSA screening results in little or no reduction in prostate 
cancer-specific mortality while leading to substantial prostate cancer overdiagnosis. 
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Based on these findings, the USPSTF recommends against routine prostate cancer 
screening. However, like other national guidelines panels (e.g., the ACS, the 
American Urological Association, the American College of Physicians), they 
recognized a role for screening in the context of appropriate patient-physician 
decision-making (34-37). Our modeling study provides clinicians with valuable 
information for such shared-decision making. Recent modelling studies indicate that 
overdiagnoses and unnecessary biopsies could be reduced by stopping prostate 
cancer screening at age 69, raising the PSA threshold for biopsy referral for men 
above this age, or restricting further screening to men with low comorbidity (17, 
18). Our results confirm these results and underscore that overdiagnosed cancers 
detected via PSA screening are orders of magnitude higher than for breast or 
colorectal cancer screening. If personalized PSA screening strategies achieve a 
sufficiently favorable balance of outcomes, our results advocate tailoring of 
screening cessation according to comorbidity-based life expectancy.  
 
Our results provide clinicians with data for use in informed decision-making 
discussions about who might consider continuing screening and for how long. For 
example, if a clinician is meeting with a regularly-screened 70-year old patient with 
COPD, our results indicate that this individual falls in the severe comorbidity level 
and, depending on patient preferences, the benefits of screening may no longer 
outweigh the potential harms. However, a 76-year old individual with no 
comorbidities might consider attending another screen. The final decision about 
screening should depend on individual patient preferences.  Prevention of death 
from cancer is one outcome to consider, but some patients may be more concerned 
with impact on other outcomes such as quality of life or functional independence. 
Individuals may also prefer to be detected at earlier stages when less intensive 
treatment may be needed, compared to somewhat later diagnosis and more 
aggressive therapy, even if survival is unchanged. In such a situation, a healthy 
patient may choose to continue (for example) breast cancer screening up to age 80, 
where the mortality benefit is small, but early detection can find the cancer early 
when less aggressive treatment is required.    
 
The fact that comorbidity-specific conclusions about age-specific benefits and 
harms differ meaningfully from those included in clinical guidelines highlights the 
tension between the need to provide public health recommendations for the general 
population and the potential advantages of using a more personalized approach. Our 
suggested approach of continuing screening in the healthy and earlier cessation in 
the sickest individuals does not increase the number of screens required in the 
population but rather leads to a more efficient allocation of resources, increasing the 
benefit and decreasing the harms to the growing older population (38). The age-, 
gender-, and comorbidity-specific life expectancies used for these analyses also 
provide clinicians and the general screening-eligible population with a foundation 
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for discussing preferences for benefits and harms, facilitating individual decision-
making.  
 
The testing intervals for colorectal and breast cancer were chosen according to the 
latest USPSTF guidelines, but our conclusions can be generalized to other intervals. 
The screening cessation ages are determined in relation to screening the average-
health population up to age 74. When choosing a different screening interval, such 
as annual mammography for breast cancer, the benefits and harms will be different 
for screening the average-health population at age 74. The benefits and harms by 
comorbidity level will change accordingly, such that the optimal screening cessation 
age by comorbidity remains the same.   
 
Despite the innovation and strengths of our approach, there are several caveats that 
should be considered in evaluating our results. First, we chose the balance of harms 
and benefits as our primary metric. We did not explicitly consider complications 
from screening and diagnostic follow-up as harms, but these would be proportional 
to the number of (false-positive) screening tests. Costs per quality-adjusted life-year 
gained are another common metric used in many countries, but this is not widely 
accepted in the US (39-43). Second, we assumed that comorbidity level only 
influenced life expectancy and not cancer risk or biology. Health conditions such as 
diabetes are known to be associated with obesity and other lifestyle factors (44) 
which, in turn, can be associated with improved mammography performance (45) 
and elevated breast (46-48) or reduced prostate (49) cancer risk. Conversely, 
adverse events of screening, such as perforations with colonoscopy, are also 
associated with comorbidities (50).  
 
In the future, it will be important to extend our work to capture the known impact of 
specific comorbidities on other model parameters. For now, competing non-cancer 
mortality is the single most germane parameter in screening decisions for the oldest 
age groups so that our conclusions should be robust (27). Third, we only estimated 
harms and benefits of screening by comorbidity for people aged 66 years and older 
because life expectancy estimates by comorbidity were obtained from SEER-
Medicare data. 
  
Next, we only considered individuals regularly screened since age 50 to 
demonstrate how current screening recommendations could be adapted based on 
comorbidity level. In general, stopping ages are higher in individuals who are 
unscreened or have skipped previous screening rounds because they have a higher 
risk of prevalent cancer. Furthermore, the models used life tables based on non-
cancer cases and, therefore, do not include cancer-specific mortality for cancers 
other than the one targeted by screening. This underestimates the true rate of 
competing other-cause mortality, and therefore the harm-benefit ratios, but does not 
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affect our internal comparisons of comorbidity level groups to the average-health 
population. Finally, we did not consider situations in which the comorbidity level 
decreased (e.g., from severe to moderate level) after the age of screening cessation. 
Given the chronic nature of the comorbid conditions in older ages, this is a 
reasonable assumption. 
 
Overall, the results across models and cancer sites were very robust and strongly 
suggest that the age of screening cessation based on comorbidity levels varies by 
nearly a 10-year interval around the age cut-point of 74 included in current breast 
and colorectal cancer screening recommendations.  Our data on common chronic 
health conditions and their associated comorbidity level, together with model 
projections of screening benefits and harms at each of these comorbidity levels, can 
inform discussions between providers and their older patients about personalizing 
decisions about when to stop cancer screening.  
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Supplementary Information 
 
Table 1. Summary of model features by cancer site and model 
 Breast Cancer Prostate Cancer Colorectal Cancer 
 MISCAN-Fadia G-E 
model 
MISCAN-
Prostate  
FHCRC 
Prostate 
MISCAN-
Colon 
CRC-
SPIN 
SimCRC 
Modeling 
software 
Borland  
Delphi 
C++ Borland  
Delphi 
C Borland  
Delphi 
Microsoft 
C# 
Microsoft 
Visual C++ 
2010 
Express  
Includes pre-
cancers * 
Yes Yes No No Yes Yes Yes 
Includes 
tumor 
biomarkers † 
Yes Yes Yes Yes No No No 
Calibrated to 
incidence?  
Yes Yes Yes Yes Yes Yes Yes 
Calibrated to 
mortality? § 
No No No No No No No 
How 
treatment 
affects 
mortality  
Cure fraction Hazard 
reducti
on 
Hazard 
reduction 
Hazard 
reduction 
Not 
explicitly 
modeled ‡ 
Not 
explicitly 
modeled ‡ 
Not 
explicitly 
modeled ‡ 
How 
screening 
affects 
mortality 
Cancer diameter 
shift, age-shift 
Stage-
shift, 
age-
shift 
Cure fraction Stage-shift, 
age-shift 
Stage-shift, 
age-shift 
Stage-shift, 
age-shift 
Stage-shift, 
age-shift 
* Pre-cancers include ductal carcinomas in situ for breast cancer and adenomas for 
colorectal cancer.  
† Tumor biomarkers include estrogen receptor / human epidermal growth factor 2 
status for breast cancer, and prostate-specific antigen level and Gleason score for 
prostate cancer 
‡ The models use the latest relative survival estimates from SEER to model the 
probability of dying from colorectal cancer 
§ The models use incidence and relative survival estimates to match observed 
mortality 
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Table 2a. Benefits and harms of screening 1,000 regularly screened individuals by 
age and comorbidity – MISCAN-prostate for prostate cancer. 
 
Comorbidity 
/ age of 
screening  
Life-
expectancy 
(years) 
Harms* 
Incremental 
benefits* 
Balance 
False-positive 
tests 
Over-
diagnosed 
cancers 
Life-years 
gained† 
Cancer 
deaths 
prevented† 
  
NNS/LYG† 
NNS/CDP† 
No 
comorbidity 
    
66 17.8 69.2 8.6 8.7 1.1 115 885 
68 16.6 76.0 10.0 8.3 1.2 120 843 
70 15.5 82.7 11.5 7.9 1.2 127 831 
72 14.4 95.3 14.2 7.5 1.3 133 796 
74 13.1 116.3 18.4 7.8 1.4 129 722 
76 11.9 135.7 22.9 7.4 1.4 135 704 
78 10.7 149.3 26.8 6.2 1.3 162 770 
80 9.6 157.5 29.9 5.0 1.1 199 877 
82 8.5 160.1 32.1 3.6 0.9 276 1073 
84 7.5 156.6 33.0 2.4 0.7 410 1463 
86 6.5 147.2 32.5 1.5 0.5 690 2116 
88 5.8 134.4 31.0 0.9 0.3 1143 3073 
90 5.1 118.9 28.3 0.5 0.2 1957 4718 
Mild 
comorbidity‡ 
 
    
66 16.7 69.2 9.2 7.9 1.0 126 967 
68 15.4 76.0 10.8 7.2 1.0 138 959 
70 14.6 82.6 12.1 7.1 1.1 140 904 
72 13.4 95.3 15.0 6.4 1.1 157 907 
74 12.5 116.3 19.0 7.0 1.3 142 775 
76  11.7 135.7 23.3 7.4 1.4 136 716 
78   9.8 149.3 28.0 5.0 1.1 198 900 
80  9.1 157.5 30.7 4.4 1.0 229 971 
82  8.3 160.1 32.5 3.1 0.9 320 1165 
84  7.3 156.6 33.4 2.4 0.7 422 1500 
86  6.2 147.2 33.0 1.3 0.4 768 2305 
88  5.7 134.4 30.9 0.8 0.3 1179 3042 
90  4.9 118.9 28.3 0.5 0.2 2091 4876 
 
 
 
 
 
 
 
 
 
 
 
 
C h a p t e r  4  | 85 
 
 
Table 2b. Benefits and harms of screening 1,000 regularly screened individuals by 
age and comorbidity – MISCAN-prostate for prostate cancer. 
 
Moderate  
comorbidity§ 
    
66  15.3 69.2 10.0 6.8 0.9 147 1108 
68  14.4 76.0 11.5 6.4 0.9 156 1072 
70  13.0 82.6 13.3 5.6 0.9 178 1113 
72  11.8 95.3 16.4 5.0 0.9 200 1109 
74  11.0 116.3 20.7 5.4 1.0 184 978 
76  9.7 135.7 25.7 4.8 1.0 207 1012 
78  8.6 149.3 29.7 3.8 0.9 266 1135 
80  7.7 157.5 32.9 2.9 0.8 342 1318 
82  6.7 160.0 35.1 2.0 0.6 495 1678 
84  6.0 156.6 35.6 1.4 0.4 709 2261 
86  5.4 147.2 34.3 1.0 0.3 1038 2929 
88  4.7 134.4 32.3 0.6 0.2 1734 4225 
90  3.9 119.0 29.8 0.3 0.1 3302 7065 
Severe 
comorbidity|| 
 
    
66  11.6 69.2 12.3 4.5 0.6 220 1621 
68  10.8 76.0 14.0 4.2 0.6 241 1598 
70  9.8 82.6 15.8 3.5 0.6 282 1688 
72  9.0 95.3 19.0 3.2 0.6 310 1652 
74  8.1 116.3 23.9 3.3 0.6 301 1551 
76  7.2 135.7 29.2 2.9 0.6 349 1593 
78  6.4 149.3 33.2 2.3 0.6 435 1778 
80  5.8 157.5 36.2 1.8 0.5 550 2028 
82  5.1 160.1 37.9 1.2 0.4 815 2658 
84  4.4 156.5 38.2 0.8 0.3 1208 3572 
86  4.0 147.2 36.6 0.6 0.2 1801 4770 
88  3.4 134.4 34.3 0.3 0.1 3321 7404 
90  3.1 119.0 30.7 0.2 0.1 5017 10382 
 
NNS/LYG: Number needed to screen to gain 1 life-year; NNS/CDP: Number needed to screen 
to prevent 1 cancer death 
Shaded row represents the age for each comorbidity group at which screening provided similar 
harms and benefits as screening at age 74 in the entire population 
 
* Results are per 1,000 individuals screened according to current practice since age 50 
† Irregular pattern by age is caused by stepwise increase in onset of prostate cancer by age 
 
‡ Mild comorbidity includes having a life expectancy associated with having a history of MI, 
acute MI, ulcer, or rheumatologic disease  
§ Moderate comorbidity includes having a life-expectancy associated with having vascular 
disease, cardiovascular disease, paralysis or diabetes, or combinations of diabetes with MI, 
ulcer, or rheumatologic disease 
|| Severe comorbidity includes having a life expectancy associated with having AIDS, COPD, 
mild liver disease, severe liver disease, chronic renal failure, dementia, or congestive heart 
failure, or combinations of aforementioned diseases not categorized under moderate 
comorbidity
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter Five 
 
Is prostate cancer different in 
black men? Answers from 
three natural history models 
 
 
 
Alex Tsodikov,  Roman Gulati, Tiago M. de Carvalho, 
Eveline A. M. Heijnsdijk,  Rachel A. Hunter-Merrill,              
Angela B. Mariotto, et al. 
 
Accepted for publication in Cancer 
 
 
Reproduced with authorization from Wiley-Blackwell 
 
© 2017 American Cancer Society 
 
 
88 | P r o s t a t e  C a n c e r  i n  B l a c k  M e n  
 
 
Abstract 
 
Background: Black men in the US have substantially higher 
prostate cancer incidence rates than the general population. The 
extent to which the incidence disparity is due to prostate cancer 
being more prevalent, more aggressive, and/or more frequently 
diagnosed in black men is unknown. 
 
Methods: We estimated three independently developed models of 
prostate cancer natural history in black men and in the general 
population using an updated reconstruction of PSA screening, 
based on the National Health Interview Survey in 2005, and 
prostate cancer incidence from the Surveillance, Epidemiology, 
and End Results program in 1975–2000. Using the estimated 
models, we compared prostate cancer natural history in black 
men and in the general population. 
 
Results: The models projected that 31–45% (range across models) 
of black men develop preclinical prostate cancer in their lifetime, 
a risk that is (relatively) 24–54% higher than in the general 
population. Among men who have had preclinical disease onset, 
black men have a similar risk of diagnosis compared with the 
general population, but their risk of progression to metastatic 
disease by the time of diagnosis is 38–75% higher than in the 
general population. 
 
Conclusions: Prostate cancer incidence patterns implicate 
higher incidence of preclinical disease and higher risk of 
metastatic progression among black men. The findings suggest 
screening black men earlier than white men and support further 
research into the benefit-harm tradeoffs of more aggressive 
screening policies for black men.  
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Introduction 
 
Prostate cancer is the most frequent cancer diagnosis and the second leading cause 
of cancer death in US men. Black men in the US have significantly higher prostate 
cancer incidence and mortality than white men, but reasons for this disparity are 
unclear. Some studies1, 2 have suggested that differential access to care may partially 
explain the greater burden of disease in blacks, but others have concluded that 
differences in outcomes are more plausibly attributed to biologic differences.3-5 
 
There is no question that the higher prostate cancer mortality in black men is at least 
partially due to their increased incidence of disease.6 What is not known, however, 
is whether the higher observed incidence in black men arises from a higher risk of 
disease onset or faster progression to an aggressive or symptomatic state. In their 
multi-ethnic study of UK men, Metcalfe et al.7 suggested that the latter is unlikely; 
however, they do not formally interrogate this hypothesis. 
 
Understanding whether and how natural history might be different in black men is 
important because, if black men have a higher susceptibility to prostate cancer 
and/or a greater tendency to develop aggressive disease, it may be of value to 
consider different screening policies for them. This issue was raised by Powell et 
al.,8 who recommended aggressive screening of black men beginning at age 40 
based on a narrowing of prostate cancer survival disparities observed following the 
adoption of PSA screening in the US. 
 
We previously studied the natural history of prostate cancer in the general 
population via statistical and computer modeling of latent disease onset and 
progression to clinical and metastatic states.9-11 By calibrating the models to 
observed population patterns of prostate cancer incidence before and after the 
advent of PSA screening, we estimated the risks of critical events in disease natural 
history and used these results to make inferences about potential impacts of 
different screening policies.12, 13 
 
In this article, we develop versions of our natural history models that pertain to 
black men and calibrate these using incidence trends in the Surveillance, 
Epidemiology, and End Results (SEER) program under updated PSA screening 
frequencies estimated specifically among the black population. We use the 
calibrated models to produce estimates of disease onset, progression, and diagnosis 
risks that pertain to the black population. We compare these risks with estimates for 
the general population (i.e., all races) to determine the extent to which the increased 
incidence among black men is explained by higher risks of disease onset, 
progression, or diagnosis. Finally, we use our results to motivate consideration of 
differential screening policies among black men. 
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Methods 
 
In this section, we describe the data and three models that we use to examine 
evidence of differential prostate cancer natural history in black men. We also 
describe a test for differences in black natural history relative to the general 
population and quantify the models’ goodness-of-fit after re-estimating key 
components of natural history. 
 
PSA screening and prostate cancer incidence data 
 
Because population-based PSA screening utilization was not tracked in real time, 
we retrospectively reconstructed PSA screening patterns in the US separately for 
black and white men in a previous study.14 Briefly, this reconstruction used 
responses to the National Health Interview Survey (NHIS) in 2000 to estimate the 
age at first PSA test, and longitudinal claims data from the linked SEER-Medicare 
database to estimate the distribution of inter-screening intervals. We updated this 
model of PSA screening patterns using responses to the NHIS in 2005, which 
moderately reduced the uptake of first PSA tests in the 1990s among the oldest age 
groups relative to our previous analysis.14 
 
We extracted prostate cancer incidence data from the SEER database before and 
after the introduction of PSA screening. Specifically, we extracted prostate cancer 
incidence for ages 50–84, years 1975–2000, SEER historic stages local-regional and 
distant, tumor grade well or moderately differentiated (low-grade) versus poorly 
differentiated or undifferentiated (high-grade), and race categories “black” or “all 
races.” Missing information on stage, grade, and race was assumed to be missing at 
random and imputed as the most frequent combination of 20 logistic regression 
imputations using the mice package in R.15 
 
Three models of prostate cancer natural history 
 
We estimated three models of prostate cancer natural history using PSA screening 
and prostate cancer incidence data separately for black men and for all races. The 
three models were previously used to study effects of PSA screening on incidence 
and mortality trends in the general US population.16, 17 
 
Briefly, the FHCRC model is a microsimulation model that links individual PSA 
growth and cancer progression. In this model, higher and increasing PSA levels are 
associated with the presence of latent cancer and shorter intervals to metastatic 
spread and clinical presentation. The MISCAN model is a microsimulation model 
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that tracks progression through combinations of cancer stages and grades. In this 
model, advanced stages and higher grades are associated with potentially higher 
screening test sensitivity and shorter intervals to clinical presentation. The UMICH 
model is an integrated suite of analytic models that estimates transition probabilities 
from earlier to later stages and from lower to higher grades during the preclinical 
detectable phase. In this model, a later stage at onset, a higher grade at onset, and 
faster progression are each associated with shorter intervals to clinical presentation. 
In each model, screening potentially detects latent cancer at an earlier stage and/or 
grade. Key differences between models are the length of the preclinical detectable 
phase, how much early detection improves tumor characteristics, and how both 
natural history and screening effects depend on age. 
   
A framework to explain incidence disparities 
 
Sequential estimation 
 
We first re-estimated natural history in all races using the SEER incidence and 
updated PSA screening data. Then, we re-estimated natural history in black men 
following a systematic sequence of steps. First, we substituted PSA screening 
patterns for black men. Then we re-estimated components of disease natural history, 
each containing a specific block of parameters. The blocks of parameters governed 
(a) risk of disease onset and initial tumor features, (b) risks of progression to 
metastasis and/or high-grade disease, and (c) risk of clinical diagnosis. At each step, 
the re-estimation involved identifying values of the natural history parameters that 
allowed the models to most closely match SEER prostate cancer incidence in black 
men. All models proceeded in this sequential fashion until final versions of the 
models were obtained that re-estimated all natural history parameters for black men. 
 
Natural history summary measures 
 
Given the final versions of the models for black men and for all races, we 
summarized natural history in terms of lifetime risks of preclinical onset, clinical 
diagnosis, and metastatic clinical diagnosis; mean ages at these natural history 
events; and mean years between consecutive events. 
 
Testing and quantifying contributions to incidence disparities 
 
We used a likelihood ratio test to evaluate whether re-estimating components of 
disease natural history significantly improved the models’ fits to the incidence data 
for black men. The likelihood uses age at diagnosis as a survival time and is fit via a 
customized age-period approach.11 To calculate likelihood ratio statistics, two 
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likelihood functions are fit, one with and one without re-estimation of the 
component. While we report the likelihood ratio test results, we anticipate that, 
given the large sample size in the SEER registry, all tests will be highly significant 
at a traditional threshold. Therefore, we also report the improvement in the 
goodness-of-fit achieved by re-estimating components of natural history, with 
goodness-of-fit expressed as the sum across years of the squared difference between 
annual model-projected and observed age-adjusted incidence rates. 
 
Results 
 
Figure 1 illustrates the annual percentage of men ages 50–84 who received at least 1 
PSA test by race and age group over the period 1988–2000 using responses from the 
NHIS in 2005. Relative to previous estimates using responses from the NHIS in 
2000,14 we find that younger men received more tests, particularly in the late 1990s, 
and older men received fewer tests; these differences were similar among black men 
and all races. The updated screening patterns indicate that, relative to the general 
population, modestly lower percentages of black men received at least 1 PSA test in 
all but the youngest ages throughout the 1990s. The greatest racial disparities in 
PSA testing were in the oldest ages. 
 
Figure 1. Annual percentage of men receiving at least 1 PSA test based on the 
updated reconstruction of PSA screening patterns in the US. 
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Figure 2 shows the results of re-estimating natural history for all races. The figure 
shows age-adjusted prostate cancer incidence rates per 100,000 men ages 50–84 
reported in SEER by historic stage and corresponding model-projected incidence 
rates. Figure 2 also shows SEER incidence rates for black men and results of the 
sequential estimation of the models’ natural history components. The sequential 
estimation found that allowing the risk of disease onset to be different for black men 
provided an immediate improvement in the models’ fits to incidence in this 
population. Allowing the risk of progression to distant stage to be different 
produced higher distant-stage but similar local-regional stage incidence projections.  
And also allowing the risk of clinical diagnosis to differ in black men provided 
modest improvements to the fit in some cases (e.g., distant-stage incidence in the 
FHCRC model). 
 
Figure 2. Age-adjusted prostate cancer incidence rates per 100,000 men ages 50–84 
years for black men (black line) and all races (gray line) and corresponding 
projections by three models (colored lines). Model projections are based on the 
models estimated for all races combined with PSA screening in black men and 
sequentially re-estimating components of natural history to allow differential risk of 
onset of preclinical cancer (“Onset”), risk of progression to metastasis and/or higher 
grade (“Onset-Progression”), and risk of clinical diagnosis (“Onset- Progression-
Diagnosis”). 
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Improvements from re-estimating each block of natural history parameters were 
highly statistically significant from likelihood ratio tests (all P < 0.0001), and the 
final models’ fits to stage-specific incidence were substantially improved by re-
estimation of the natural history components. Table 1 shows that sums of squared 
differences between observed and projected age-adjusted incidence rates declined 
dramatically once disease onset was re-estimated, confirming the importance of 
disease onset risk in explaining incidence disparities. All models obtained the best 
fits (i.e., smallest errors) when all parameter blocks were re-estimated. 
 
 
Table 1. Squared differences between age-adjusted prostate cancer incidence rates 
per 100,000 men ages 50–84 years for black men and corresponding model 
projections, summed across years 1975–2000. Model projections are based on the 
models estimated for all races combined with PSA screening in black men (“Black 
screening”) and sequentially re-estimating components of natural history to allow 
differential risk of onset of preclinical cancer (“Onset”), risk of progression to 
metastasis and/or higher grade (“Onset-Progression”), and risk of clinical diagnosis 
(“Onset-Progression-Diagnosis”). 
 
Run FHCRC MISCAN UMICH 
Black screening 287160 271140 340010 
Onset 41130 18340 38960 
Onset-Progression 121280 23180 30360 
Onset-Progression-Diagnosis 39250 18670 18010 
 
 
 
Table 2 summarizes natural history measures among black men and for all races 
estimated by the three final models. In the general population, the lifetime risk of 
developing preclinical disease is 25–29% (range across models). In black men, 
however, these risks rise to 31–45%, reflecting risks that are (relatively) 24–54% 
higher than the general population. According to the models, the risk of clinical 
diagnosis in black men is 25–66% higher than the general population; the 
corresponding observed risk in SEER prior to the advent of PSA screening was 53% 
higher in black men than white men (range 42%–62% higher) over the period 1975 
to 1986. Among men who have had disease onset, the risk of clinical diagnosis is 
comparable for blacks (39–88% across models) and all races (36–85% across 
models), and this translates into sojourn times from disease onset to diagnosis that 
are very similar for black men and the general population. However, among men 
with preclinical disease, the models estimate a 38–75% higher risk of metastasis 
before diagnosis among black men, reflecting greater risk of progression in this 
population. 
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Table 2. Natural history summary measures for black men (Blacks) and for all races 
(All) projected by the three models. Lifetime risks are given as percentages; mean 
ages and durations are given in years. 
Measure 
FHCRC MISCAN UMICH 
Blacks All Blacks All Blacks All 
Lifetime risk of onset 45 29 31 25 37 29 
Lifetime risk of clinical diagnosis 17 10 15 12 33 24 
Lifetime risk of metastatic clinical 
diagnosis 
5 2 4 3 4 2 
Lifetime risk of clinical diagnosis 
given onset 
39 36 48 47 88 85 
Lifetime risk of metastatic clinical 
diagnosis given onset 
10 6 14 10 12 7 
Mean age at onset 58 60 65 68 65 66 
Mean age at clinical diagnosis 73 74 72 74 80 81 
Mean age at metastatic clinical 
diagnosis 
73 75 73 76 74 74 
Mean years from onset to clinical 
diagnosis 
19 18 10 10 17 18 
Mean years from onset to 
metastatic clinical diagnosis 
16 16 12 13 16 21 
Lifetime risk of PSA or clinical 
diagnosis* 
18 11 20 17 33 24 
Lifetime risk of PSA or clinical 
diagnosis given onset* 
41 39 66 68 88 85 
Mean age at PSA or clinical 
diagnosis* 
72 73 70 72 78 80 
Mean years from PSA to clinical 
diagnosis* 
7 7 8 9 7 7 
* These measures are in the presence of modeled PSA screening patterns in 1987–
2000 and are included for reference. 
 
 
Discussion 
 
The observation that prostate cancer is more frequent and more lethal among black 
men than among white men has never been fully explained. Our study uses three 
models9-11 previously calibrated to US population incidence trends. After updating 
the frequency of PSA testing and re-estimating these models for all races, we 
substituted PSA testing frequencies among black men into the models for all races 
and then systematically explored re-estimating individual components of disease 
natural history to fit disease incidence patterns in this population. The model results 
consistently showed that the risk of onset of a preclinical prostate cancer explains a 
large majority of the observed incidence disparities. Additional improvements 
achieved by re-estimating other natural history components produced moderate 
additional improvements in reproducing overall observed incidence among black 
men but yielded noticeable improvement in reproducing observed advanced-stage 
incidence. Estimation of natural history summaries based on the full race-specific 
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models confirmed that, in addition to the risk of onset, the risk of progression to 
metastatic disease before clinical diagnosis was higher among black men, but the 
risk of clinical diagnosis was not higher than in the general population. 
 
Based on these results, we conclude that black men have more preclinical and 
progressive prostate cancer than the general population. They are more likely to 
develop prostate cancer at a younger age, and they are more likely to progress to a 
metastatic state and/or higher grade before clinical diagnosis. Their higher risk of 
progression agrees with a previous study based on autopsy and surgical pathology 
data4 that concluded that black men had an earlier transformation to clinically 
significant cancer than white men. This study found similar age-specific prevalence 
of prostate cancer among autopsies conducted in black and white men from the 
Detroit metropolitan area between 1992 and 2001. The study also found evidence of 
more aggressive disease in radical prostatectomy specimens from black men, 
consistent with their markedly higher incidence of metastatic disease at diagnosis. 
These findings led the authors to conclude that the risk of prostate cancer initiation 
did not differ by race, but the risk of disease progression was higher among black 
men. However, similar latent prevalence and greater metastatic clinical incidence of 
disease among black men is in fact only possible if latent incidence is also higher in 
this subgroup. For, if latent incidence is similar among black men but progression is 
faster, this would actually lead to lower latent prevalence at autopsy. Therefore, we 
conclude that the prior study results are in fact consistent with our finding that the 
risks of latent incidence and progression are likely both higher among black men. 
 
Our findings motivate explicitly considering more intensive screening, e.g., 
beginning earlier and/or screening more frequently among black men than among 
the general US population. Figure 3 shows the cumulative incidence of “relevant 
disease,” i.e., disease fated to present before other-cause death. At all ages, the 
cumulative incidence is higher for black men than for all races. At ages 46–52 
(range across models), the cumulative incidence among black men reaches the value 
estimated at age 55 among all races. Thus, if it is agreed that prostate cancer 
screening is worthwhile, and starting at age 55 is determined for the general 
population, our results suggest starting 3–9 years earlier for black men. 
 
We recognize that a consensus about general population screening is still lacking. 
The US Preventive Services Task Force18 recommends against routine prostate 
cancer screening in men of average risk, while the American Cancer Society19 
recommends shared decision making around prostate cancer screening beginning at 
age 50 and the American Urological Association20 provides similar guidance with a 
starting age of 55. However, black men are not average risk and the benefit-harm 
tradeoffs of screening are likely to be different for this population.21 
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Figure 3. Cumulative incidence of onset of preclinical prostate cancer that would be 
clinically diagnosed in black men and all races projected by the models. Line 
segments show ages at which black men have incidence corresponding to levels 
estimated at age 55 in all races. 
 
 
 
 
While starting at an earlier age is unlikely to impact overdiagnosis, other more 
aggressive screening policies, e.g., shortening intervals between screens or lowering 
the PSA threshold for biopsy referral, could increase risks of overdiagnosis.22 A 
comprehensive policy development process addressing whether and how best to 
screen black men will have to carefully weigh benefit-harm tradeoffs of candidate 
policies. Understanding race-specific natural history will be a critical pre-requisite 
for this important work. At this point, however, our findings do support starting 
screening at an earlier age in black men than in the general population. Powell et 
al.8 also recommend aggressive early prostate cancer PSA testing of African 
American men. Our work adds to theirs by providing a formal, quantitative 
justification for an age to initiate screening in black men. 
 
In practice, the policy development process will require going beyond examining 
incidence patterns to projecting mortality in the presence and absence of screening. 
Since screening benefit is contingent on access to efficacious therapies, benefits of 
screening in different race groups may be affected by any disparities in access to 
treatment and any racial differences in treatment efficacy. Future work will extend 
the models used in this article to project the downstream outcomes of different 
screening policies in black men under race-specific treatment distributions and 
efficacies. 
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Limitations of this study relate primarily to modeling assumptions and data 
limitations. While the use of multiple models provides some sense of robustness to 
the specific assumptions made, all models assume that disease is progressive. Thus, 
none of the models explicitly includes an indolent subpopulation, although each 
allows heterogeneity of disease progression with some cases progressing rapidly 
and others slowly. The FHCRC model allows the likelihood of developing high-
grade disease to vary with age but does not model grade progression; the other 
models allow both grade and stage progression. Other differences across models are 
also driven by differences in the conceptualization of onset and how the risk of 
onset depends on age. In the FHCRC model, onset refers to the latent incidence of 
disease that would be detectable by biopsy, which can occur as early as age 35, 
while in the MISCAN and UMICH models onset refers to the latent incidence of 
disease that can be detected based on elevated PSA and diagnostic workup, and this 
rarely occurs before age 40. Finally, the PSA screening rates used by all models are 
based on a retrospective reconstruction rather than a prospective tracking of prostate 
cancer screening dissemination in the US population. 
 
In conclusion, this study represents the first examination of how prostate cancer 
natural history must differ in black men to account for racial variation in patterns of 
disease incidence before and after the advent of PSA screening. We use observed 
patterns of disease incidence and screening to learn about key events in the latent 
process of disease by race. Our results provide quantitative information about the 
prostate cancer natural history that may justify exploring different screening 
policies among white and black men. In pursuit of policies that will reduce 
disparities in disease outcomes, it may ultimately be necessary to intervene with 
greater intensity among population subgroups at higher risk. 
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Abstract  
 
Objective: To estimate the increase in prostate cancer mortality 
(PCM) and the reduction in overtreatment resulting from 
different Active Surveillance (AS) protocols, compared to treating 
men immediately.   
 
Subjects and Methods: We use a microsimulation model 
(MISCAN-Prostate), with natural history based on ERSPC data. 
We estimate probabilities of referral to radical treatment while on 
AS, depending on disease stage, with data from Johns Hopkins 
AS cohort. We sample 10 million men representative of the US 
population and we project the effects of applying AS protocols 
differing by time between biopsies, compared to treating men 
immediately.  
 
Results: AS with yearly follow-up biopsies for low-risk patients  
(≤ T2a-stage and Gleason 6) increases the probability of PCM to 
2.6% (1% increase) and reduces overtreatment from 2.5% to 2.1% 
(18.4% reduction). With biopsies every three years after the first 
year, PCM increases by 2.3% and overtreatment reduces from 
2.5% to 1.9% (30.3% reduction). Including intermediate-risk men  
(> T2a-stage or Gleason 3+4) in AS increases PCM by 2.7% and 
reduces overtreatment from 2.5% to 2.0% (23.1% reduction). 
These results may not apply to African-American men. 
 
Conclusions: Offering AS for low-risk patients is relatively safe. 
Increasing the biopsy interval from yearly to up to every 3 years 
after the first year will significantly reduce overtreatment among 
low-risk men, with limited PCM risk.   
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Introduction 
 
In a time of widespread debate about prostate specific antigen (PSA) screening for 
prostate cancer, Active Surveillance (AS) has emerged as a way to prevent the 
unnecessary treatment of  some patients with prostate cancer, or at least, to delay the 
treatment of the disease [1]. The benefit of not treating a patient immediately is the 
avoidance of the side-effects of radical treatment. 
 
AS consists of the carefully monitoring of men diagnosed with prostate cancer, but 
not yet treated, with PSA tests or repeat biopsies. What still needs to be determined 
is whether the benefits of avoiding side effects outweigh the risk that a patient 
misses his cure window by not treating immediately. 
 
Currently, there are some AS cohort studies designed to answer this question: 
Prostate Cancer Research International Active Surveillance (PRIAS) [2], UCSF 
cohort [3], Johns Hopkins (JH) [4] or the Toronto cohort [5] among others [6,7]. 
However, with the exception of the Toronto cohort, their median follow-up times 
are shorter than 5 years. In their latest publications, very few prostate cancer deaths 
were reported [2-5,7]. 
 
Most AS cohorts contain only one AS protocol, usually selecting low-risk patients, 
with stage <T2a and Gleason Score 6 or lower (T2GS6) [6,7]. While in some 
cohorts follow-up biopsies occur yearly (JH [4]), in others biopsy occurs up to 
every 3 years after the first year (PRIAS [2]). It is not yet clear whether AS is safe 
for intermediate risk patients. While in the UCSF cohort  [3] it was found that the 4-
year treatment-free survival (TFS) did not significantly differ between low-risk and 
intermediate risk men, intermediate risk patients had significantly worse outcomes 
in the Toronto cohort [5].  
  
Given the multitude of possible avenues for selecting and following men during AS, 
and the limited follow-up data, the use of modeling to evaluate the outcomes of AS 
protocols is necessary. Previously, Xia et al [9] compared immediate radical 
prostatectomy (RP) and AS for low-risk patients in a simulation study and found 
that AS has a modest effect on prostate cancer mortality (PCM).   
 
In this article we use a well-validated simulation model (MISCAN) of natural 
history of prostate cancer, that uses JH-AS data to predict TFS, Gleason score and 
volume progression. We project the lifetime risk of PCM and overtreatment in the 
situation where AS is given to newly screen-detected low and intermediate risk 
men, under different follow-up biopsy intervals, and we compare these strategies 
with treating all men immediately.  
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Methods 
 
Simulation Model 
 
MISCAN is a microsimulation model, which simulates individual life-histories. A 
detailed description is available in http://cisnet.cancer.gov/prostate/profiles.html and 
in previously published studies [10-13].   
 
Before detection or death, the model contains 18 health states corresponding to the 
combination of 3 stages (T1, T2 and T3), 3 grades (Gleason less than 7, 7, and more 
than 7) and whether or not cancer is metastasized. Additionally, T2-stage Gleason 6 
men are classified as T2a or T2bc and Gleason 7 men are classified as 3+4 or 4+3, 
depending on their remaining lead-time and age group, with their respective 
proportions based on European Randomized Study of Screening for Prostate Cancer 
(ERSPC)  data. Some natural history parameters were calibrated to ERSPC data 
(durations, transition probabilities, among others), while PSA growth parameters 
were calibrated to jointly to SEER incidence and ERSPC PSA distribution. [13].  
In case the patient is detected outside of screening (“clinically detected”) we assume 
that he is immediately treated. If screen-detected he can either be immediately 
treated or be assigned to AS. 
 
If immediately treated, we assume an equal chance of being referred to RP or 
radiation therapy (RT). The prostate cancer survival without treatment is assigned at 
clinical detection and depends on stage and grade. It was estimated based on SEER 
data from the pre-PSA era (1983-1986). In order to correct for improvements on the 
survival not directly associated with screening or primary treatment, we add a 
hazard ratio for prostate cancer survival of 0.82, which was calibrated to the 
observed PCM in the ERSPC control (no screening) group (Model Appendix Tables  
5-7).  
 
The hazard ratios for prostate cancer survival after radical treatment equal 0.56 for 
RP based on [14] and 0.63 for RT (maintaining the same ratio of benefit between RP 
and RT from [15]). The effect of early detection is applied through an additional 
probability of cure which decreases exponentially with lead-time for non-metastatic 
cases,  
Cure probability = 1 - exp(cure parameter * lead-time).   
 
The cure parameter was calibrated to the observed PCM reduction in the ERSPC 
trial after 11 years of follow-up and equals -0.22.  (Model Appendix  Tables 5-7, 
Model Appendix Figure 4)  
C h a p t e r  6  | 107 
 
 
 
Modelling referral to treatment in AS 
 
A patient in AS may be referred to treatment in four ways: volume progression, 
gleason upgrade, clinical detection and in absence of evidence of biopsy 
progression. If any of these events occurs then we assume that all men are treated.  
(Model Appendix Table 8)   
 
Since the benefit of screening is dependent on lead-time, men who are referred to 
AS will experience a smaller benefit of screening, depending on how much time 
they are on AS. For instance, a patient with a lead-time of 10 years at screen-
detection, referred to immediate treatment, will have a probability of cure as 
follows:  1- exp(-0.22 * 10) = 0.89.  That is, there is an 89% probability that he is 
cured, and an 11% probability that he dies from prostate cancer.  If the patient 
would choose AS and be referred to treatment 6 years later, its corresponding cure 
would become,  1- exp(-0.22 * 4) = 0.59.    
 
TFS is defined as time from screen-detection to radical treatment. We validate TFS 
projected by the model, together with the number of men who experienced volume 
or Gleason upgrade, with data from the JH-AS study (Model Appendix Table 9).  
We simulated the study 100 times, by selecting patients to AS, with approximately 
the same age distribution and  entrance criteria close to the  JH cohort (maximum 
disease state T1 stage and GS6 and PSA ≤ 10) (Model Appendix Table 9).  
 
Screening and Active Surveillance Policies 
 
We sample 10 million men representative of the US age distribution based on US 
life tables. In the base case, we screen men yearly between ages 55 and 69, with a 
PSA threshold for biopsy referral (PSAt) equal to 4, biopsy compliance based on the 
PLCO trial and every screen-detected man is immediately treated.    
 
We compare the outcomes of treating every man immediately, with admitting low 
risk patients (≤ T2a, Gleason 6, PSA <10) in AS.  We run a set of AS protocols 
where after the first year, biopsy frequency reduces to every 2, 3 or 5 years. We also 
project the effects of AS, with a reduced (biennial) and increased (annual, up to age 
74) screening schedule. Assuming that the referral rates from AS to radical 
treatment, for intermediate risk men (≤ T2-stage and Gleason 3+4) are similar to 
those of low risk men, given [7], we also project the effects of admitting low and 
intermediate risk men (≤ T2-stage, Gleason 3+4) in AS. (Table 1) 
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Table 1: Active Surveillance protocols and Screening policies considered. 
Basecase 
1.  55-69, yearly screening, PSAt=4, No AS* 
(All Runs with biopsy compliance based on the observed PLCO (41%), except Run 10) 
  
Active Surveillance 
2.  55-69, yearly screening, PSAt=4,  AS for ≤ T1GS6 men, with yearly biopsies. 
3.  55-69, yearly screening, PSAt=4,  AS for ≤ T2aGS6 men, with yearly biopsies. 
4.  55-69, yearly screening, PSAt=4,  AS for ≤ T2aGS6 men, with biannual biopsies after 1st year. 
5.  55-69, yearly screening, PSAt=4,  AS for ≤ T2aGS6 men, with triannual biopsies after 1st year. 
6.  55-69, yearly screening, PSAt=4,  AS for ≤ T2aGS6 men, with biopsy every 5 years after 1st year. 
7.  55-69, yearly screening, PSAt=4,  AS for ≤ T2aGS7 (3+4)  men, with yearly biopsies. $ 
Sensitivity Analyses  # 
8.  55-69, biennial screening, PSAt=4. 
9.  55-74, yearly screening, PSAt=4. 
10. 55-69, yearly screening, PSAt=4  with biopsy compliance according to observed ERSPC (86%). 
11.  Sensitivity for Gleason Progression, probability of volume progression and leave AS increase or 
decrease by 20%. & 
12.  Null Efficacy of Treatment.  § 
13.  Men referred only to either RP or RT.  (Basecase: 50% referral for RP and the other 50% for RT) § 
*PSAt denotes PSA threshold for biopsy referral. AS denotes Active Surveillance and 
GS denotes Gleason Score. ERSPC denotes European Randomized Study of 
Screening for Prostate Cancer Trial.  
# Each run in the sensitivity analyses is combined with run 1 (no AS), run 3 (AS with 
yearly biopsies) and run 5 (AS with biopsies every 3 years).  
$ Also with 20% higher referral rates to treatment, as a sensitivity analysis, in 
Supplementary Table 3. 
& See Supplementary Table 3. 
§  See Supplementary Table 4. 
 
 
Outcomes 
 
The main outcome measures are the lifetime risk of PCM, treatment free life years 
(TFLY), which is the duration from onset of the disease until treatment and the 
probability of overtreatment (defined as the risk that a man is referred to radical 
treatment, and would not be clinically detected in absence of screening, or in other 
words, an overdiagnosed man who goes through radical treatment). Additionally we 
report the average number of years spent on AS, the probability of PCM due to 
entering AS and the proportion of men in AS left untreated. 
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Sensitivity Analyses 
 
We run the no AS, yearly and every 3-year biopsy protocols, in combination with 
differential screening intensities and referral rates to treatment while in AS. We also 
examine the effect of no efficacy of treatment, and referring men only to either RP 
or RT. Since the model parameters are subject to uncertainty, we run a multivariate 
probabilistic sensitivity analysis including, the cure parameter, hazard ratios for 
treatment and the probabilities of detection in AS (Table 2).  We also examined the 
assumption of an exponentially decreasing cure benefit, by comparing the best fit, 
with the fit of a linearly decreasing cure benefit. (Model Appendix Table 7). 
 
 
Table 2: Overview of included uncertainty in the probabilistic sensitivity analyses 
Parameter Value Distribution 
hazard ratio improvement baseline 
survival 
0.82 Lognormal(-0.20, 0.03) &  
hazard ratio of RP* 0.56 Lognormal(-0.48,0.17)  #      
hazard ratio of RT* 0.63 Lognormal( -0.60, 0.19) # 
cure parameter -0.22 Beta (60.18, 213.38) & 
probability of volume progression T2a 0.1 Uniform, Min=-20%, Max = +20%  
probability of volume progression  >T2a 0.4 Uniform, Min=-20%, Max = +20%  
sensitivity Gleason progression 0.5 Uniform, Min=-20%, Max = +20%  
probability leave AS without progression 0.04 Uniform, Min=-20%, Max = +20%  
* Hazard ratio is relative to the survival without treatment. It is based on Bill-
Axelson et al [14]. For hazard ratio of RT, we extrapolated based on the same ratio 
from Etzioni et al [15].  
#The standard deviation was calculated such that the confidence interval in [14] 
would include approximately 95% of random draws.  
& We first calculated how much would we need to vary the parameter until the model 
fit would become significantly worse, using as threshold 5% less or extra prostate 
cancer deaths (See Supplementary Table 2). Using this as a confidence interval for 
the parameter, we calculated a standard deviation such that 95% of the random 
draws would fall inside this confidence interval. Additionally, see Supplementary 
Table 2, for the comparison of the linearly decreasing fit with the exponentially 
decreasing fit. 
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Results 
 
Active Surveillance with different entrance and follow-up 
protocols 
 
Screening yearly between ages 55 and 69, with a PSAt of 4 (basecase) and treating 
every man immediately results in a lifetime risk of PCM of 2.6%. This strategy 
amounts to 7.4 treatment free life years (TFLY) per person, which contrasts with 8.7 
TFLY per person (17.3% increase) if no PSA-based screening is performed and treat 
every men immediately. However, no screening results in a lifetime risk of PCM of 
3.3% (Table 3). 
  
On average, patients who entered AS remained untreated between 5.8 and 9.0 years 
depending on the screening and AS policy. If one refers patients in disease state 
T2aGS6 to AS then PCM  increases to 2.6% (1.0% increase), TFLY from 7.4 to 7.7 
and overtreatment reduces from 2.5% to 2.1% (18% reduction). About 27% of all 
AS men referred to AS remained untreated and the probability of dying due to AS is 
1.8%.   
 
Increasing the biopsy interval after the first year of follow-up from yearly, to two, 
three or five years increases PCM to about 2.6% (respectively, from 1.0% to 1.7%, 
2.3% and 3.2% increase), and the proportion of men who die from prostate cancer 
due to AS rises from 1.8% to 3.0%, 4.1% and 5.9%, respectively. On the other hand, 
the probability of overtreatment reduces from 2.1% to 2.0% (25% reduction), 1.9% 
(30% reduction) and 1.8% (36% reduction). Average years spent on AS increases 
from 5.9 to 9.0.    
 
Referring intermediate risk men to AS increases PCM to about 2.6% (2.7% 
increase), while overtreatment decreases from 2.5% to 2.0% (23.1% decrease). The 
risk of PCM due to AS is 3.6%. By contrast if we only admit low-risk men and a 
with biennial biopsies after the first year, the risk of PCM due to AS is only 3.0%, 
but with a higher overdiagnosis reduction (25.4% decrease). For univariate and 
multivariate sensitivity analyses see Supplementary Table 2-5 and Supplementary 
Figure 2. 
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Table 5: Active Surveillance outcomes under different screening policies and follow-
up protocols.*#  
 Outcomes for All Men Outcomes for Men in AS 
 Lifetime 
Risk PCM    
(+ %) 
TFLY per 
person          
(+ %) 
Lifetime 
Risk   
Overtreat.              
(- %) 
Years 
per 
person 
in AS 
AS and 
not 
treated 
(%) 
Risk 
of 
PCM  
AS$  
Basecase  
     
55-69, yearly, PSAt=4, biopsy compliance PLCO (41%) 
No Screen 3.26  8.7 (17.3) - - - - - 
No AS 2.55  7.4  2.51  - - - 
T1GS6, yearly 
biopsy 
2.57 (0.6) 7.6 (2.8) 2.26 (-11.0) 6.4 26.8 1.8 
T2aGS6, yearly 
biopsy 
2.58 
 
(1.0) 7.7 (4.2) 2.12 (-18.4) 6.0 27.1 1.8 
T2aGS6, 2-year 
biopsy 
2.60 (1.7) 7.8 (4.9) 2.00 (-25.4) 7.6 35.4 3.0 
T2aGS6, 3-year 
biopsy 
2.61 (2.3) 7.8 (5.5) 1.92 (-30.3) 8.5 40.6 4.1 
T2aGS6, 5-year 
biopsy 
2.64  (3.2) 7.9 (6.2) 1.84 (-36.4) 9.0 46.6 5.9 
Sensitivity Analyses          
Increased Screening intensity (55-74, yearly, PSAt=4) 
No AS 2.38  6.7  3.88     
T2aGS6, yearly 
biopsy 
2.42 (1.6) 7.3 (7.1) 3.09 (-25.6) 6.6 35.8 1.8 
T2aGS6, 3-year 
biopsy 
2.45 (3.1) 7.4 (9.0) 2.85 (-36.0) 8.5 46.4 3.5 
Reduced Screening intensity (55-69, two-years, PSAt=4) 
No AS 2.66  7.7  2.10  - - - 
T2aGS6, yearly 
biopsy 
2.68  (0.7) 7.9 (2.4) 1.84 (-15.6) 6.0 32.8 2.0 
T2aGS6, 3-year 
biopsy  
2.70 (1.1) 8.0 (3.3) 1.71 (-24.3) 8.5 47.4 4.7 
Biopsy Compliance ERSPC (86%)  
No AS 2.41  7.1  3.10  - - - 
T2aGS6, yearly 
biopsy 
2.45 (1.8) 7.6 (6.8) 2.42  (-27.0) 6.1 27.3 1.8 
T2aGS6, 3-year 
biopsy 
2.51 (2.9) 7.8  (9.4) 2.10 (-46.7) 8.6 40.7 3.0 
Intermediate Risk Men         
T2GS7 (3+4), 
yearly  
2.62  (2.7) 7.8  (5.2) 2.04 (-23.1) 5.8 23.6 3.6 
* All men included in AS, had a PSA < 10 at diagnosis and a biopsy after one year. For instance, 
in “T2GS6, 3-year biopsy” the biopsy occurs at 1st year, 4th year and 7th year. 
# PCM denotes prostate cancer mortality, TFLY denotes treatment free life years, AS  stands for 
active surveillance, PSAt denotes PSA threshold for biopsy referral. PLCO denotes the Prostate, 
Lung, Colorectal and Ovarian Cancer Screening Trial and ERSPC denotes European 
Randomized Study of Screening for Prostate Cancer Trial. 
$ Risk of PCM due to AS, is the difference in PCM between the situation where every man is 
immediately treated and where some men are referred to AS, depending on the specific AS 
protocol, divided by the number of men who entered in AS.  
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Active Surveillance with different screening intensities  
 
In the situation where every men is immediately treated, increasing the stopping age 
to 74 or increasing biopsy compliance lowers the PCM from 2.6% to 2.4% (7.4% 
and 6.1% decrease, respectively). On the other hand, probability of overtreatment 
increases from 2.5% to 3.9% (35.3% increase) or 3.1% (18.5% increase). 
Introducing AS, with the more intensive screening schedule seems to result in a 
larger effect both on overtreatment reduction and PCM increase (Table 3).   
 
 
Discussion 
 
In this study we use a novel approach to model AS, by modelling rates of volume 
and Gleason progression, instead of modelling durations [9] or by using a simplistic 
assumption of reduced treatment benefit for men in AS [17].  
 
Introducing AS for screen-detected men results, on average, in an interval of 
between 5.8 and 9.0 years free of treatment, depending on the AS protocol. If we 
accept T2aGS6 men in AS with yearly biopsies or a biopsy every 3 years after the 
first year, overtreatment reduces from 2.5% to 2.1% (18.4% reduction) or 1.9% 
(30.3% reduction), PCM remains about 2.6% (1.0% or 2.3% increase), with a 
probability of dying from prostate cancer due to AS of 1.8% or 4.1%, respectively.   
 
To put these numbers in perspective, in 2014, about 233000 men were expected to 
be diagnosed with prostate cancer in the US [18]. Assuming half of them are screen-
detected between ages 55 and 69 (116500) and that 30% of these men are low-risk 
and are referred to AS (34950), our model predicts that for men with yearly biopsies 
or a biopsy every three years after the first year, either about 9250 or 14250 men 
will not be overtreated and an extra 625 or 1450 men will die of prostate cancer due 
to entering AS, respectively. 
 
Our sensitivity analyses showed that these effects will become larger if the intensity 
of screening increases (increased stopping age or higher biopsy compliance), as 
more screen-detected men are classified as low-risk and have a longer lead-time. 
Admitting intermediate risk men in AS seems not to be as efficient as increasing the 
biopsy interval in AS for low-risk men.  
 
Our modelling of AS uses a previously validated model of the natural history of 
prostate cancer [10-14], which is mostly based on ERSPC data [19], with US 
incidence validated to SEER [13,14]. By calibrating the sensitivity to Gleason 
Progression and the probability of detecting volume progression given that there is 
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an increase in stage, we are able to match the treatment free survival and the 
number of men experiencing volume and Gleason progression during AS to 
observed data in JH AS cohort.  
 
This has some advantages relative to calibration based only on an AS cohort. First, 
durations and transitions between health states (which in large part determine time 
on AS) are based on a large randomized control trial. Second, the median follow-up 
of the ERSPC trial is much larger than most AS cohorts, which makes our PCM 
projections potentially more reliable.   
 
On the other hand, MISCAN makes some simplifications of the AS protocol 
compared with the current practice in most AS cohorts. The entrance criteria for AS 
used in MISCAN include T-stage, GS and PSA but not the number of positive cores 
or PSA density. Additionally, there is some variability regarding TFS, and number 
of men experiencing volume and/or Gleason progression across AS cohorts [6,7].   
 
The results in this study may not apply to African-American population [20], as the 
benefit of screening is estimated based on an European cohort, and the probabilities 
of referral to treatment while in AS are estimated based on a cohort with very few 
African-American men [4].  
 
In contrast, with [9], where AS was modelled as duration from diagnosis to 
treatment, our approach for modelling AS allows one to project the effects of 
multiple AS strategies, without resorting to multiple AS cohort datasets. An 
additional advantage of this framework is that it allows us to jointly model 
screening and AS strategies. The main disadvantage of this approach is that given 
the difficulty of modelling directly volume progression, we need to make the 
assumption that volume progression can only occur, if there is an increase in T-
stage in the model.      
 
Our validation shows that MISCAN is slightly more pessimistic than the observed 
data in JH cohort (2 against 0 observed prostate cancer deaths). Other cohorts 
showed no PCM at 5 years except [21] with 1 prostate cancer death at 3.7 years of 
follow-up.  This is likely due to the very low risk selection of patients in most AS 
cohorts, which contrasts with the ERSPC population used to inform natural history 
in MISCAN.   
 
Importantly, we verify that a key statistic, probability of dying due to AS,  which 
equals 1.8% in our model, is in line with previous studies where no benefit of early 
detection is assumed, and where AS was modelled as duration from diagnosis to 
treatment (Xia et al [9]: 1.2%) or as an assumption about reduced benefit  (Hayes et 
al [17]: 2%). This rate is also comparable with the observed PCM (1.5%) in the 
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Toronto cohort, after 10 years of follow-up [6].  
 
In this study we did not model quality of life. Heijnsdijk et al [22] found that 
introducing quality of life adjusted years (QALY’s) reduces the screening benefit by 
23%. Delaying treatment with AS is a way to mitigate this reduction, due to the 
avoidance of side-effects. For instance, Hayes et al [17] compared AS with several 
forms of radical treatment and found that AS gives the highest expected QALY’s. 
Using QALY’s will likely favor AS protocols that are less biopsy intensive, given 
the increased risk of biopsy complications [23-25].     
 
As previously suggested [1-9], our model predicts that AS for low-risk men is 
relatively safe.  We project the harms of benefits of several AS strategies and we 
find that if we increase the interval between biopsies after the first year to three 
years, which is close to the strategy used in the PRIAS cohort [2], overtreatment 
may reduce up to 30%, though with a small increase in PCM. These results apply 
mostly to US population of European ancestry.  
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Supplementary Information 
 
Supplementary Table 1: Active Surveillance outcomes under different screening 
policies and follow-up protocols.*# (Sensitivity Analyses) 
Reduction (-) or increase (+), in percentage,  relative to basecase (55-69, PSAt=4, yearly 
screening, No Active Surveillance) 
 
 Outcomes for All Men Outcomes for Men in AS 
 Lifetime 
Risk PCM    
(+ %) 
TFLY per 
person          
(+ %) 
Lifetime Risk   
Overtreatment              
(- %) 
Years per 
person 
in AS 
AS and 
not 
treated 
(%) 
Risk of 
PCM 
AS # 
Basecase  
     
55-69, yearly, PSAt=4, biopsy compliance PLCO (41%) 
Stop Screen 2012 3.09  8.7 (17.3) - - - - - 
No AS 2.55  7.4  2.51  - - - 
T2aGS6, yearly 
biopsy 
2.57 (1.0) 7.7 (4.2) 2.13 (-17.9) 5.9 26.5 1.8 
T2aGS6, 3-year 
biopsy 
2.61 (2.3) 7.8 (5.5) 1.92 (-30.3) 8.5 40.6 4.1 
20% lower 
Sensitivity         
 
T2aGS6, yearly 
biopsy 
2.58  (1.3) 7.7 (4.4) 2.06 (-21.4) 6.7 30.8 2.3 
T2aGS6, 3-year 
biopsy 
2.63 (2.8) 7.9 (6.0) 1.85 (-35.3) 9.3 45.6 5.2 
20% higher 
Sensitivity         
 
T2aGS6, yearly 
biopsy 
2.58 (0.9) 7.7 (3.7) 2.16 (-16.2) 5.6 24.4 1.6 
T2aGS6, 3-year 
biopsy 
2.60 (1.9) 7.8 (5.1) 1.98 (-26.3) 7.9 36.4 3.4 
T2GS7 (3+4), 
yearly 
2.62 (2.6) 7.8 (5.2) 2.04  (-22.8) 5.8 23.4 3.5 
* All men included in AS, had a PSA < 10 at diagnosis and a biopsy after one year. 
For instance, in “T2GS6, 3-year biopsy” the biopsy occurs at 1y, 4y, 7y.  
# PCM denotes prostate cancer mortality, TFLY denotes treatment free life years, AS  
stands for active surveillance, PSAt denotes PSA threshold for biopsy referral. PLCO 
denotes the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial and 
ERSPC denotes European Randomized Study of Screening for Prostate Cancer Trial. 
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Supplementary Table 2: Active Surveillance outcomes under different treatment 
assumptions.*# (Sensitivity Analyses) 
Reduction (-) or increase (+), in percentage,  relative to basecase (55-69, PSAt=4, yearly 
screening, No Active Surveillance) 
 
 Outcomes for All Men Outcomes for Men in AS 
 Lifetime 
Risk PCM    
(+ %) 
TFLY per 
person          
(+ %) 
Lifetime Risk   
Overtreatment              
(- %) 
Years per 
person 
in AS 
AS and 
untreate
d (%) 
Risk of 
PCM 
due to 
AS # 
Basecase  
     
55-69, yearly, PSAt=4, biopsy compliance PLCO (41%) 
Stop Screen 2012 3.09  8.7 (17.3) - - - - - 
No AS 2.55  7.4  2.51  - - - 
T2aGS6, yearly 
biopsy 
2.57 (1.0) 7.7 (4.2) 2.13 (-17.9) 5.9 26.5 1.8 
T2aGS6, 3-year 
biopsy 
2.61 (2.3) 7.8 (5.5) 1.92 (-30.3) 8.5 40.6 4.1 
Only RP used          
No AS 2.49  7.4  2.51  - - - 
T2aGS6, yearly 
biopsy 
2.51 (1.0) 7.7 (4.2) 2.13 (-17.9) 5.9 26.5 1.8 
T2aGS6, 3-year 
biopsy 
2.54 (2.3) 7.8 (5.5) 1.92 (-30.3) 8.5 40.6 4.0 
Only RT used          
No AS 2.62  7.4  2.51  - - - 
T2aGS6, yearly 
biopsy 
2.65 (1.0) 7.7 (4.2) 2.13 (-17.9) 5.9 26.5 1.9 
T2aGS6, 3-year 
biopsy 
2.68 (2.2) 7.8 (5.5) 1.92 (-30.3) 8.5 40.6 4.2 
Null Efficacy of Treatment (and Screening) 
     
 
No Screening 4.06  7.4  2.51  - - - 
No AS 4.06 (0.0) 7.7 (4.2) 2.13 (-17.9) 5.9 26.5 - 
T2aGS6, 1-year 
biopsy 
4.06 (0.0) 7.8 (5.5) 1.92 (-30.3) 8.5 40.6 0.0 
* All men included in AS, had a PSA < 10 at diagnosis and a biopsy after one year. 
For instance, in “T2GS6, 3-year biopsy” the biopsy occurs at 1y, 4y, 7y.  
# PCM denotes prostate cancer mortality, TFLY denotes treatment free life years, AS  
stands for active surveillance, PSAt denotes PSA threshold for biopsy referral. PLCO 
denotes the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial and 
ERSPC denotes European Randomized Study of Screening for Prostate Cancer Trial. 
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Supplementary Figure 1: Probabilistic Sensitivity Analyses* 
 
*In the y-axis is the the lifetime risk of overdiagnosis, in the x-axis the percentile of 
the overdiagnosis distribution over a 1000 model runs. Running the model 1000 
times,  resulted in an approximately 95% tolerance interval of  2.27-2.82 for PCM, if 
every man is treated immediately. Critically it seems that the absolute effects of 
introducing AS on the lifetime risk of prostate cancer mortality and overtreatment do 
not vary much, if we change the parameter values up to about 20%. 
 
 
Supplementary Table 3: Probabilistic Sensitivity Analyses: distribution of the 
lifetime risk of PCM and overtreatment* (%) 
Lifetime Risk PCM 
Percentil 2.5 10 20 40 
Model 
Estim. 60 80 90 97.5 
NoAS 2.27 2.34 2.40 2.49 2.55 2.57 2.66 2.73 2.82 
AS, 1y 2.29 2.36 2.42 2.51 2.58 2.59 2.68 2.75 2.85 
AS, 3y 2.32 2.40 2.45 2.55 2.61 2.63 2.72 2.79 2.89 
Lifetime Risk Overtreatment 
Percentil 2.5 10 20 40 
Model 
Estim.  60 80 90 97.5 
NoAS 2.51 2.51 2.51 2.51 2.51 2.51 2.51 2.51 2.51 
AS, 1y 2.10 2.10 2.11 2.12 2.12 2.13 2.14 2.14 2.15 
AS, 3y 1.88 1.89 1.90 1.92 1.92 1.93 1.95 1.95 1.96 
*PCM denotes Prostate Cancer Mortality, AS denotes Active Surveillance.  
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Abstract 
 
A significant proportion of screen-detected men with prostate 
cancer is likely to be overtreated, especially in older age groups. 
We aim to find which groups of screen-detected older men (65+) 
benefit the most from Immediate Radical Treatment or Active 
Surveillance (AS) for prostate cancer, depending on age, screening 
history, health status and prostate cancer stage at detection.   
 
We used a microsimulation model (MISCAN) of the natural 
history of prostate cancer based on ERSPC data. Individual life 
histories are simulated with US comorbidity lifetables based on a 
random sample of MEDICARE data. Different screening histories 
are simulated and we count outcomes for men screen-detected 
from ages 66 to 72.  
 
For immediately treated men with low-risk disease (≤ T2a, 
Gleason 6) the probability of overtreatment ranges from 61% to 
86% decreasing to between 37% and 46%, if they are assigned to 
AS. For intermediate risk men (≤ T2, Gleason 3+4) overtreatment 
ranges from 23% to 60%, which reduces to between 16% and 31% 
for AS. For high risk men (T3, or  ≥ Gleason 4+3) overtreatment 
ranges from 11% to 51%. The disease stage at screen-detection is 
a critical risk factor for overtreatment.  
 
For low risk men, AS seems to significantly reduce overtreatment 
at a modest cost. For intermediate risk men, the decision between 
immediate treatment or AS depends on age and comorbidity 
status. Men screen-detected in a high risk disease stage may 
benefit from immediate treatment even beyond age 69. 
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Introduction 
 
Overdiagnosis consists of the detection of cancer that would not develop into 
clinical cancer in absence of screening, or eventually be life-threatening. If an 
overdiagnosed man is referred for radical treatment then he is considered to be 
overtreated.  In a context of limited healthcare resources, it is crucial to identify 
which patients are at risk of overtreatment and therefore could be better handled by 
Active Surveillance (AS) or be left untreated. 
 
Estimates of overdiagnosis in prostate cancer can vary considerably. Depending on, 
whether an excess incidence approach is used or, on the specific microsimulation 
model, estimates range between 23% and 60% of screen-detected men1,2. 
 
Due to these estimates, and to the controversy surrounding the magnitude of the 
benefit of screening in the two largest prostate cancer screening randomized control 
trials 3,4, the US Preventative Services Task Force recommended in 2012 against 
PSA screening for prostate cancer 5. Others, like the AUA recommend shared 
decision making about screening between ages 55 and 69 6. 
 
Translating these results from the population level to an individual patient though, 
can be an arduous task. The probability that an individual benefits from screening 
and treatment can vary substantially depending on the individual person’s 
characteristics. Namely age, health status and past screening history could have an 
influence on the risk of being overdiagnosed and overtreated.  
 
Previous studies7,8  have assessed the association between PSA, age and 
overdiagnosis, finding that the majority of overdiagnosed cases occurs in men older 
than 60. On the other hand, Wever et al 9 studied the relationship between 
overdiagnosis and disease stage at detection and found that for men in age group 
65-69, the probability of overdiagnosis ranges from 9% to 50%. None of these 
studies included Active Surveillance (AS) as an option for newly screen-detected 
men.  
 
AS for prostate cancer consists on the frequent monitoring of newly screen-detected 
men, through PSA tests and repeat biopsies. It has recently emerged as a viable 
alternative to immediate treatment, namely for low risk men 10.  For men older than 
65, it could be an avenue to significantly reduce overtreatment. Additionally, no 
study has yet modelled the association between overdiagnosis and comorbidity in 
prostate cancer for screen-detected men. This association could have a critical 
impact on the estimates of 7,9, especially for men with significant comorbidities. 
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In this study, we use a simulation model to compute personalized estimates of 
overtreatment, prostate cancer mortality (PCM), number needed to treat (NNT) and 
life-years saved given age at screen-detection, health status, disease stage and 
screening history. We present results for men older than 65, which is the age group 
where the benefit of immediate treatment is most debatable.  
 
Materials and Methods 
 
Microsimulation Model 
 
Microsimulation Screening Analysis (MISCAN) is a microsimulation model 
designed to study the effect of screening on incidence and prostate cancer mortality. 
A description is available in http://cisnet.cancer.gov/prostate/profiles.html.  and in 
the Model Appendix. 
 
Each of MISCAN’s health states denote different disease, detection and treatment 
phases. We model 18 disease states, consisting of the combination of 3 stages (T1, 
T2, T3), 3 grades (which correspond to Gleason Score 2-6, 7 and > 7) and whether 
the cancer is metastasized. Additional disease states were created to model AS, 
including dividing Gleason 7 cancers in 3+4, 4+3 and T2GS6 (GS6 denotes 
Gleason Score 6 or lower) cancers between T2a and T2bc.  
 
The transition probabilities and durations between different stages, grades until 
metastasized cancer and clinical diagnosis are calibrated to European Randomized 
Study of Screening for Prostate Cancer (ERSPC) data 11,12. The model for PSA 
growth is based on 13 and is calibrated jointly to SEER incidence and ERSPC PSA 
distribution data 4 (Model Appendix Tables 2-4, Model Appendix Figures 2 and 3). 
 
In an “immediate treatment” run, all screen-detected men are assigned with equal 
chance to either radiation therapy (RT) or radical prostatectomy (RP). In an “AS” 
run, all low-risk (≤ T2a Gleason 6), and intermediate-risk (Gleason 3+4, T2bc and 
Gleason 6) screen-detected men are assigned to AS. In the absence of treatment, a 
baseline survival is assigned at clinical detection, which depends on Gleason Score 
and is based on SEER data from the pre-PSA era. The baseline survival is further 
corrected by adding a hazard ratio of 0.82, which was found by calibration to the 
observed prostate cancer mortality in the control (no screening) group of the 
ERSPC 4 trial (Model Appendix Tables 5 and 6).   
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The hazard ratio of prostate cancer survival after treatment equals 0.56 for RP 14 or 
0.63 for RT, using the same ratio as in 15. Additionally, there is an effect of early 
detection: a probability of cure which decreases exponentially with lead-time for 
non-metastatic cases,  
 
Cure probability =  exp(cure parameter * lead-time).   
 
The cure parameter was calibrated to the observed prostate cancer mortality 
reduction due to screening in the ERSPC 4 and equals -0.22.  (Model Appendix 
Tables 5 and 6, Model Appendix Figure 4). 
 
Active Surveillance  
 
If a man is assigned to AS, the disease progresses as if not screen-detected. Referral 
to radical treatment may occur by volume progression (if there is an increase in T-
stage), gleason progression, in case the patient would be clinically diagnosed or due 
to their own personal preference (Model Appendix Table 8). Rates of progression 
are dependent on the disease stage and are calibrated to Johns Hopkins cohort data 
16 (Model Appendix Table 9). In the base case, we stop AS after 6 years (six 
biopsies) if no progression is detected, since we are modelling older men.  
 
Comorbidity Lifetables 
 
Three cohorts of 5 million men born in 1960 are simulated with life tables 
corresponding to no comorbidity, moderate comorbidity or severe comorbidity. 
Each comorbidity group was identified using a comorbidity index defined by 
conditions included in the Charlson index 17, based on a random sample of 
Medicare data from SEER areas. The estimation of these lifetables, corresponding 
life expectancies, and prevalences of each comorbidity type are extensively 
described in Cho et al 18. In Vogelaar et al 19, the life expectancies corresponding to 
each comorbidity for several ages are shown.  
 
For instance, moderate comorbidity includes conditions like diabetes or 
cerebrovascular disease, while severe comorbidity includes chronical renal failure, 
chronic obstructive pulmonary disease or dementia, among others. This results in an 
estimated prevalence at age 69 of 75% for no comorbidity, about 12% for moderate 
comorbidity and 13% for severe comorbidity 19. 
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Outcomes 
 
We present three ages of screen-detection, 66, 69 and 72, and we consider two 
screening histories. In the first, the person is being screened yearly from age 55 and 
with a PSA threshold for biopsy referral (PSAt) of 4 until age of screen-detection.  
In the second, age of screen-detection is the age of first screening. These two 
screening histories provide a range for the outcomes that will contain most 
screening histories.  
 
We follow men from screen-detection to PCM or other causes death.  These are 
divided by age and disease stage at screen-detection, comorbidity status and 
screening history.  The low risk group consists of men detected in stages ≤ T2aGS6. 
The intermediate risk group contains ≤ T2 stage, Gleason7 (3+4) men. Whereas the 
high risk group contains any men in either T3 disease stage and/or Gleason equal or 
higher than 4+3.  
 
The main outcome measures are number needed to treat to save a life (NNT), 
probability of overtreatment (defined as a treated man, who is overdiagnosed) and 
life years (LY) saved. A man is counted as overtreated, if he is referred to radical 
treatment and in absence of screening, he would not be clinically diagnosed during 
his lifetime.  
 
Scenario Analyses 
 
We examine the effects of considering different AS follow-up protocols on our 
estimates. We vary the stop age of AS from six years after diagnosis to ten years, 
and we change the biopsy frequency from yearly to every three years after the first 
year.   
 
Sensitivity Analyses 
 
We run an univariate sensitivity analysis where the cure parameter and the 
probabilities of detection in AS decrease or increase by 20%. Additionally, we run a 
multivariate probabilistic sensitivity analysis, where parameters related to the 
benefit screening and treatment benefit are varied simultaneously (Table 1). 
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Table 1: Overview of included uncertainty in the probabilistic sensitivity analyses 
Parameter Value Distribution 
hazard ratio improvement baseline 
survival 
0.82 Uniform,  Min=-20%, Max = +20% 
hazard ratio of RP* 0.56 Normal, Standard Deviation: 0.11*      
hazard ratio of RT* 0.63 Normal, Standard Deviation: 0.12* 
cure parameter -0.22 Uniform, Min=-20%, Max = +20% 
* Hazard ratio is relative to the survival without treatment. It is based on Bill-
Axelson et al 14. For hazard ratio of RT, we extrapolated based on the same ratio from 
Etzioni et al 15. The standard deviation was calculated such that the confidence 
interval in 14 would include approximately 95% of random draws.  
 
Results 
 
In Table 2, we show estimates of the probability of overtreatment, PCM, and NNT, 
divided by age of screen-detection (66, 69, 72), comorbidity levels, prostate cancer 
disease stage at detection and screening history.  
 
The prostate cancer stage at detection has a large influence both on NNT and the 
probability of overtreatment. For men detected in a low-risk stage, the NNT ranges 
from 11 to 47 and overtreatment from 61% to 86%. By contrast, men detected in a 
high risk disease stage have a NNT ranging from 2 to 8 and overtreatment between 
12% to 51%. 
 
The probability of overtreatment and NNT increases with age at screen-detection. 
For men detected at age 66 and screened once, with low risk disease and no 
comorbidity, the NNT increases from 11 to 15, for age 69, and to 20, for age 72.  In 
a similar fashion, overtreatment and NNT increase with the level of comorbidity. 
For instance, at age 66 the probability of overtreatment for men with no 
comorbidity is 61% while for men with severe comorbidity is 77%.   
 
Comorbidity and age play a special role for men screen-detected in an intermediate 
risk disease stage. Men with no comorbidity younger than 70 have a NNT ranging 
from 5 to 6 and a probability of overtreatment from 23% to 28%, which is closer to 
the estimates for high risk men. By contrast, men older than 70 with disease burden 
have a NNT between 10 and 15 and overtreatment between 41% and 52%, which is 
close to the predicted ranges for low risk men. 
 
Men can also choose to delay treatment with Active Surveillance.  For low risk 
man, this results in a large reduction of overtreatment. For instance, for a men aged 
66 with no comorbidity, overtreatment decreases from 61% to 37%, with PCM 
increasing from 1% to 2.8%. This reduction in overtreatment becomes larger with 
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higher age and comorbidity, while the increase in PCM becomes smaller.  For 
intermediate risk men, aged 66 with no comorbidity, overtreatment reduces from 
23% to 16%, with PCM increasing from 5% to 10%.  
 
In Figure 1, LY saved per screen-detected men, by disease stage, 
comorbidity and age are shown, for men which were yearly screened. LY 
saved by treatment decrease with both age and comorbidity. There are 
large differences in life years saved per disease stage at detection. In 
most cases, the amount of life years saved more than doubles if a man is 
detected in a higher risk disease stage than another. Referring men to 
AS results in a decrease in LY saved, especially for intermediate risk 
men.  
 
Scenario Analyses  
 
Increasing the biopsy interval to three years after the first year, and stopping AS 
after 10 years reduces overtreatment from 39.3% to 30.2% and increases PCM from 
2.5% to 3.8%, compared to base case AS. By contrast, increasing the maximum 
time on AS from 6 to 10 years reduces PCM from 2.5% to 1.8% and increases 
overtreatment to 50%. (Supplemental Information Table 1).  
 
 
Sensitivity Analyses 
 
In Supplemental Information Table 2, the univariate sensitivity analyses are shown. 
Varying the cure rate by 20% has little effect on NNT. Changing the probabilities of 
detection by 20%, has a maximum effect on overtreatment of 4 percentual points. 
Both analyses have a modest impact on prostate cancer mortality. The probabilistic 
sensitivity analysis resulted in a range for NNT of men screen-detected at age 66, 
with low risk prostate cancer,  between 10 and 14 (1th and 99th percentile runs). 
(Figure 2, Supplemental Information Figures 1-2). 
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Table 2: Probabilities of PCM and overtreatment at screen-detection by current age, 
comorbidity, screening policy and disease stage.* 
 Age at detection 66 69 72 
Scr PCa Comorbid. No Mod Sev No Mod Sev     No Mod Sev 
Pol Risk   
55-
Age 
Low Overtreat. 
[IRT] 
64.2 71.0 80.3 68.8 75.5 83.5 73.5 80.3 86.4 
  PCM [IRT] 0.8 0.7 0.4 0.8 0.6 0.4 0.6 0.5 0.1 
  Overtreat. 
[AS] 
39.3 41.4 38.4 41.9 44.0 39.8 44.2 45.5 39.4 
  PCM [AS] 2.5 1.9 1.3 2.2 1.7 1.1 1.6 1.2 0.3 
  NNT # 12 15 24 16 22 35 21 31 45 
            
 Int. Overtreat. 
[IRT] 30.7 37.9 50.7 35.5 43.1 54.6 41.1 49.4 59.8 
  PCM        
[IRT] 5.1 4.4 3.3 4.7 3.8 2.8 4.2 3.3 2.4 
  Overtreat. 
[AS] 20.3 24.2 28.1 23.2 27.1 29.7 26.2 30.1 31.3 
  PCM       
[AS] 10.5 8.8 6.4 9.5 7.6 5.5 8.3 6.3 4.4 
  NNT 5 7 10 7 8 12 8 11 16 
            
 High Overtreat. 19.9 28.9 46.1 22.9 31.9 47.9 26.9 36.8 51.1 
  PCM 16.5 14.9 11.4 14.9 12.8 9.6 13.5 11.3 8.4 
  NNT 2 2 3 4 4 6 4 5 8 
   
      
   
1x Low  Overtreat. 
[IRT] 
60.6 67.6 77.1 65.7 72.8 81.4 71.0 78.3 84.8 
  PCM [IRT] 1.0 0.8 0.5 0.9 0.7 0.5 0.9 0.7 0.5 
  Overtreat. 
[AS] 
36.7 39.4 36.8 39.8 42.4 38.1 41.8 43.9 38.2 
  PCM [AS] 2.8 2.4 1.6 2.3 1.67 1.2 2.0 1.5 1.0 
  NNT 11 14 22 15 20 32 20 29 47 
            
 Int. Overtreat. 
[IRT] 
22.7 29.5 41.7 28.2 35.5 47.4 33.2 40.8 51.5 
  PCM [IRT] 5.1 4.6 3.3 5.2 4.4 3.0 4.6 3.7 2.8 
  Overtreat. 
[AS] 
15.9 20.1 24.2 19.2 23.5 26.6 22.6 26.6 28.4 
  PCM [AS] 10.5 9.0 6.8 9.1 7.6 5.4 8.4 6.6 4.8 
  NNT 5 6 8 6 8 11 7 10 15 
            
 High Overtreat. 11.5 17.3 32.8 13.9 21.4 35.8 18.6 27.0 41.4 
  PCM  18.1 16.3 12.6 16.3 13.8 10.7 16.2 13.7 10.4 
  NNT 3 4 5 3 4 6 4 5 7 
*Screen-Policies include annual screening starting at age 55 and stop at the age of screen-
detection (55-Age), and one time screening at the age of screen-detection (Once). Disease Risk 
at screen-detection is divided in Low (≤ T2aGS6), Intermediate ( ≥ T2aGS6, Gleason 3+4) and 
High (either Gleason 4+3 or higher, or stage T3 or higher). The outcome measures are 
probability of overtreatment (Overtreat),  probability of prostate cancer mortality (PCM) and 
number needed to treat to save one life (NNT). NNT is measured as the inverse of the absolute 
risk difference of PCM between treated and untreated men. Treatment modalities are 
Immediate Radical Treatment (IRT), which comprises Radical Prostatectomy (RP) and 
Radiation Therapy (RT) or Active Surveillance (AS). Comorbidity categories include no 
comorbidity (“No”), moderate comorbidity (“Mod”) and severe comorbidity (“Sev”). 
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Figure 1: Life Years Saved by treated person presented by age, comorbidity status 
and disease stage at detection.*# 
 
* Disease Risk at screen-detection is divided in Low Risk (≤ T2aGS6), Intermediate Risk ( > 
T2aGS6, Gleason 3+4) and High Risk (either Gleason ≥  4+3, or stage ≥  T3). 
#Life years saved (LY) is the difference between the life years per screen-detected person with 
radical treatment or active surveillance and no treatment. 
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Figure 2: Distribution of the NNT for low risk men, aged 66 and no comorbidity. * 
 
*In the x-axis the percentile of the NNT distribution is shown, and in the y-axis the 
corresponding NNT. See Table 1 for details on included uncertainty and 
Supplemental Information Figures 1 and 2, for intermediate and high risk men. 
 
 
Discussion 
 
Individual characteristics, like age, comorbidity status and disease stage at detection 
have a decisive effect in the risk that a man does not benefit from prostate cancer 
screening, AS or treatment. The main strength of this study is that the effects of 
these individual factors are, as far as we know, for the first time quantified together 
when deciding between immediate treatment, AS and no treatment. 
 
If we consider a man screened yearly since age 55 and screen-detected at age 66 
with no comorbidity and in a low risk disease stage then the probability of 
overtreatment is 64% and NNT is 12. If this person was in a high risk disease stage 
this probability would decrease to 20% and NNT to 5. By contrast, if he had a 
severe comorbidity, NNT increases to 24 and the probability of overtreatment to 
80%. If he was detected at age 69 his NNT would be 16 and probability of 
overtreatment would equal 69%.  
 
Men screen-detected in a high risk disease stage have a relatively low NNT, 
probability of overtreatment and the largest amount of LY saved by screening. Even 
beyond the 55-69 age group there seems to be a significant benefit on treating these 
men. The same holds for intermediate risk men, younger than 70 and no 
comorbidities.  
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By contrast, for men detected in a low risk disease stage the probability of 
overtreatment and NNT are large. Offering AS to low-risk men older than 65 seems 
to be an attractive alternative to immediate treatment. Our projections show that 
overtreatment can be sharply reduced (> 30%), at the cost of a small PCM increase. 
For men older than 70 or with significant comorbidity these gains are even more 
pronounced.  
 
Currently, most ongoing observational cohorts of AS select these men and so far the 
results seem promising with few or none prostate cancer related deaths 20-22 
However, with the exception of  Klotz et al 23, the median follow-up is small (< 5 
years). There is some evidence in favor of including intermediate risk men in AS 24. 
We find that for intermediate risk men, the overtreatment reduction and PCM 
increase due to AS are proportionally similar to low risk men. However, this means 
for intermediate risk men, aged 66 and with no comorbidity that PCM increases 
from 5% to 11%, which many could consider to be a bar too high. By contrast, for 
men aged 72 with severe comorbidity, PCM increases only from 2.8% to 4.8%, 
which means that personal characteristics are important when choosing between 
immediate treatment and AS for intermediate risk men.   
 
Running a probabilistic sensitivity analysis with all parameters in the model would 
be too computationally expensive. Therefore we run an univariate sensitivity 
analysis for the cure parameter and the probabilities of detection in AS and a 
multivariate probabilistic sensitivity analysis with parameters related to the benefit 
of treatment and early detection only. Through this analysis we show that our results 
are relatively robust, since varying the values of the parameters by 20% would have 
a small impact in the projections.    
 
In this study we had to limit our analyses to men older than 65. This is the case 
since the comorbidity lifetables were based on Medicare data. While this can be 
considered a serious limitation, it was already shown that a large proportion of 
overdiagnosis occurs in men older than 60 7-9.  
 
Compared to Gulati et al 7, our study tries to address some of the criticisms given in 
Freidlin and Korn 25. For instance, they refer that the new USPSTF 
recommendation, would have a profound impact on screening patterns, and hence, 
on their estimates. We show that considering once in a lifetime screening (the most 
limited possible screening policy), changes the estimates of overtreatment and NNT, 
however the size of the change would have a negligible impact on any 
recommendation.   
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This model is a simplification of the natural history of prostate cancer. The 
comorbidity lifetables do not consider the possibility of interactions between 
comorbidity and the effect of treatment or cancer biology. Additionally, there is 
considerable uncertainty regarding the benefit of screening. Nonetheless, our results 
seem to be consistent with previous literature 7-9. 
 
In this study we did not model quality of life. It was previously shown 26, that the 
side effects of treatment could decrease the benefit of PSA testing up to 23%. 
Extrapolating this result to this study would likely mean that the QALY’s  saved 
will be of a smaller magnitude than the LY saved shown in Figure 1. 
 
We did not take into account the PSA level at screen-detection.  Gulati et al 7 found 
that men at lower PSA levels at detection are at a higher risk of being overtreated.   
Extrapolating this result to this study would likely translate to lower NNT for men 
with high PSA values at detection.  
 
Men screen-detected in a low risk disease stage (≤ T2aGS6) and their physicians 
should carefully consider the potential harms before deciding on aggressive 
treatment, as they are at great risk of overtreatment. A large majority of them could 
be safely handled with AS, and then, about a third will avoid treatment.  By 
contrast, those in a high risk disease stage (T3 or ≥ Gleason 4+3)  have a relatively 
low chance of overtreatment, and unless they have significant morbidities they are 
likely to benefit from immediate radical treatment even beyond age 69.   
 
Our findings highlight the importance of taking several risk factors into account, 
when making treatment decisions. We find that the pivotal variable is disease stage 
at screen-detection. However, age and comorbidity should also play a significant 
role on the decision to do radical treatment, active surveillance or watchful waiting, 
especially for intermediate risk men.  
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Supplemental Information 
 
Sensitivity Analyses 
 
Figure 1: Distribution of the NNT for intermediate risk men. * 
 
 
*In the x-axis the percentile of the NNT distribution is shown, and in the y-axis the 
corresponding NNT. See Table 2 for details on included uncertainty.   
 
 
 
Figure 2: Distribution of the NNT for high risk men, aged 66 and no comorbidity.* 
 
 
*In the x-axis the percentile of the NNT distribution is shown, and in the y-axis the 
corresponding NNT. See Table 2 for details on included uncertainty.   
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Table 1: Probabilities of PCM and overtreatment at screen-detection for men aged 66 
screened once, for different AS protocols.*  
AS protocol AS (basecase) 10 years 10 years, with triennial 
biopsies 
Disease Comorbid. No Mod Sev No Mod Sev No Mod Sev 
Risk  
Low Overtreat. 39.30 41.40 38.41 50.04 51.11 45.32 30.21 30.25 25.77 
 PCM 2.54 1.93 1.33 1.82 1.39 0.94 3.83 2.91 1.97 
           
Interm Overtreat. 20.34 24.24 28.13 24.32 27.86 30.78 7.74 11.31 18.65 
 PCM 10.49 8.82 6.42 9.61 8.15 5.97 12.31 10.32 7.41 
*Screen-Policies include annual screening starting at age 55 up to the age of screen-
detection of 66. Disease Risk at screen-detection is divided in Low (≤ T2aGS6), 
Intermediate ( ≥ T2aGS6, Gleason 3+4) Risk. Active Surveillance (AS) is only offered 
to low and intermediate risk men in all protocols. “AS (basecase)” denotes 6 years in 
in Active Surveillance with annual biopsies. “10 years” denotes 10 years in AS with 
annual biopsies. “10 years, with triennial biopsies” denotes a biopsy follow-up 
protocol where after the first year, there is a biopsy every three years. Comorbidity 
categories include no comorbidity (“No”), moderate comorbidity (“Mod”) and severe 
comorbidity (“Sev”). PCM denotes prostate cancer mortality.  
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Table 2: Univariate Sensitivity Analyses* 
Age at detection Basecase 20% Less Sensitivity 20% More   
Sensitivity 
PCa Comorbidity No Mod Sev No Mod Sev       No Mod Sev 
Risk  
Low  Overtreat. [IRT] 64.2 71.0 80.3       
 PCM [IRT] 0.8 0.7 0.4       
 Overtreat. [AS] 39.3 41.4 38.4 35.2 37.0 34.1 42.5 44.8 42.1 
 PCM [AS] 2.5 1.9 1.3 3.0 2.3 1.6 2.3 1.7 1.2 
 NNT 12 15 24       
           
Interm.  Overtreat. [IRT] 30.7 37.9 50.7       
 PCM [IRT] 5.1 4.4 3.3       
 Overtreat. [AS] 20.3 24.2 28.1 19.0 22.7 26.4 21.3 25.4 29.4 
 PCM [AS] 10.5 8.8 6.4 11.1 9.3 6.7 10.1 8.5 6.2 
 NNT 5 7 10       
     20% Less Cure 20% More Cure 
 Comorbid. No Mod Sev No Mod Sev No Mod Sev 
Low  Overtreat. [IRT] 64.2 71.0 80.3       
 PCM [IRT] 0.8 0.7 0.4 1.2 1.0 0.6 0.6 0.5 0.3 
 Overtreat. [AS] 39.3 41.4 38.4       
 PCM [AS] 2.5 1.9 1.3 2.9 2.2 1.5 2.4 1.8 1.2 
 NNT 12 15 24 12 16 25 12 15 23 
           
Interm.  Overtreat. [IRT] 30.7 37.9 50.7       
 PCM [IRT] 5.1 4.4 3.3 6.4 5.4 4.0 4.3 3.7 2.8 
 Overtreat. [AS] 20.3 24.2 28.1       
 PCM [AS] 10.5 8.8 6.4 11.3 9.4 6.8 9.9 8.3 6.1 
 NNT 5 7 10 6 7 10 5 6 9 
           
High  Overtreat.  19.9 28.9 46.1       
 PCM 16.5 14.9 11.4 18.9 17.0 12.8 14.5 13.2 10.1 
 NNT 2 2 3 3 4 6 3 4 5 
* First half of the table concerns sensitivity analyses about probabilities of detection 
in Active Surveillance (AS), therefore only AS estimates are affected. Lower half of 
the table concerns the cure rate and therefore only prostate cancer mortality (PCM) 
and number needed to treat to save a life (NNT) are affected. Screen-Policies include 
annual screening starting at age 55 up to the age of screen-detection of 66. Disease 
Risk at screen-detection is divided in Low (≤ T2aGS6), Intermediate ( ≥ T2aGS6, 
Gleason 3+4) and High (≥ Gleason 4+3 or ≥ T3). Active Surveillance (AS) is only 
offered to low and intermediate risk men in all protocols. Comorbidity categories 
include no comorbidity (“No”), moderate comorbidity (“Mod”) and severe 
comorbidity (“Sev”). 
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Abstract  
 
Purpose: Active Surveillance (AS) for prostate cancer is a way to 
decrease overtreatment due to prostate specific antigen (PSA) 
based screening, among low-risk men. We estimate the cost-
effectiveness of different Active Surveillance protocols compared 
to immediate treatment.  
 
Methods:  We use a microsimulation model of screening and AS, 
based on data from ERSPC and SEER, for the natural history of 
prostate cancer and Johns Hopkins AS cohort data to inform 
probabilities of referral to treatment during AS. We simulate a 
cohort of 10 million men based on US lifetables. We project the 
lifetime costs and effects of multiple screening and AS protocols 
and determine their cost-effectiveness. 
 
Results: Quadrennial screening between ages 55-69 with AS for 
low-risk men and yearly biopsies or triannual biopsies resulted in 
an incremental cost per QALY of $51,918 or $69,380, respectively. 
Most policies where screening was followed by immediate 
treatment were dominated. In most sensitivity analyses, we found 
a policy where cost per QALY remained below $100,000.   
 
Conclusions: AS is more cost-effective than immediate 
treatment. Within the AS protocols considered, admitting only 
low-risk men with triannual biopsies seems to be more efficient, 
however the differences between AS protocols are small. Limited 
screening combined with AS could be cost-effective at a $100,000 
threshold. 
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Introduction 
 
Frequent PSA-based screening in the US has led to concerns that a substantial 
proportion of screen-detected men may be overdiagnosed and overtreated. Active 
Surveillance (AS) for prostate cancer consists in the monitoring of newly diagnosed 
and not yet treated men through PSA tests and/or repeat biopsies.  
 
The main goal of AS is to delay or avoid the treatment of patients who will likely 
derive no benefit from immediate treatment, and hence, to significantly reduce the 
harms of prostate cancer screening, while preserving the prostate cancer mortality 
(PCM) reduction. 
 
There are currently several cohorts following the outcomes of men on AS: Prostate 
Cancer Research International Active Surveillance (PRIAS) [1], University of 
California at San Francisco [UCSF] cohort [2], Johns Hopkins [JH] [3], the Toronto 
cohort [4] among others [5,6]. However, with the exception of the Toronto cohort, 
their median follow-up times are shorter or equal to 5 years, which is not long 
enough to establish the long term effects [1-6].  
 
Currently, the rates of prostate cancer specific mortality in AS are relatively low and 
there is an emerging consensus that AS is safe for low-risk (T-stage T2a, Gleason 6) 
patients [7,8]. Some cohorts include intermediate risk patients (Gleason 3+4) 
though with mixed outcomes [2,4].  
 
Given the limited nature of the follow-up data of most AS cohorts, computer 
modelling was used to make projections of the potential effects of AS on PCM and 
overtreatment.  Previous modelling studies  [9,10] found that compared to 
immediate treatment, AS results in a modest increase in PCM. 
 
However, a critical aspect missing from these studies is not to consider quality of 
life and costs associated with AS, when comparing with immediate treatment.  For 
instance, Heijnsdijk et al [11] found that considering quality of life will decrease the 
benefits of screening by 23%, which suggests that including quality-adjusted life 
years (QALYs) will have a major impact on the projected harms and benefits of 
immediate treatment when compared to different AS protocols. Previous studies 
[12, 13] found that watchful waiting and AS are more cost-effective than immediate 
treatment, but without explicitly modelling the AS protocol. 
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In this study we present estimates of the cost-effectiveness of several screening 
policies combined with immediate treatment against screening combined with AS 
for low-risk men. Additionally we study whether AS protocols could be improved 
by admitting intermediate risk men, or by having a lower biopsy frequency.    
 
Methods 
 
Simulation Model 
 
MISCAN is a microsimulation model designed to evaluate the effects of prostate 
cancer screening. A detailed description is available in [10,14], 
http://cisnet.cancer.gov/prostate/profiles.html and in previously published studies 
[15-17]. 
   
The natural history model contains 18 health states corresponding to the 
combination of 3 stages (T1, T2 and T3), 3 grades (Gleason < 7, 7, > 7) and whether 
or not cancer is metastasized. Additional states were created to model AS. Men in 
T2-stage, Gleason 6 are classified as T2a or T2bc and Gleason 7 men as 3+4 or 4+3, 
depending on their remaining lead-time and age group. Initially, natural history 
parameters, which include onset of the disease, durations and transition probabilities 
between health states were calibrated to observed ERSPC incidence data [15,16]. 
This model was adapted to the US situation by adding an extra hazard of clinical 
diagnosis and obtaining US-specific estimates for other parameters, using SEER 
data.  
 
The prostate cancer survival without treatment is assigned at clinical detection and 
depends on Gleason score. It was estimated based on SEER data from the pre-PSA 
era (1983-1986). In order to correct for improvements on survival not directly 
associated with screening or primary treatment, we add a hazard ratio for prostate 
cancer survival of 0.82, which was calibrated to the observed PCM in the ERSPC 
control (no screening) group [14].  
 
In case the patient is screen-detected and referred to AS, natural history progresses 
as if he was not screen-detected. A patient may exit AS due to Gleason or volume 
progression (which is assumed can only occur after an increase in stage) at each 
biopsy round, due to personal preference or if he would be clinically detected at the 
time. The probabilities of referral to radical treatment are estimated based on JH-AS 
observed treatment-free survival data, with the rate of disease progression based on 
our natural history model. For intermediate risk men we assume that the 
probabilities of referral to treatment, given progression are similar to low-risk men. 
(Model Appendix Tables 8 and 9).  
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The hazard ratios for prostate cancer survival after radical treatment equal 0.56 for  
radical prostatectomy (RP) based on Bill-Axelsson et al [18] and 0.63 for radiation 
therapy (RT) (maintaining the same ratio of benefit between RP and RT from [19]). 
The effect of screening is dependent on the remaining lead-time for non-metastatic 
cases,   
Cure probability =  exp(cure parameter * lead-time).   
 
The cure parameter was calibrated to the observed PCM reduction in the ERSPC 
trial after 11 years of follow-up and equals -0.22 [14]  (Model Appendix Table 5 and 
6).  
 
Screening and AS protocols 
 
We simulate a cohort of 10 million men, aged 55 in 2015, based on US lifetables. In 
the basecase, men are screened between 55-69 (with an attendance rate of 90%), 
with PSA threshold for biopsy referral of 4, biopsy compliance equal to 41%, based 
on the PLCO trial [20], and every man is immediately treated. 
   
We compare the immediate treatment situation with assigning low risk men (T2a-
Stage, Gleason 6, PSA<10) to AS, followed with yearly biopsies. Other AS 
protocols, also include intermediate risk men or a triannual interval between 
biopsies, after the first year. We assume all men classified as low-risk are selected 
for AS. The biopsy compliance during AS is based on PRIAS observed biopsy 
compliance (See ref. 21 and Model Appendix Table 10).  
 
Additionally, we also examine the effect of changing the intensity of screening, by 
combining AS with screening strategies with an earlier stopping age (61) or lower 
screening frequency (2 and 4-year).   
 
Quality of Life and Costs  
 
QALYs were calculated by using utility estimates ranging between 0 (death or worst 
imaginable health) and 1 (full health). Utility estimates and durations concerning all 
stages of early detection are based on [11, 22, 23]. In particular, the utility for the 
post-recovery from radical treatment was calculated based on [22,23] (Model 
Appendix Table 11).  The costs of screening are based on [11]. The cost of 
immediate treatment is an estimate from another simulation model [24]. Costs of 
palliative therapy are based on [25]. Costs do not include indirect costs (except in 
sensitivity analysis). (Table 1) 
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Table 1: Utilities, durations and costs of screening and treatment* 
Event Utility Duration (Years) Cost (US dollars) 
Screening 0.99 0.02 151 
Biopsy 0.90 0.06 743 
Cancer Diagnosis 0.80 0.08 - 
RT , < 2 months 0.73 0.16 23,565# 
RT , 2-12 months 0.78 0.84  
RP , < 2months 0.67 0.16 16,946# 
RP, 2-12 months 0.77 0.84  
AS (Surveillance 
Costs)§ 
- 6 245 (per year) 
Post-Recovery 0.95** 9  
Palliative Therapy 0.60 2.5 48,472 & 
Terminal Illness 0.40 0.5  
* All utilities and durations based on [11].  
# Cost of radical prostatectomy (RP) and radiation therapy (RT) includes surveillance costs 
[24].  
§ Surveillance costs of AS, include 4 PSA tests and one visit to the doctor per year, for 6 years. 
These costs do not include yet the cost of biopsy, as this depends on the AS protocol.  
& Based on [25].  
** Based on data from [11, 22, 23]. For calculation, see Supplementary Table 3. 
 
Outcomes 
 
We estimate the cost-effectiveness of each AS protocol and immediate treatment. 
The main outcome is the incremental cost effectiveness ratio (ICER).  The average 
cost per QALY gained is relative to the situation with no screening and assuming 
every clinically detected man is treated immediately. We also show cancers 
diagnosed and overdiagnosed, prostate cancer mortality and life years (LYs), and 
the overall cost of the screening program.  
 
Sensitivity Analyses 
 
In order to assess the effect of uncertainty around the parameter estimates on the 
outcomes, several multivariate sensitivity analysis are performed including the 
utility and cost estimates for each event, the parameters of the model related to 
treatment benefit and referral to treatment while in AS, the benefit due to early 
detection, and the effect of discounting (Table 2).   
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Table 2: Overview of included uncertainty in the multivariate sensitivity analyses* 
Parameter Value Range 
Cure Parameter   
cure parameter -0.22 Min=-20%, Max = +20% 
Hazard Ratio Treatment and baseline Survival  
hazard ratio improvement baseline survival 0.82 Min=-20%, Max = +20% 
hazard ratio of RP 0.56 0.41, 0.77 # 
hazard ratio of RT 0.63 0.46, 0.87 # 
Active Surveillance Parameters   
sensitivity to Gleason Progression  0.4 Min=-20%, Max = +20% 
probability detection volume upgrade (T2a) 0.1 Min=-20%, Max = +20% 
probability detection volume upgrade (>T2a) 0.5 Min=-20%, Max = +20% 
probability referral to treatment without 
progression 
0.04 Min=-20%, Max = +20% 
Utilities (Favourable , Unfavourable) &   
Screening 0.99 1.00, 0.98 
Biopsy 0.90 0.87, 0.94 
cancer diagnosis 0.80 0.85, 0.75 
RT , < 2 months 0.73 0.75, 0.71 
RT , 2-12 months 0.78 0.88, 0.68 
RP , < 2months 0.67 0.78, 0.56 
RP, 2-12 months 0.77 0.84, 0.70 
post-recovery 0.95§ 0.93, 0.97 
palliative therapy 0.60 0.24, 0.86 
terminal illness 0.40 0.24, 0.56 
*  In two additional separate analyses, all costs are varied by more and less 50% and cost-
effectiveness is recalculated with 0% and 6% discount.  RP denotes radical prostatectomy, RT 
denotes radiation therapy.  
# Confidence interval for hazard ratio of RP, is the observed in [18]. The confidence interval of 
RT was extrapolated using the same ratio as in [19]. 
& Adapted from [11].  “Favorable/Unfavorable” refers to whether this utility gives a 
higher/lower  QALY gained by screening, respectively.  
§ Based on [11, 22 and 23].  See Supplement Table 3 for details.  
 
 
Results 
 
Effects 
 
In Table 3, the effects of screening yearly, followed by immediate radical treatment 
or AS are shown. 158 cancers per 1000 screened men were diagnosed of which 53 
were screen-detected, resulting in 23 overdiagnosed cancers and in a prostate cancer 
mortality reduction of 23%.  We estimated, at a 3% discount rate, that 30 life years 
were saved by screening, but adjusting for quality of life, this number reduced to 17 
(See Supplementary Information Table 1 for the undiscounted values).   
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By referring all low-risk patients to AS, life years gained reduced to 28, however 
QALYs increased to 18. Selecting intermediate risk men for AS resulted on 16 
QALY’s gained. Stopping screening at age 61 resulted on 12 QALY’s gained, both 
with immediate treatment and AS. Reducing the frequency of screening to every 2 
years resulted in about 14 to 15 QALY’s gained depending on the AS protocol, or 
10 to 11 QALY’s gained, for quadrennial screening.  
 
Costs    
 
The cost of screening and treatment, yearly, between ages 55 and 69, relative to the 
no screening situation was about $1.8 million for 1000 screened men, for immediate 
treatment and $1.7 million AS with yearly biopsies. If we stop screening at age 61 
or reduce the frequency to every 2 or 4 years the cost becomes, respectively, $0.9 
million, $1.0 million or $0.6 million per 1000 screened men. 
 
Average Cost per QALY   
 
The cost per QALY gained of screening men yearly between 55 and 69 and treating 
every man immediately was about $103,037. By referring low-risk men to AS, with 
yearly or 3-year biopsies this reduced, respectively, to $91,979 or $91,654. 
Reducing the number of screens by stopping screening at age 61, or screen every 2 
or 4 years resulted in a cost per QALY of $75,510 or $73,590 or $55,673, 
respectively.  
 
Incremental Cost-Effectiveness 
 
Of all the screening and AS policies considered, we determined which were the 
most efficient based on their incremental cost-effectiveness ratio.  Most policies 
where screening was followed by immediate treatment or where screening was 
followed with AS for low and intermediate risk men were dominated, that is, they 
were more expensive and resulted on less QALYs gained.  
Screening between ages 55 and 69 every four years and offering AS for low-risk 
men, with yearly or triannual biopsies resulted in an incremental cost per QALY 
lower than the $100,000 threshold.  
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Table 4: Costs and Effects of immediate radical treatment (IRT) compared to Active 
Surveillance (AS), per screening intensity.* 
Screen 
Policy 
Treatm. & Over
dx 
PCM 
reducti
on (%) 
LYs QALY’
s 
Total 
Cost# 
Averag
e Cost 
per 
QALY 
ICER 
** 
55-69,              AS, 3-year  11 13.8 10.0 0.52 51,645 51,645 
4-year§ AS, Interm  11 13.6 9.8 0.52 53,304 Domin. 
 AS, yearly   12 14.6 10.3 0.54 51,991 64,436 
 IRT 11 12 15.2 9.9 0.55 56,171 Domin. 
55-61, AS, 3-year  9 12.9 10.4 0.83 80,035 Weak D 
Yearly AS, Interm  9 13.1 10.5 0.85 80,857 Weak D 
 AS, yearly   10 14.0 11.1 0.86 76,869 Weak D 
 IRT 6 10 15.4 11.3 0.87 77,500 Weak D 
55-69,              AS, 3-year  17 20.4 14.1 0.94 66,310 104,628 
2-year AS, Interm  16 19.5 13.7 0.95 68,912 Domin. 
 AS, yearly   18 21.7 14.5 0.97 67,220 105,695 
 IRT 18 19 22.8 13.4 1.02 75,620 Domin. 
55-69,  AS, 3-year  20 24.6 17.2 1.61 93,443 Weak D 
Yearly AS, Interm  20 24.1 16.9 1.63 96,816 Domin. 
 AS, yearly   22 26.9 17.9 1.66 93,108 203,135 
 IRT 23 23 28.7 16.2 1.73 106,822 Domin. 
* Effects per 1000 screened men. Costs and Effects are discounted at 3%. Costs are shown in 
millions of 2015 US dollars. QALYs were calculated by multiplying the loss in utility with the 
duration of the phase and the number of men who experienced the event, as predicted by 
MISCAN. See Supplement Table 4 for additional effects. 
& IRT, denotes immediate radical treatment, which can be either radical prostatectomy or 
radiation therapy with equal probability. AS denotes Active Surveillance. “yearly” denotes 
yearly biopsies, “3-year” denotes a biopsy every three years after the first year and “Interm” 
denotes admitting low and intermediate risk patients for AS, with yearly biopsies.  
§ Screening at ages 55, 59, 63 and 67. 
# Includes screening costs, treatment costs and palliative therapy costs, which we assume was 
given to all men who died of prostate cancer. Net costs were calculated by the difference in total 
costs in a situation without screening and the total costs in a situation with screening. 
** “Domin.” denotes dominated. A policy is classified as, dominated,  if there is another policy 
that has a lower cost and results in more QALY’s gained.  “Weak D” denotes weakly dominated 
policies, that is, they are less effective policies that have a higher cost-effectiveness ratio than 
the next ranked policy. 
 
 
Multivariate Sensitivity Analyses 
 
In the multivariate sensitivity analyses we focus on screening between 55 and 69 
every 4 years. If the set of “unfavorable utilities” is used, the (incremental) cost per 
QALY significantly increases in all cases, and AS with yearly biopsies which was 
efficient in the basecase, becomes dominated. With the set of “favorable utilities” 
immediate treatment dominates the other alternatives. (Supplementary Information 
Table 2, Figure 1). Computing the cost-effectiveness with a 6% discount rate 
resulted in a situation where no policy has a cost per QALY lower than $100,000. If 
there was no discounting, AS would lose its advantage and immediate treatment 
would become cost-effective.  (Supplementary Information Table 2, Figure 1). 
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Figure 1: Incremental Costs per QALY gained (ICER) by screening and Active 
Surveillance under different  modelling assumptions.* § 
 
 
 
*Basecase includes the cost per QALY of screening between ages 55 and 69, every 4 
years, with a PSA threshold for biopsy referral of 4 and a biopsy compliance of 41% 
(in the screening phase),  compared with no screening and immediate treatment. The 
AS protocol in the basecase consists of yearly biopsies, with biopsy compliance given 
by observed PRIAS data [21].  
 
 
 
We also varied several sets of model parameters. In all situations immediate radical 
treatment and AS for low and intermediate risk men remain dominated. In 
particular, a lower hazard ratio for treatment and baseline survival (more lives saved 
by treatment), results in a higher cost per QALY in all cases. Varying the 
probabilities of referral from AS to immediate treatment has a low impact on the 
cost per QALY of AS (Supplementary Information Table 3, Figure 1). 
 
Discussion 
 
In this study we estimate the costs and effectiveness associated with screening 
followed with active surveillance or immediate treatment, compared with no 
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screening. We find that AS is more cost-effective than Immediate Treatment. In 
most cases, AS results in more QALYs and less costs than immediate treatment.  
We find two screening and AS policies that result in a cost per QALY lower than 
$100,000. This is the case if we screen every 4 years between ages 55 and 69 and 
refer low-risk men to AS with yearly or triannual biopsies. Referring intermediate 
risk men for AS, does not seem to be cost-effective. While the AS protocol with 
triannual biopsies seems more efficient, the differences between the AS protocols 
are small. 
 
The gain of AS is explained by the overall lower costs, due to less treatment costs, 
combined with the fact that it maintains a similar or higher level of effectiveness 
than immediate radical treatment, when we discount the effects at 3% and adjust life 
years gained with quality of life loss due to treatment.  
 
Our sensitivity analyses show that these findings are robust to changes in the most 
important model parameters, utilities and costs, though the most efficient screening 
and AS protocol may change. The only scenarios where AS would lose its 
advantage relative to immediate treatment would occur if we would not use 
discounting or if we would use the set of more favourable utilities towards 
screening and treatment. Screening every 4-years with AS may result in an 
incremental cost per QALY higher than $100,000 if we would increase the discount 
rate to 6%.  
 
Previous literature suggests that AS has the potential to significantly reduce the 
harms of prostate cancer screening, while keeping a large portion of the benefit 
[7,9-13]. Some studies focused on the costs of AS relative to other therapies [12, 13, 
24, 26-29]. The majority of these studies report that AS has lower costs than 
immediate treatment, a fact which we also found in our study. Only two studies 
focused on the cost-effectiveness of AS [12,13]. 
 
Our study is the first to link the cost-effectiveness of AS with the screening 
schedule and to compare the cost-effectiveness of different AS protocols. 
Furthermore, our model has a natural history of prostate cancer based on a large 
randomized control trial, with probabilities of progression while on AS, based on 
the JH cohort. In contrast to [12,13] we model AS explicitly. Additionally [12] was 
criticized by using a debatable set of assumptions [30].  
 
The results of this study are also subject to some limitations. The costs of treatment 
were obtained from the lifetime estimates from another microsimulation model 
[24]. We found the utility estimates have a significant effect in the cost per QALY. 
In particular, the results are sensitive to the utility of post-recovery of treatment, 
since it has a duration of 9 years, by assumption.  
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Our AS model uses a simplification of the actual criteria for selection and later, 
referral to treatment. For instance, while our model uses PSA, T-stage and Gleason, 
as selection criteria, most AS cohorts also use number of positive biopsy cores or 
PSA density [6].  
 
The probabilities of referral to treatment while in AS are based on a single cohort 
[3]. Other cohorts have slightly different populations, usually with less strict 
selection criteria than JH, and may have different follow-up protocols [6]. For 
instance, in the Toronto cohort [4], which does a biopsy every 3 or 4-years, the 
treatment-free survival is significantly higher than in JH.   
Our model of AS assumes 100% referral of low-risk men to AS. The pattern of 
usage of AS by low-risk men seems to be changing rapidly, as it went from 14% to 
about 40% in the CaPSURE registry in the period 2010-2013 [31], but it is still far 
from 100%.   
 
Prostate cancer screening is still a controversial topic. The USPSTF [32] 
recommended against PSA-based prostate cancer screening, however, in a previous 
study it was suggested that limited screening could be cost-effective [33]. This 
study did not model the effect of including all low risk men in AS.  Since we found 
that for most screening policies, referring low-risk men for AS is more cost-
effective, adding AS to [33] could change the optimal age to stop screening to a 
later age. 
 
We believe there is room for improvement in the cost per QALY [34]. For instance, 
Siddiqui et al [35] found that the so called “targeted” MR-guided biopsy has a 
significantly higher sensitivity and specificity for intermediate and high-risk tumors 
than standard biopsy, while diagnosing less low-risk prostate cancers. The 
application of this technology could therefore substantially reduce the amount of 
progression during AS. 
 
In this study we found that AS is more cost-effective than immediate treatment, 
after considering a variety of screening policies and AS protocols. Out of the three 
AS protocols considered, it seems that offering AS to low-risk men and triannual 
biopsies is more efficient, however, the differences between protocols are relatively 
small and may change depending on the screening schedule. Additionally, this study 
suggests that limited screening (every 4 years) together with AS could be cost-
effective at a willingness to pay threshold of  $100,000.  
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Supplementary Information 
 
Additional Outcomes  
 
Table 1: Effects of immediate radical treatment (IRT) compared to Active 
Surveillance (AS), per screening intensity. * 
 Treatment
& 
Dx Screen-
Detected 
PCM  LYs QALYs 
55-69, 4-year § AS, 3-year   29 33 31 
 AS, Interm   29 31 29 
 AS, yearly    29 35 33 
 IRT 149 27 29 36 33 
55-61, Yearly AS, 3-year   29 30 29 
 AS, Interm   29 30 29 
 AS, yearly    29 33 33 
 IRT 142 19 29 35 34 
55-69,  2-year AS, 3-year   27 49 45 
 AS, Interm   27 46 43 
 AS, yearly    26 52 48 
 IRT 154 44 26 55 48 
55-69,  Yearly AS, 3-year   26 58 54 
 AS, Interm   26 55 50 
 AS, yearly    25 64 58 
 IRT 158 53 25 68 60 
* Effects per 1000 screened men. Effects are shown undiscounted.  QALYs were 
calculated by multiplying the loss in utility with the duration of the phase and the 
number of men who experienced the event, as predicted by MISCAN.  
§ Screening at ages 55, 59, 63 and 67. 
& Dx denotes diagnosis, IRT, denotes immediate radical treatment which can be 
either radical prostatectomy or radiation therapy. AS denotes Active Surveillance. 
“yearly” denotes yearly biopsies, “3-year” denotes a biopsy every three years after the 
first year and “Interm” denotes admitting low and intermediate risk patients for AS, 
with yearly biopsies.  
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Sensitivity Analyses 
 
Table 2: Costs and Effects of immediate radical treatment (IRT) compared to Active 
Surveillance (AS),  for men screened between ages 55 and 69 every 4 years, under 
several asssumptions.* 
Assumption Treatment& LYs QALY’s Total 
Cost# 
Average 
Cost per 
QALY 
ICER ** 
Favorable  AS, 3-year 14.6 14.6 0.54 36,650 Weak D 
Utility  AS, Interm 13.6 13.6 0.55 40,382 Domin 
 AS, yearly  15.4 15.3 0.56 36,162 Weak D 
 IRT 16.0 15.9 0.57 35,834 35,834 
Unfavorable  AS, 3-year 14.6 6.2 0.54 86,460 86,460 
Utility  AS, Interm 13.6 5.7 0.55 95,870 Domin 
 AS, yearly  15.4 6.1 0.56 90,289 Domin 
 IRT 16.0 5.3 0.57 107,360 Domin 
50% lower AS, 3-year 14.6 10.3 0.27 25,959 25,959 
Costs AS, Interm 13.6 9.6 0.27 28,526 Domin 
 AS, yearly  15.4 10.6 0.28 26,199 34,690 
 IRT 16.0 10.2 0.29 27,836 Domin 
50% higher AS, 3-year 14.6 10.3 0.80 77,877 77,877 
Costs AS, Interm 13.6 9.6 0.82 85,579 Domin 
 AS, yearly  15.4 10.6 0.83 78,597 104,070 
 IRT 16.0 10.2 0.85 83,509 Domin 
Including AS, Interm 13.6 9.6 0.72 74,949 Weak D 
Indirect costs AS, 3-year 14.6 10.3 0.72 69,995 69,995 
 AS, yearly  15.4 10.6 0.74 70,147 75,525 
 IRT 16.0 10.2 0.75 73,296 Domin 
No discount AS, 3-year 33.1 30.5 0.51 16,863 Weak D 
 IRT 36.4 32.5 0.53 16,451 16,451 
 AS, yearly  35.0 31.8 0.54 16,873 Domin 
 AS, Interm 31.1 28.3 0.55 19,605 Domin 
6% Discount AS, Interm 6.4 2.4 0.51 208,036 Weak D 
 AS, 3-year 6.9 2.5 0.51 207,304 207,304 
 AS, yearly  7.3 2.4 0.52 218,317 Domin 
 IRT 7.6 1.7 0.55 325,765 Domin 
* Effects per 1000 screened men. Costs and Effects are discounted at 3%. Costs are 
shown in millions of 2015 US dollars. QALYs were calculated by multiplying the loss 
in utility with the duration of the phase and the number of men who experienced the 
event, as predicted by MISCAN.  
& IRT, denotes immediate radical treatment, which can be either radical 
prostatectomy or radiation therapy with equal probability. AS denotes Active 
Surveillance. “yearly” denotes yearly biopsies, “3-year” denotes a biopsy every three 
years after the first year and “Interm” denotes admitting low and intermediate risk 
patients for AS, with yearly biopsies.  
# Includes screening costs, the difference in treatment costs between the situation 
with and without screening and the difference in costs due to the reduction in 
palliative therapy, which we assume was given to all men who died of prostate 
cancer.  
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Table 3: Costs and Effects of immediate radical treatment (IRT) compared to Active 
Surveillance (AS),  for men screened between ages 55 and 69 every 4 years, under 
several asssumptions.* 
Assumption Treatment
& 
LYs QALY’s Total 
Cost# 
Average 
Cost per 
QALY 
ICER ** 
More Cure AS, 3-year 15.5 11.4 0.53 46,607 46,607 
(20%) AS, Interm 14.5 10.6 0.54 51,129 Domin 
 AS, yearly  16.4 11.7 0.55 46,944 58,099 
 IRT 17.0 11.3 0.56 49,694 Domin 
Less Cure AS, 3-year 13.3 8.8 0.54 61,465 61,465 
(20%) AS, Interm 12.4 8.2 0.56 67,620 Domin 
 AS, yearly  14.0 9.0 0.56 62,184 90,038 
 IRT 14.6 8.7 0.58 66,529 Domin 
Lower HR AS, 3-year 11.7 6.9 0.55 79,527 79,527 
Treatment AS, Interm 10.9 6.5 0.56 86,975 Domin 
(20%) AS, yearly  12.3 7.0 0.57 81,319 196,617 
 IRT 12.8 6.5 0.59 90,219 Domin 
Higher HR AS, 3-year 17.8 14.0 0.52 36,902 36,902 
Treatment AS, Interm 16.6 13.0 0.53 40,772 Domin 
(20%) AS, yearly  18.8 14.5 0.54 36,963 38,694 
 IRT 19.6 14.3 0.55 38,333 Domin 
Higher AS, 3-year 14.8 10.4 0.54 51,730 51,730 
Probabilities AS, Interm 14.0 9.8 0.54 56,437 Domin 
of referral   AS, yearly  15.5 10.6 0.56 52,496 87,596 
 IRT 16.0 10.2 0.57 55,673 Domin 
Lower AS, 3-year 14.4 10.2 0.53 52,172 52,172 
Probabilities AS, Interm 13.2 9.4 0.55 57,645 Domin 
of referral   AS, yearly  15.2 10.6 0.55 52,242 54,185 
 IRT 16.0 10.2 0.57 55,673 Domin 
* Effects per 1000 screened men. Costs and Effects are discounted at 3%. Costs are 
shown in millions of 2015 US dollars. QALYs were calculated by multiplying the loss 
in utility with the duration of the phase and the number of men who experienced the 
event, as predicted by MISCAN.  
& IRT, denotes immediate radical treatment, which can be either radical 
prostatectomy or radiation therapy with equal probability. AS denotes Active 
Surveillance. “yearly” denotes yearly biopsies, “3-year” denotes a biopsy every three 
years after the first year and “Interm” denotes admitting low and intermediate risk 
patients for AS, with yearly biopsies.  
# Includes screening costs, the difference in treatment costs between the situation 
with and without screening and the difference in costs due to the reduction in 
palliative therapy, which we assume was given to all men who died of prostate 
cancer.  
** ICER stands for, Incremental Cost-Effectiveness Ratio.  “Domin” denotes 
dominated. A policy is classified as “Dominated” if there is another policy that has a 
lower cost and results in more QALY’s gained.  “Weak D” denotes weakly dominated 
policies, that is, they are less effective policies, that have a higher cost-effectiveness 
ratio than the next ranked policy. 
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Abstract 
 
Background: A significant proportion of screen-detected men 
with prostate cancer may be overdiagnosed. Active Surveillance 
(AS) has emerged as a way to mitigate this problem, by delaying 
treatment of men, who are at low-risk until this becomes 
necessary. However, it is not known after how much time or 
biopsy rounds should patients stop AS and transition to 
conservative management (CM), if no progression is detected.  
 
Methods: We used a microsimulation model with natural history 
of prostate cancer based on ERSPC and SEER data. We modeled 
referral to treatment while in AS, based on Johns Hopkins 
treatment-free survival data. We projected lifetime costs and 
effects of AS (and radical treatment, if progression is detected) 
under different biopsy follow-up schedules compared to CM, 
where radical treatment only occurs when men would be clinically 
diagnosed in absence of screening.    
 
Results: For men with low-risk disease in younger age groups 
(55-65), AS is cost-effective for up to 7 yearly biopsy rounds. For 
men older than 65, even one biopsy round results in quality 
adjusted life years (QALYs) lost, though it may result in QALYs 
gained for men without previous screening. For men with 
intermediate risk disease AS is cost-effective even for men in 65-
75 age group. 
 
Conclusion: The benefit of AS when compared to CM is strongly 
dependent on life expectancy and disease risk. Clinicians should 
take this into account when selecting men to AS, deciding on 
biopsy frequency and when to stop AS surveillance rounds and 
transition to CM.  
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Introduction 
 
Active Surveillance (AS) has emerged as a way to minimize overtreatment due to 
frequent PSA-based prostate cancer screening. It consists of the monitoring of 
newly diagnosed and not yet treated men through PSA tests and/or repeat biopsies. 
The goal of AS is to delay or avoid radical treatment in patients who are unlikely to 
become symptomatic 1. In the conservative management (CM) regimen patients are 
also monitored, although not with invasive procedures like, prostate biopsies, and 
without curative intent, unless the patient becomes symptomatic. It is similar to 
watchful waiting, though this term often refers only to older men, or men with 
major comorbidities 1.  
 
The majority of clinical cohorts following men on AS  have a limited follow-up, 
which is not long enough to establish the long term effects 2-7, however there is an 
emerging consensus regarding the safety of AS for low-risk men 8-10, and the rate of 
low-risk men assigned to AS is increasing rapidly 11. Still there is substantial 
uncertainty about what is the most optimal way of performing AS, namely about 
whom to include and the follow-up protocol 8-10.  
 
Computer modelling has been used to make projections of the potential effects of 
AS on prostate cancer mortality (PCM) and overtreatment. Previous studies 12, 13 
found that compared to immediate treatment, AS results in a modest increase in 
PCM (1.4% and 1.8%, respectively). Others 14-17 have compared the costs or cost-
effectiveness of AS and/or CM to immediate treatment and found that AS seems to 
be more advantageous. As far as we know, no simulation study has tried to optimize 
the age to stop AS and start CM. 
 
There are virtually no clinical studies on when can a patient safely discontinue AS, 
if no progression is detected and stop being considered for radical treatment, which 
may potentially lead to treatment decisions to depend on personal or physician’s 
preferences. In the PRIAS cohort, the compliance with PSA testing during AS was 
relatively high, however the compliance with prostate biopsies is relatively low and 
decreases rapidly over time from 81% at 1 year to 33% after 10 years 18. A recent 
study 19 using SEER data found that only 13% of men underwent prostate biopsy 
after 2 years, in a community setting. For older patients or men suffering from 
significant comorbidities, this is probably reasonable, however, for patients with a 
longer life expectancy there could be a danger of progression to advanced disease, 
due to non-adherence to the biopsy protocol.  
 
The aim of this study is to determine at which age it is safe and more cost-effective 
to leave AS and transition to a CM context, for different age and disease risk 
groups. We use a previously validated 12, 20 microsimulation model of prostate 
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cancer screening and AS, and compare the incremental cost-effectiveness of each 
additional AS biopsy round with CM.  
 
Methods 
 
Simulation Model 
 
MISCAN is a microsimulation model designed to evaluate the lifetime effects of 
prostate cancer screening. A detailed description is available in the Model 
Appendix, in http://cisnet.cancer.gov/prostate/profiles.html and in previously 
published studies 12, 21.   
 
Men may experience onset of prostate cancer, based on a constant hazard per age 
group. In each disease stage, a man may progress to a higher T-stage, a higher 
grade, become metastasized or clinical diagnosed. We modeled 18 health states 
corresponding to the combination of 3 stages (T1, T2 and T3), 3 grades (Gleason 
less than 7, 7, and more than 7) and whether or not cancer is metastasized.  
 
Additional states were created specifically to model AS. Men in T2-stage, Gleason 
6 were classified as T2a or T2bc and Gleason 7 men as classified as Gleason 3+4 or 
4+3, depending on their remaining lead-time (i.e. time to clinical diagnosis in 
absence of screening) and age group, based on ERSPC data. We also modeled PSA 
growth from onset until detection. The parameters of the natural history, which 
include onset of the disease, durations, transition probabilities between health states 
and PSA growth were calibrated to observed ERSPC’s PSA distribution data and 
SEER incidence data 21, 22 and Model Appendix Figures 2 and 3.  
 
At clinical detection, a baseline survival is assigned, which depends on Gleason 
score (< 8 or ≥ 8) and was estimated based on SEER data from the pre-PSA era 
(1983-1986). This was adjusted, for improvements on survival not directly 
associated with screening or primary treatment, by adding a hazard ratio for prostate 
cancer survival of 0.82, which was calibrated to the observed PCM in the ERSPC 
control (no screening) group (Model Appendix Table 5-7).   
 
We add a benefit of treatment and a benefit of screening (in case the patient is 
screen-detected) to the baseline survival. The hazard ratio for the benefit of 
treatment equals 0.56 for radical prostatectomy 23. For radiation therapy this equals 
0.63 using the same rationale as in 24. The effect of screening is modelled through a 
lead-time dependent cure rate for non-metastatic cases, 
Cure probability = exp(cure parameter * lead-time).   
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The cure parameter was calibrated based on the observed prostate cancer mortality 
reduction due to screening in the ERSPC trial 25 (Model Appendix Tables 5-7 and 
Model Appendix Figure 4).  
 
When the patient is referred to AS, natural history progresses as if the patient was 
not screen-detected. Referral to radical treatment may occur due to detection of 
Gleason or volume progression (which is assumed to occur after an increase in 
stage) at each biopsy round, due to personal preference (randomly selected from all 
men in AS) or due to clinical detection at the time (Model Appendix Table 8). The 
probabilities of referral to radical treatment for low-risk men are estimated based on 
JH-AS observed treatment-free survival data 4 (Model Appendix Table 9). For 
intermediate risk men, we assume that given the risk of progression (which is 
Gleason and T-stage dependent), the probabilities of referral to treatment are the 
same as for low-risk men.  
 
At the time of referral to treatment, survival differs compared to what would have 
happened if the patient would be treated at the time of screening diagnosis, by 
assuming a decrease in the benefit of screening, depending on the remaining lead-
time for the patient.   
 
Active Surveillance 
 
We simulate a cohort of 10 million men, based on US lifetables. In the basecase, 
men are screened between 55 and the upper bound of the age group selected for AS 
(with an attendance rate of 90%), with a PSA threshold for biopsy referral of 4 and 
biopsy compliance equal to 41%, based on the PLCO trial 26.  Biopsy Compliance 
during AS is based on the PRIAS study 17 and Model Appendix Table 11. 
We only follow men who are selected for AS in a particular age group (55-59, 60-
64, 65-69, 70-74). Men selected for AS have either low risk (Gleason 6, <= T2 
stage, PSA <10) or intermediate risk (up to Gleason 3+4, T2 stage and PSA < 20) 
disease. We compare AS protocols differing by follow-up (1, 4, 7 and 10 biopsy 
rounds) and biopsy frequency (annual or triannual) with CM, where men are only 
treated when clinical diagnosis would occur in absence of screening (See Figure 1, 
for an example).  
 
Initially, the rate of clinical diagnosis in absence of screening was based on the 
control group and interval cancers in the screening group of the ERSPC trial. Since 
the model was adapted to US, an extra hazard of clinical diagnosis was added, 
reflecting an earlier probability of detection. This was calibrated to SEER incidence 
data from before the introduction of PSA-based screening.  
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We assume that the main difference between AS and CM surveillance regimens is 
that AS includes prostate biopsies, i.e. we assume a similar rate of PSA tests or 
visits to the doctor between the two regimens. We also assume that the main driver 
of referral to treatment while in AS is the result of the prostate biopsy.  
 
Figure 1: An example of what would happen to a man who would experience clinical 
diagnosis and prostate cancer death in absence of screening, by follow-up protocol.   
 
* In “AS, One Biopsy” protocol, AS stops after one biopsy, in “AS, two biopsies” protocol, AS 
stops after two biopsies.  
& In this example we show the life history of a men who would be clinically diagnosed in 
absence of screening, and die from prostate cancer, but that could be saved by treating early. 
This men also experiences progression during AS, after the time of the first biopsy.   
 
 
Quality of Life and Costs  
 
QALYs were calculated by using utility estimates ranging between 0 (death or worst 
imaginable health) and 1 (pre-diagnosis health, which is assumed to be full health). 
Estimates for the utilities and its durations for all stages of AS, including, prostate 
biopsies, radical treatment, post-recovery and palliative therapy are based on 27-29 
(Table 1). QALYs were calculated by multiplying the loss in utility with the 
duration of the phase and the number of men who experienced the event, as 
predicted by MISCAN.  
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Table 1: Utilities, durations and costs of screening and treatment 
Event Utility Duration (Years) Cost (US dollars) 
Biopsy 0.90 0.06 743 
RT , < 2 months 0.73 0.16 23,565# 
RT , 2-12 months 0.78 0.84  
RP , < 2months 0.67 0.16 16,946# 
RP, 2-12 months 0.77 0.84  
AS (Surveillance Costs)§ - 6 245 (per year) 
Post-Recovery 0.95 9  
Palliative Therapy 0.60 2.5 48,472 & 
Terminal Illness 0.40 0.5  
* All utilities and durations based on 27-29.  
# Cost of radical prostatectomy (RP) and radiation therapy (RT) includes 
surveillance costs 15.  
§ Surveillance costs of AS, include 4 PSA tests and one visit to the doctor per year, for 
6 years. 
& Based on Yabroff et al 31.  
 
 
Costs of AS compared to CM include the cost of prostate biopsies and the extra cost 
of radical treatment, since in CM regimen only men who are clinically diagnosed 
are treated. The cost of immediate treatment is the average lifetime cost for men 
treated at age 65, including adverse events, indirect costs and post-treatment 
surveillance 30. Costs of palliative therapy are based on 31. All costs were inflated to 
2015 US Dollars.   
 
We calculate the cost per QALY using a 3% discount rate for all costs and effects. 
The most efficient AS policies are determined based on their incremental cost-
effectiveness ratio (ICER). An AS protocol is considered to be cost-effective if its 
ICER is below $100,000. 
 
Outcomes 
 
We estimated the cost-effectiveness of each AS protocol compared to CM (no 
treatment) for men who are selected to AS. The main outcome is cost per QALY 
gained of the AS protocol compared to CM. Other important outcomes include 
overtreatment, prostate cancer mortality, life years gained (LYG) and costs.  
 
Sensitivity Analyses 
 
We analyzed the effects of some plausible alternative scenarios. For the age groups 
55-59 and 60-64, we studied whether a lower biopsy frequency (triannual after the 
first year) or a higher biopsy compliance (81% for the whole follow-up) would have 
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a large impact on QALYs gained. For the age group 65-69, we projected the effects 
of starting screening at age 65, and we split the age group in smaller intervals (65-
66, 65-67, 65-68). In order to assess the effect of uncertainty around the parameter 
estimates on the outcomes, several multivariate sensitivity analyses were performed, 
including the utility and cost estimates for each event, the parameters of the model 
related to treatment benefit, the benefit due to early detection,  and the rate of 
clinical diagnosis (Supplemental Information Table 1).   
 
Results 
 
Effects 
 
In figure 2, LYG compared to the CM situation are plotted against overtreated men 
per 1000. Both outcomes are highly dependent on the age group of selection for AS. 
In the age group 55-59, performing 4 biopsy rounds results in 723 LYG at a cost of 
120 overtreated men per 1000 men in AS. By contrast, for the age group 70-74, 4 
biopsy rounds result in only 98 LYG with 224 overtreated men per 1000.  
 
Figure 2: Life Years Gained (LYG) and Overtreatment for Low-Risk Men (≤ T2a 
Gleason 6, PSA <10) in AS by number of yearly biopsy rounds (1, 4, 7 and 10 rounds) 
compared with CM.  
 
* All values are undiscounted. Biopsy frequency is yearly. The points in the figure are 
respectively after 1, 4, 7 and 10 biopsy rounds. 
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In table 2, all effects are shown, with QALYs and LYG discounted at 3%. AS results 
in life years gained for all age groups. However after adjusting life years for quality 
life, our model projects that for men older than 65, even one biopsy round results in 
QALYs lost, relative to CM situation. For men aged between 55-59 after 4 biopsy 
rounds, the model projects about 264 QALYS gained and for men aged between 60-
64, 118 QALYs gained.  
 
Table 2: Costs and Effects of Active Surveillance (AS) for low-risk men per number of 
biopsy rounds.* 
Age Group Biopsy 
Rounds 
Treat.
& 
Overtreat. PCM 
(%) 
LY QALY 
 
Total 
Cost# 
Mean 
Cost 
per 
QALY 
ICER 
** 
55-59 1 626 28 16 81 64 0.9 13,755 WD 
 4 719 120 11 326 264 2.8 10,665 10,665 
 7 793 193 8 461 368 4.0 10,875 11,412 
 10 833 233 6 511 402 4.6 11,331 16,199 
60-64 1 509 38 11 52 27 1.1 41,318 WD 
 4 631 159 7 209 118 3.7 31,684 31,684 
 7 724 252 5 291 157 5.3 33,927 40,658 
 10 773 300 4 319 163 6.1 37,106 113,909 
65-69 1 399 48 7 29 -3 1.4 - - 
 4 548 196 4 105 -14 4.6 - - 
 7 658 306 3 144 -31 6.6 - - 
 10 711 359 2 157 -43 7.5 - - 
70-74 1 310 55 4 15 -22 1.5 - - 
 4 479 224 3 54 -84 5.2 - - 
 7 594 339 2 73 -124 7.3 - - 
 10 647 392 2 79 -141 8.2 - - 
* Effects per 1000 screened men (unless denoted otherwise). Costs and Effects (LYs and 
QALYs) are discounted at 3%. Costs are shown in millions of 2015 US dollars. QALYs were 
calculated by multiplying the loss in utility with the duration of the phase and the number of 
men who experienced the event, as predicted by MISCAN.  
# Includes the cost of prostate biopsy, treatment costs and palliative therapy costs, which we 
assume was given to all men who died of prostate cancer. Net costs were calculated by the 
difference in total costs in the AS and CM situation. 
** “W D” denotes a weakly dominated strategy.  
& Includes men who are clinically diagnosed, during and after AS follow-up. 
 
 
Costs 
 
In table 2, the total cost of AS is shown. Cost of AS increases with number of 
biopsy rounds and age group. Cost varied between $0.9 million, per 1000 men in 
AS, for one biopsy for 55-59 men and $8.2 million for men aged 70-74 after 10 
biopsy rounds.  
 
Cost-Effectiveness 
 
We show the cost-effectiveness of AS compared to CM in table 2. For low-risk men 
in age groups 65-69 and 70-74 AS is not effective. For men in age group 55-59, the 
estimated ICER after 10 yearly biopsy rounds (yearly biopsies) is $16,199. For the 
age group 60-64 the ICER is $113,909.  
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Other Scenarios 
 
Under the assumption that biopsy compliance during AS remains 81% for the whole 
follow-up (observed biopsy compliance in the first year of the PRIAS 14), we see 
that after 4 biopsy rounds QALYs gained increase from 264 to 300 for the 55-59 
age group, and from 118 to 131  for the 60-64 age group (Table  3). If the biopsy 
frequency becomes triannual after the first year, QALYs gained decrease from 264 
to 196 for the 55-59 age group, and from 118 to 71 for the 60-64 age group (Table 
3). For men aged between 70-74, with intermediate-risk prostate cancer, AS may be 
cost-effective up to 7 biopsy rounds. For men aged 65-69 the ICER is only $21,299 
after 10 biopsy rounds. AS for low-risk men aged 65-69 may results in QALYs 
gained if screening only started at age 65 or if AS is restricted for men younger than 
68 (Supplemental Information Table 2).  
 
 
Table 3: Costs and Effects of Active Surveillance (AS) per number of biopsy rounds 
under different scenarios.* & 
Age 
Group and 
Scenario 
Biopsy 
Rounds 
Treate
d& 
Overtreatm
ent 
PCM 
(%) 
LY QALY Total 
Cost# 
Mean 
Cost 
per 
QALY 
ICER*
* 
55-59 4 733 134 10 369 300 3.1 10,451 10,451 
Compli.  7 823 224 6 515 406 4.7 11,554 14,688 
60-64  4 650 178 7 233 131 4.2 31,709 31,709 
Compli.  7 763 291 4 324 168 6.2 36,779 54,936 
55-59 2 666 68 14 196 163 1.5 9,239 WD 
Triannual  3 706 107 12 275 227 2.0 8,272 8,272 
60-64 2 562 92 9 122 71 2.1 29,387 WD 
Triannual  3 612 141 8 172 100 2.8 28,103 28,103 
          
65-69 1 634 25 17 53 40 0.7 18,119 18,119 
Intermed. 4 720 110 13 211 167 2.2 13,273 13,273 
Risk 7 789 178 11 297 230 3.1 13,348 13,545 
 10 821 210 10 325 248 3.4 13,905 21,299 
70-74 1 539 31 12 31 13 0.9 67,734 WD 
Intermed. 4 642 133 10 121 55 2.9 52,145 52,145 
Risk 7 719 209 8 167 72 4.0 56,149 69,588 
 10 754 244 8 182 74 4.5 60,373 173,88
2 
* Effects per 1000 screened men. Costs and Effects are discounted at 3%. Costs are shown in 
millions of 2015 US dollars. QALYs were calculated by multiplying the loss in utility with the 
duration of the phase and the number of men who experienced the event, as predicted by 
MISCAN.  
& “Compli.” denotes a scenario where biopsy compliance remains at 81% instead of decreasing 
through time as observed in 18. “Triannual” denotes a scenario where biopsies occur every three 
years after the first year in AS. “Intermediate Risk” denotes men who are Gleason 3+4 and/or 
have a PSA at diagnosis between 10 and 20.  
# Includes the cost of prostate biopsy, treatment costs and palliative therapy costs, which we 
assume was given to all men who died of prostate cancer. Net costs were calculated by the 
difference in total costs in the AS and CM situation. 
** “W D” denotes a weakly dominated strategy.  
& Includes men who are clinically diagnosed, during and after AS follow-up. 
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Sensitivity Analyses 
 
Our sensitivity analyses focus on the age group 60-65. At four biopsy rounds we 
find a range for the ICER between $15,842 (50% higher costs) and $78,709 
(unfavorable utilities for prostate biopsies and treatment).  At seven biopsy rounds 
the ICER ranges between $20,329 and $217,517. Of all the sets of parameters 
considered, utilities have the largest effect on the cost per QALY (Supplemental 
Information Table 7 and 8). The only scenario where AS after 7 biopsy rounds was 
not cost-effective was when we applied unfavorable utilities towards screening and 
treatment procedures. By contrast, if we would apply more favorable utilities, lower 
costs, lower treatment benefit and a higher rate of clinical diagnosis then AS would 
become cost-effective after 10 biopsy rounds (Supplemental Information Table 3 
and 4).  
 
Discussion 
 
In this study we determine for the first time, how much time should men stay on AS 
and be considered for treatment. Previous clinical studies have ascertained AS is 
relatively safe for low-risk men 2-7, 11, 12. Additionally, most studies 14-17 found that 
AS is less expensive or more cost-effective than immediate treatment. However, no 
clinical cohort or simulation study has examined how much time should men be on 
AS or how the age group or life expectancy could determine the intensity of the 
follow-up schedule.  
 
In this study we find that AS with 7 yearly biopsy rounds for low-risk men is cost-
effective compared to CM, but only for age group 55-65 and for men up to age 75 
with intermediate risk disease. We performed this by calculating the cost-
effectiveness of AS with different follow-up biopsy schedules (1, 4, 7 and 10 yearly 
biopsy rounds) compared to a CM group where men can only be treated if they 
would be clinically diagnosed in absence of screening.  
 
The inclusion of low-risk men younger than 60 in AS is not consensual 10. These are 
the best candidates for immediate treatment and have a relatively low probability of 
being overtreated 32, 33. We find that if these men are included on AS, they require an 
intensive yearly biopsy schedule, which should continue for at least 10 yearly 
biopsy rounds. A low biopsy compliance or biopsy frequency may result in QALYs 
lost and in a significant increase in PCM. By contrast, for men older than 70, AS is 
not cost-effective,  and does not result in QALY’s  gained, though some lives are 
saved. For men aged between 60-64, AS appears to be cost-effective up to 7 biopsy 
rounds, and for men aged 65-69 AS results on QALYs lost. With a finer analysis, we 
find that for men aged 65-67, and for men who started screening after age 65 AS 
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results in QALYs gained but it is still not cost-effective. Just like for men younger 
than 60, selecting intermediate risk men for AS is still under debate 34. We find that 
if these men are selected, an intensive AS regime with many follow-up biopsies is 
recommended (for men younger than 70, at least 10 yearly biopsy rounds). 
 
Sensitivity Analyses found that the results in this study are the most sensitive to the 
utilities. For instance, using more unfavorable utilities about biopsies and treatment 
made the ICER become higher than $100,000 at 7 years for the age group 60-65. 
However, there were more scenarios (higher cure rate, lower treatment effect, 
favorable utilities), where AS with 10 yearly biopsy rounds became cost-effective.  
This study is subject to some limitations. Our AS model uses a simplification of the 
criteria of selection for AS and to be referred to treatment compared to most clinical 
cohorts. For instance, we do not model the number of positive biopsy cores and we 
assume volume progression can only occur, if there is an increase in T-stage. The 
probabilities of referral to treatment are based on the JH cohort, which has slightly 
different selection criteria to AS and referral to treatment criteria than other cohorts 
like PRIAS or the Toronto cohort 7. We also assume that all men whose progression 
is detected are referred to radical treatment, which may not happen in clinical 
practice 4.   
 
Changes in the rate of clinical diagnosis could affect the cost-effectiveness of the 
intervention. We examined the effect of parametric uncertainty around the hazard of 
clinical diagnosis parameters in predicted QALYs and costs. We found that while 
the proportion of men treated may change significantly (Supplemental Information 
Table 8) the cost per QALY did not vary substantially when we changed the values 
of the clinical diagnosis parameters by 20%. 
 
These results apply for the average US population. Populations at higher risk, for 
instance African-Americans, may need a more intensive schedule compared to their 
Caucasian peers, for the same age and disease group 10, 35. Comorbidity level should 
also be taken into account when building a personalized AS biopsy schedule.   
While most clinical cohorts find that AS for low-risk men is safe, there is still some 
debate about the most optimal way to perform AS. In particular, it is not known, 
when should a person stop AS, if no progression is detected.  
 
We conclude that the AS protocol for younger low-risk men (55-65) and for older 
(65-75) intermediate-risk men could consist of at least 7 yearly biopsy rounds. For 
older (65-75) low-risk men, AS is not effective compared to CM, after taking into 
account quality of life outcomes. Therefore for these men, there is no need for an 
intensive yearly biopsy schedule or to remain for many years on AS.  
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Supplementary Information 
 
Uncertainty included in Sensitivity Analyses 
 
Table 1: Overview of included uncertainty in the multivariate sensitivity analyses* 
Parameter Value Range 
Cure Parameter   
cure parameter -0.22 Min=-20%, Max = +20% 
Hazard Ratio Treatment   
hazard ratio of RP 0.56 0.41, 0.77 # 
hazard ratio of RT 0.63 0.46, 0.87 # 
Utilities (Favourable , Unfavourable) &   
screening 0.99 1.00, 0.98 
biopsy 0.90 0.87, 0.94 
cancer diagnosis 0.80 0.85, 0.75 
RT , < 2 months 0.73 0.75, 0.71 
RT , 2-12 months 0.78 0.88, 0.68 
RP , < 2months 0.67 0.78, 0.56 
RP, 2-12 months 0.77 0.84, 0.70 
post-recovery 0.95 0.93, 0.97 
palliative therapy 0.60 0.24, 0.86 
terminal illness 0.40 0.24, 0.56 
*  In an additional separate analysis, all costs are varied by more and less 50%.  RP denotes 
radical prostatectomy, RT denotes radiation therapy.  
# Confidence interval for hazard ratio of RP, is the observed in Bill-Axelsson et al (23). The 
confidence interval of RT was extrapolated using the same ratio as in Etzioni et al (24). 
& Adapted from Heijnsdijk et al (27).  “Favorable/Unfavorable” refers to whether this utility 
gives a higher/lower  QALY gained by screening, respectively.  
 
 
Analyses cost-effectiveness age group 65-70 
 
Table 2: Costs and Effects AS by number of biopsy rounds,  for men between ages 65 
and 69, under several asssumptions.* 
Scenario AS schedule  LYs QALY’s Total 
Cost# 
Average 
Cost per 
QALY 
ICER ** 
65-66 1 round 34 3 1.3 466,404 WD 
 4 rounds 130 13 4.6 340,012 340,012 
65-67 1 round 32 0 1.4 46,041,175 WD 
 4 rounds 120 2 4.6 2,224,253 2,224,253 
65-68 1 round 30 -2 1.4 - - 
 4 rounds 113 -5 4.6 - - 
No Screening  1 round 33 5 1.4 279,439 279,439 
Before age 65 4 rounds 115 -5 4.6 - Domin. 
* Effects per 1000 men on AS. Costs and Effects are discounted at 3%. Costs are shown in 
millions of 2015 US dollars. QALYs were calculated by multiplying the loss in utility with the 
duration of the phase and the number of men who experienced the event, as predicted by 
MISCAN.  
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Sensitivity Analyses 
 
Table 3: Costs and Effects AS by number of biopsy rounds,  for men between ages 60 
and 64, under several asssumptions.* 
Assumption AS schedule  LYs QALY’s Total 
Cost# 
Average 
Cost per 
QALY 
ICER ** 
Favorable  1 round 52 47 1.1 23,736 W D 
Utility  4 rounds 209 196 3.7 18,964 18,964 
 7 rounds 291 271 5.3 19,621 21,349 
 10 rounds 319 293 6.1 20,683 33,890 
Unfavorable  1 round 52 9 1.1 121,066 W D 
Utility  4 rounds 209 47 3.7 78,709 78,709 
 7 rounds 291 55 5.3 97,309 217,517 
 10 rounds 319 47 6.1 128,411 Domin. 
50% lower 1 round 52 27 0.6 20,659 W D. 
Costs 4 rounds 209 118 1.9 15,842 15,842 
 7 rounds 291 157 2.7 16,963 20,329 
 10 rounds 319 163 3.0 18,553 56,955 
50% higher 1 round 52 27 1.6 61,977 W D 
Costs 4 rounds 209 118 5.6 47,526 47,526 
 7 rounds 291 157 8.0 50,890 60,988 
 10 rounds 319 163 9.1 55,659 170,863 
* Effects per 1000 men on AS. Costs and Effects are discounted at 3%. Costs are shown in 
millions of 2015 US dollars. QALYs were calculated by multiplying the loss in utility with the 
duration of the phase and the number of men who experienced the event, as predicted by 
MISCAN.  
# Includes the difference in treatment costs between the situation with AS and CM, prostate 
biopsies and the difference in costs due to the reduction in palliative therapy for men in AS, 
which we assume was given to all men who died of prostate cancer.  
** ICER stands for, Incremental Cost-Effectiveness Ratio.  A policy is classified as “Domin.” if 
there is another policy that has a lower cost and results in more QALY’s gained.  “W D” denotes 
weakly dominated policies, that is, they are less effective policies, that have a higher cost-
effectiveness ratio than the next ranked policy.  
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Table 4: Costs and Effects AS by number of biopsy rounds,  for men between ages 60 
and 64, under several asssumptions.* 
Assumption AS schedule  LYs QALY’s Total 
Cost# 
Average 
Cost per 
QALY 
ICER ** 
More Cure 1 round 54 30 1.1 36,537 W D 
(20%) 4 rounds 219 129 3.7 28,571 W D 
 7 rounds 323 194 5.1 26,426 26,426 
 10 rounds 334 180 6.0 33,108 Domin. 
Less Cure 1 round 49 24 1.1 47,822 W D. 
(20%) 4 rounds 195 101 3.8 37,563 37,563 
 7 rounds 272 134 5.4 40,409 49,125 
 10 rounds 299 139 6.2 44,408 157,407 
Lower HR 1 round 47 22 1.1 52,025 W D 
treatment 4 rounds 194 100 3.8 38,091 38,091 
 7 rounds 272 133 5.4 40,866 49,297 
 10 rounds 298 138 6.2 44,902 158,320 
Higher HR 1 round 57 28 1.3 46,473 W D 
treatment 4 rounds 228 134 3.8 28,469 28,469 
 7 rounds 317 181 5.4 29,559 32,649 
 10 rounds 347 190 6.1 32,037 84,142 
Higher Rate 1 round 51 31 1.0 31,421 W D 
Clinical 4 rounds 197 125 3.1 24,974 24,974 
Diagnosis 7 rounds 273 170 4.3 25,312 26,247 
 10 rounds 298 180 4.8 26,861 53,324 
Lower Rate 1 round 54 27 1.2 43,065 W D. 
Clinical 4 rounds 211 109 4.1 37,199 37,199 
Diagnsis 7 rounds 295 143 5.9 40,919 52,725 
 10 rounds 324 147 6.7 45,730 217,470 
* Effects per 1000 men on AS. Costs and Effects are discounted at 3%. Costs are shown in 
millions of 2015 US dollars. QALYs were calculated by multiplying the loss in utility with the 
duration of the phase and the number of men who experienced the event, as predicted by 
MISCAN.  
# Includes the difference in treatment costs between the situation with AS and CM, prostate 
biopsies and the difference in costs due to the reduction in palliative therapy for men in AS, 
which we assume was given to all men who died of prostate cancer.  
** ICER stands for, Incremental Cost-Effectiveness Ratio.  A policy is classified as “Domin.” if 
there is another policy that has a lower cost and results in more QALY’s gained.  “W D” denotes 
weakly dominated policies, that is, they are less effective policies, that have a higher cost-
effectiveness ratio than the next ranked policy.  
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Abstract  
Background: Microsimulation models have been extensively 
used in the field of cancer modelling. However, there is 
substantial uncertainty regarding estimates from these models, 
for example, overdiagnosis in prostate cancer. This is usually not 
thoroughly examined due to the high computational effort 
required.  
 
Objective: To quantify the effect of parameter uncertainty on 
model outcomes, using a computationally efficient emulator 
(Gaussian Process Regression) instead of the model.   
 
Methods: We use a microsimulation model of prostate cancer 
(MISCAN) to simulate individual life histories. We analyze the 
effect of parametric uncertainty on overdiagnosis with 
probabilistic sensitivity analyses (ProbSA). To minimize the 
number of MISCAN runs needed for ProbSA, we emulate 
MISCAN, using data pairs of parameters values and outcomes to 
fit a Gaussian Process regression model. We evaluate to what 
extent the emulator accurately reproduces MISCAN by computing 
its prediction error.   
 
Results: Using an emulator instead of MISCAN, we may reduce 
the computation time necessary to run a ProbSA by more than 
85%. The average relative prediction error of the emulator for 
overdiagnosis equaled 1.7%. We predicted that 42% of screen-
detected men are overdiagnosed, with an associated empirical 
confidence interval between 38%-48%. Sensitivity analyses show 
that the accuracy of the emulator is sensitive to which model 
parameters are included in the training runs.  
 
Conclusions: Even for a model with a large number of 
parameters and expensive to run, we show that it is possible to 
conduct a ProbSA including all parameters, within a reasonable 
computation time by using a Gaussian process regression 
emulator.    
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Introduction 
 
Microsimulation Models (MSMs) can be used to describe complex disease 
processes at the individual patient level. They combine different data sources to 
project population-level health effects of a novel treatment or intervention 
compared to standard care. In the field of cancer modelling they have been 
extensively used to model colorectal cancer, breast cancer and prostate cancer, 
among others 1-6.  
 
Projections resulting from these models are used to inform health policy decisions, 
for example regarding early detection recommendations from the USPSTF 7) or 
updating guidelines from medical associations 8. However, there is substantial 
uncertainty regarding estimates from these models, which is usually not thoroughly 
examined and reported since simulation models of cancer tend to be 
computationally intensive with a large number of model parameters 1-6.     
 
Usually we distinguish between three types of uncertainty. First-order uncertainty is 
related to simulation error, and can be eliminated by simulating a large number of 
disease histories until the effect of individual random draws on the outcomes 
becomes negligible. In this study, we focus on the effect of parametric or second-
order uncertainty in the outcomes of a cancer microsimulation model, that is, we 
quantify the effect of uncertainty around model parameters on the model outcomes 
by carrying out a probabilistic sensitivity analysis (ProbSA. The third type, 
structural or model uncertainty, i.e. uncertainty due to the assumptions used to build 
the model, can be examined by comparing results across several models 2-4, or by 
showing a range of results obtained when imposing different sets of assumptions 9. 
 
An example of a substantially uncertain model outcome is overdiagnosis of prostate 
cancer. A person is overdiagnosed if he would not be clinically diagnosed with 
cancer in absence of screening. MSMs estimates for overdiagnosis of prostate 
cancer range between 23-42% of screen-detected cases 10. Although several study 
features can affect estimates of overdiagnosis 11, e.g. definition of overdiagnosis, 
method of estimation or study population, the role of parametric uncertainty is 
notoriously absent from this debate. 
 
In this study we carry out a ProbSA to quantify the uncertainty due to model 
parameters in two important outcomes of our simulation model (MISCAN), 
overdiagnosis and prostate cancer mortality. Since the ProbSA procedure is 
computationally expensive, we emulate MISCAN using Gaussian Process (GP) 
regression 12-14 in order to minimize the amount of MISCAN runs. Furthermore, we 
investigate under which conditions a GP emulator produces reliable estimates of the 
behavior of a microsimulation model.  
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Methods 
 
Simulation Model 
 
MIcrosimulation SCreening ANalysis (MISCAN) is a microsimulation model 
designed to study the effect of screening on incidence and prostate cancer mortality. 
A detailed description is available elsewhere 6,15, at 
http://cisnet.cancer.gov/prostate/profiles.html  and in the Model Appendix. We 
model 18 disease states, consisting of the combinations of three stages (T1, T2, T3), 
three grades (corresponding to Gleason Score 2-6, 7 and > 7), and presence/absence 
of metastasis. In each of these disease states there are four possible events: 
progression to a higher disease state, clinical or screen-detection and death. The 
transition probabilities and durations of different disease states are calibrated to the 
ERSPC study 16 (model version for Europe) and/or SEER data (model version for 
US) 6.  
 
After detection, an individual is assigned to either radiation therapy (RT) or radical 
prostatectomy (RP). In absence of treatment, a baseline survival is assigned at 
clinical detection, based on data from the pre-PSA era. If an individual is screen-
detected, there is a probability of cure that decreases exponentially with lead-time 
and is calibrated to the observed mortality reduction due to screening in the ERSPC 
trial 15, 16 (Model Appendix). Each run of MISCAN produces a range of outcomes 
including, among others, prostate cancer incidence and mortality, life years gained 
and overdiagnosis 6, 15.  
 
Probabilistic Sensitivity Analyses (ProbSA) using 
Gaussian Process Regression 
 
The impact of parameter uncertainty on model outcomes is examined by running a 
ProbSA. A ProbSA consists of repeatedly drawing parameter values from a relevant 
sampling distribution, and using those to generate an empirical distribution for the 
outcome of interest. Conducting a ProbSA for microsimulation models of cancer, 
like MISCAN, is often not feasible, since, we may need many model evaluations to 
build a reliable empirical distribution of the outcome(s). Therefore we propose to 
use a Gaussian Process regression model to emulate MISCAN, and minimize the 
number of MISCAN runs needed for ProbSA.  
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Gaussian Process Regression 
 
We model the outcome Y, as a function of the input parameters X (defined as an n 
by p matrix, containing in each row, p by 1 vectors, 𝑥1, 𝑥2, … , 𝑥𝑖 , … , 𝑥𝑛) as a 
Gaussian Process (GP). Formally, a GP is a sequence of random variables 𝑌1  , … , 𝑌𝑛 
, jointly normally distributed,  
𝑌1  , … , 𝑌𝑛   ̃  𝑁 (𝑚( 𝑋 𝛽 ) , 𝜎
2 𝐶 (𝑥𝑖 , 𝑥𝑗;  𝜓)).   
 
We define the mean function m(.) as a simple linear function Xβ, and for the 
covariance function  C(. ) ,  we choose the commonly used squared exponential 17, 
which is defined as, 
𝐶(𝑥𝑖 , 𝑥𝑗;  𝜎) =
(𝑥𝑖−𝑥𝑗)
2
𝜓2
 ,   
where ψ is a p by 1 vector of correlation length parameters, which regulates the 
amount of variation in the outcome due to changes in each of the input parameters. 
 
Step 1: Building a sampling distribution for ProbSA 
 
The first step is to elicit probability distributions for each parameter. We usually 
calibrate our model using the Nelder-Mead algorithm 18, which does not directly 
produce confidence intervals.  
 
In general, if there is information about the parameter in the literature we just use its 
corresponding published confidence interval to determine the level of uncertainty 
(example: biopsy compliance 19). If there is no information in the literature, which is 
the case for most parameters, we derive an empirical confidence interval, based on 
the distance between observed and predicted data, as measured by a Poisson 
deviance (Model Appendix). Namely, we vary a parameter (or a block of 
parameters) until we see an increase in the deviance by more than a certain 
threshold.    
 
The threshold is based on the 95-th percentile of the chi-square distribution centered 
at the best-fit value of the deviance. In Table 1 and Supplementary Information 
Table 1 we show, respectively, the variability associated with each parameter block 
and the distributions associated with each parameter.   
 
Distributions for each parameter were chosen based on its domain. Parameters 
which can take any value are assumed to be normally distributed, whereas non-
negative parameters (hazard ratios) are assumed to be lognormal distributed, and 
bounded parameters (probabilities) are assumed to be beta distributed.  
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Table 1: Summary of included uncertainty in the probabilistic sensitivity analyses* 
Parameter Block Uncertainty Level Distributions 
Onset 0.7% Beta, Lognormal 
Transition Matrix (Odds) 40% Lognormal 
Transition Matrix (Durations) 4% Lognormal 
Extra Clinical Diagnosis US 20% Lognormal 
Hazard Metastasis 10% Lognormal 
PSA growth &    Based on model parameters Truncnormal 
Screening Parameters Based on Literature  Beta 
Baseline Survival  2%  Normal 
Effect of Treatment Based on Literature Lognormal 
Effect of Screening (Cure 
Parameter) 
20% ¥ Beta 
* For a complete list with parameter values and their tolerance ranges, see Appendix Table 2. 
Some parameters were excluded from the overdiagnosis analyses, since they were considered 
irrelevant a priori, namely all parameters related to survival and some hazard of metastasis 
parameters. In the column Uncertainty level, we show the maximum percentage that a 
parameter can vary relative to the parameter value. This was determined based on the 
minimum value that increases the deviance of the incidence fit beyond a threshold based on the 
95th-percentile of the chi-square distribution. 
& The model for PSA growth is based on an earlier study by de Carvalho et al (6) and is 
calibrated jointly to SEER incidence and ERSPC PSA distribution data. 
¥ First the uncertainty in the survival parameters was determined based on the deviance fit of 
the prostate cancer mortality in the control group of the ERSPC trial. Given these values, the 
uncertainty in the cure parameter was determined by assessing the deviance between modeled 
and observed prostate cancer mortality in the screen group of the ERSPC trial (See Appendix 
Table 1). 
 
 
Step 2: Choosing model parameters for training 
  
A significant hurdle for the implementation of GP regression for MISCAN lies in 
the relatively high number of model parameters. For instance, if we would use all 
39 parameters (Table 1, Supplementary Information Table 2) to build the emulator, a 
large number of model runs would be necessary and it would become 
computationally expensive to obtain an estimate for its parameters, which would 
limit the emulator’s advantage.  
 
Instead, we propose to build a GP emulator on the basis of 10 carefully chosen 
parameters. We chose the parameters based on two criteria: (1) the parameters are 
highly influential in the outcome (example: for overdiagnosis, duration in a low-risk 
disease stage was included, duration in a high-risk disease stage excluded) and (2) if 
possible, the parameters to include are in different parameter blocks than those 
already included in the emulator (See Supplementary Information Table 2, for the 
composition of each parameter block). 
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Step 3: Training the Gaussian Process Emulator 
 
Given the space spanned by the distributions in Table 1, we build a training dataset, 
using latin hypercube sampling (R package: lhs). We run MISCAN 100 times at 
the sampled parameter values. The pairs of input parameters and corresponding 
outcomes are used to estimate parameters β, σ, and ψ of the GP model.    
We estimate β and σ  using the formulas in 17. There is no direct formula to estimate 
ψ . For this we use the same strategy as in 12, 17, which consists of repeatedly 
plugging in the maximum likelihood estimate for ψ (conditional on the β and σ 
estimates) in the emulator (using R command optim). 
 
Step 4: Validation  
 
For validation, we assume that we can obtain an 95% empirical confidence interval 
of the outcome by running the MISCAN model 1000 times at different sampled 
parameter values. We define 95% empirical confidence interval as the interval 
formed by the 2.5-th and 97.5-th percentile of the sorted values of the outcome of 
interest, either by running MISCAN or the emulator at different sample points.  
The discrepancies between the model and emulator outcomes are quantified by 
computing the average prediction error (as a proportion of the outcome), the 
standardized individual prediction errors 17 and by comparing the confidence 
interval obtained with MISCAN and the emulator. We also tested for systematic 
differences between the emulator an MISCAN using the Mahalanobis distance test 
17. 
 
Sensitivity Analyses 
 
Using an emulator instead of the model to perform a ProbSA requires making 
decisions about the size of the emulator training sample, and choice of parameters. 
Therefore we conducted several sensitivity analyses to study under which 
conditions this procedure produces valid results. We use smaller (50) and larger 
(150) number of MISCAN runs to train the emulator. We run the same procedure 
including only 5 parameters, instead of 10 and including a randomly chosen set of 
parameters instead of carefully chosen parameters. We also study by how much 
prediction error will decrease if the true model only contained the 10 parameters 
used to train the emulator. Finally we apply the same procedure to examine 
parametric uncertainty in prostate cancer mortality.  
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Results 
 
Validation 
 
In Figure 1, the prediction error of the emulator for overdiagnosis is shown. On 
average, the prediction error equals 1.7% (as a percentage of overdiagnosis). About 
97% of the predictions have a prediction error smaller than 5%, and about 37% have 
an error smaller than 1%. All the standardized individual prediction errors are 
within their expected values (i.e., smaller than 2 in absolute value, Supplementary 
Information Figure 2). Despite these favorable outcomes, the value of the 
Mahalanobis distance statistic is higher than its expected value, which means, there 
is some discrepancy between the emulator and MISCAN. (Supplementary 
Information Table 4).  
 
Potential Running Time Savings 
 
The value of using an emulator is dependent on the running time of the particular 
simulation model. The cost of running a ProbSA with an emulator equals the time 
needed to produce the training data with MISCAN, plus the time needed to fit the 
GP model. In Table 2, MISCAN and emulator fitting running times are shown. For a 
typical MISCAN-prostate model it would take several days to perform a ProbSA, 
since a single run takes almost 30 minutes. By contrast, fitting a GP emulator for 
overdiagnosis takes about the same time as a single MISCAN run. Adding more 
parameters, for the prostate cancer mortality emulator increases the running time to 
about two standard MISCAN runs. Therefore instead of running MISCAN 1000 
times, we would run MISCAN 100 times, plus about the computing time equivalent 
of two runs. If we carry out an additional 30 runs for validation as in 14, 17 this 
procedure will result in a reduction of more than 85% in computation time.  
 
Predicting Overdiagnosis 
 
In Figure 2 we show the predicted overdiagnosis with the emulator. For a screen 
policy of annual screening of men aged 55 to 69, with a PSA threshold for biopsy 
referral of 4, MISCAN predicts about 42% of screen-detected men are 
overdiagnosed. Using the GP emulator based on 100 MISCAN training runs, we 
find that the 95% empirical predicted confidence interval (obtained with 1000 
emulator samples) equals  (38.0% - 48.0%), which is close to the 95% empirical 
confidence interval  (37.4% - 48.1%), obtained by running MISCAN 1000 times. 
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Figure 1: Validation of the Gaussian Process Emulator for overdiagnosis. 
 
*The panel above contains a scatter plot of the prediction errors.  The panel below 
the cumulative distribution of the absolute predicted errors as a percentage. 
 
 
Table 2: Running Times of model runs and Gaussian process regression fit.* 
  Duration 
MISCAN (1 million life histories) 2 min 49 sec. 
MISCAN (10 million life histories) 27 min 10 sec. 
GP fit and prediction (10 parameters) 18 min 42 sec. 
GP fit and prediction (15 parameters) 47 min 28 sec. 
* MISCAN is programmed in Delphi (Embarcadero Technologies, Inc.), and all runs were 
performed in an Optiflex 7010 (Dell Inc.) machine. The Gaussian process emulator was 
programmed in R (R Foundation for Statistical Computing). In this study, the pre-defined 
sample size was 1 million, since we only use one cohort and in order to make validation feasible. 
In a typical run we sample 10 million life histories (6,15).   
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Figure 2: Predicted Overdiagnosis based on Gaussian process emulator. 
 
 
*The panel above contains a scatterplot of predicted overdiagnosis, the panel below the 
cumulative distribution of overdiagnosis.  
 
 
Predicting Prostate Cancer Mortality 
 
In Figure 3 we show the predicted prostate cancer mortality with the emulator. In 
order to build the emulator for prostate cancer mortality we use five extra 
parameters (i.e. 15 parameters in total). The “true model” contains 12 additional 
parameters (Supplementary Information Table 2 and 3).  For validation, we run 
MISCAN 50 times and we verify that the average predicted error is about 3%, 
which is higher than what we found for overdiagnosis.  The majority of the 
standardized individual prediction errors are within their expected values (Appendix 
Figure 3). The predicted value for prostate cancer mortality per 1000 screened men 
is 25, and the empirical confidence interval obtained with 1000 samples from the 
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emulator is (21.4-27.9), which is comparable to the interval found with 50 
MISCAN runs (21.6-28.6).  
 
Figure 3: Predicted Prostate Cancer Mortality (PCM) based on Gaussian process 
emulator. 
 
* The panel above contains a scatter plot of prostate cancer mortality per 1000 screened men.  
The panel below the distribution of prostate cancer mortality per 1000 screened men.  
 
Sensitivity Analyses 
 
In the sensitivity analyses, we study under which conditions using GP regression 
will result in a low prediction error. For prostate cancer mortality, we verify that the 
prediction error increases when fewer MISCAN parameters are included in the 
emulator. The prediction error did not change significantly by adding or reducing 
the number of runs to fit the emulator, which means that the 100 runs used to build 
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the emulator could be excessive. The way that one chooses the parameters to be 
included in the emulator is important. If we choose them randomly, the average 
prediction error jumps to about 5%, and the predicted empirical confidence interval 
with the emulator becomes substantially different from the observed, namely it 
becomes too small. The same holds, if we would exclude some the parameters that 
we considered important. Finally, we verify that the average prediction error would 
decrease to just 0.2%, if in the reference ProbSA (1000 runs with the MISCAN 
model) we only varied the same 10 parameters as in the emulator.  
 
Discussion 
 
ProbSA are essential to improve the transparency of simulation models and are 
required by organizations like NICE in the UK 20. While between-model variability 
has been analyzed before in numerous Cancer Intervention and Surveillance 
Modelling Network (CISNET) studies 1-4, few microsimulation studies of cancer 
screening evaluation assess the impact of parameter uncertainty including all model 
parameters, like in a ProbSA. This is mostly because it is a computationally 
expensive procedure and for models like MISCAN, also due to difficulties related to 
obtaining confidence intervals for the parameters. Previous studies 13, 14, 17, 21 using 
GP regression to emulate microsimulation models focused on simple models or in a 
small subset of the model, with at most six input parameters. Our model has more 
than 50 parameters in total. We have shown that GP regression also works in this 
context, which is important, since typically, cancer simulation models contain at 
least ten parameters 1-4. 
 
The computational gain of using a GP regression emulator is dependent on the 
running time of the simulation model, the number of runs used to train and validate 
the emulator and the number of parameters included in the emulator. Assuming it is 
necessary to run the model at least 1000 times to perform a ProbSA, computation 
time may be reduced by more than 85%, by doing a ProbSA with the help of an 
emulator. In the sensitivity analyses, we showed that this running time could even 
be reduced further, by optimizing the number of MISCAN runs to use as data to 
build the emulator. The prediction error could also be reduced, by optimizing which 
parameters are included and/or the number of parameters included in the emulator. 
On the other hand, both of these steps would require additional analyses. The 
computation time may increase depending on how many validation runs are done 
with the simulation  model. 
 
 
The performance of the emulator is critically dependent on whether all the 
important parameters are included. Excluding parameters that may affect every 
man, instead of a subgroup, or that are expected to affect the disease stages that are 
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relevant for the outcome of interest, has a significant impact on the emulator’s 
performance. For instance, if the outcome of interest is overdiagnosis, parameters 
related to low-risk health states are more important than parameters related to the 
evolution on the disease while in a high-risk disease state, since men in these health 
states are unlikely to become overdiagnosed. Despite a favorable prediction error, 
there seem to be some discrepancies in the overall fit, as indicated by a relatively 
high value of the Mahalanobis distance between the emulator and MISCAN 
(Supplementary Information Table 4). This is, in principle, due to the fact that we 
exclude many model parameters, while training the emulator. It could also be due to 
violations of the assumptions behind the GP model, namely non-normality of the 
outcome or heteroscedasticity. 
 
MISCAN is calibrated using Nelder-Mead which does not directly produce 
confidence intervals for each parameter. Our method to determine the uncertainty 
level for each parameter is based on the difference between the observed data and 
predicted model output by MISCAN. However, this is just an approximation as we 
use blocks of correlated parameters, and condition on the values of the other 
parameters. That is, we implicitly assume that parameters not included in the 
parameter block (Supplementary Information Table 2) are independent of the 
included ones, which is likely to be too strong. Consequently, letting parameters 
vary independently when they are correlated will result in an overestimation of the 
uncertainty in the outcome. By contrast, models which are calibrated following 
Bayesian principles using Markov Chain Monte Carlo-like techniques could use the 
estimated confidence intervals directly in a ProbSA 22-23.  
 
Using GP regression will be most helpful when the simulation model is relatively 
slow, and with a relatively large number of parameters. For instance, we do not 
expect that the simulation model in Gulati et al 24, which only contains 12 
parameters, would need GP regression to evaluate uncertainty, unless its running 
time would be in orders of magnitude larger than ours. 
  
In conclusion, using a GP regression emulator instead of the model we may reduce 
the computational effort necessary to carry out a ProbSA by more than 85%, at a 
cost of a small error. This turns a full ProbSA of a simulation model with a large 
number of parameters and with a relatively long running time into a feasible task.  
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Supplementary Information 
 
Appendix Table 1a: Complete list of parameters and their distributions for 
probabilistic sensitivity analyses (continues next page)* 
Parameter Value Distribution Parameters 
Onset **   
 
Probability of onset 0.51 Beta (14160.5, 13605.18) 
Hazard onset age 30 and 
under 
-14.34 LogNormal (2.66, 0.00) 
Hazard onset age 30-50 -6.73 LogNormal (1.91, 0.00) 
Hazard onset age 50-70 -3.46 LogNormal (1.24, 0.00) 
Hazard onset age 70 and 
older 
-1.62 LogNormal (0.48, 0.00) 
Transition Matrix (odds of a transition compared to Clinical 
Diagnosis) 
 
Odd T1G6 -> T2G6 3.48 LogNormal (1.23,  0.20) 
Odd T1G6 -> T1G7 
 
2.49 LogNormal (0.89, 0.20) 
Odd T1G7 -> T1G8 2.28 LogNormal (0.80, 0.20) 
Odd T1G7 -> T2G7 3.63 LogNormal (1.27, 0.20) 
Odd T1G8 -> T2G8 -7.67 LogNormal (2.02, 0.20) 
Odd T2G6 -> T3G6 1.72 LogNormal (0.52, 0.20) 
Odd T2G6 -> T2G7 0.99 LogNormal (-0.03, 0.20) 
Odd T2G7 -> T3G7 -12.24 LogNormal (2.49, 0.20) 
Odd T2G7 -> T2G8 0.60 LogNormal (-0.54, 0.20) 
Odd T2G8 -> T3G8 -5.25 LogNormal (1.64, 0.20) 
Odd T3G6 -> T3G7 19.92 LogNormal (2.97, 0.20) 
Odd T3G7 -> T3G8 2.47 LogNormal (0.88, 0.22) 
Transition Matrix (durations in each disease stage) 
 
T1G6 2.67 LogNormal (0.98, 0.02) 
T1G8 
 
 
 
13.68 LogNormal (2.62, 0.02) 
T1G7 4.90 LogNormal (1.59, 0.02) 
T2G6 5.19 LogNormal (1.65, 0.02) 
T2G7 11.12 LogNormal (2.41, 0.02) 
T2G8 20.35 LogNormal (3.01, 0.02) 
T3G6 3.27 LogNormal (1.18, 0.02) 
T3G7 10.58 LogNormal (2.36, 0.02) 
T3G8 20.95 LogNormal (3.04, 0.02) 
Clinical Diagnosis (extra for US population) 
 
T1 stage -4.25 
 
LogNormal (1.44, 0.10) 
T2 Stage -4.15 LogNormal (1.42, 0.10) 
T3 Stage -3.84 LogNormal (1.34,  0.11) 
Metastasis 5.00 
 
LogNormal (1.60, 0.10) 
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Appendix Table 1b: Complete list of parameters and their distributions for 
probabilistic sensitivity analyses (continued)* 
Hazard Metastasis #    
T1G6 3.26 LogNormal (1.18, 0.05) 
T1G7 2.63 LogNormal (0.96, 0.05) 
T2G6 1.72 LogNormal (0.54, 0.05) 
T2G7 2.04 LogNormal (0.71, 0.05) 
PSA growth    
PSA growth without 
onset 
0.02 TruncNormal (0.33, 0.024) 
PSA growth after onset 0.33 TruncNormal (0.02, 0.001) 
Screening Parameters #    
Biopsy compliance 0.41 Beta (991.38, 1426.62) 
Attendance 0.9 Beta (21.6, 2.4) 
Sensitivity T1G6 0.85 Beta (18.42, 3.25) 
Treatment and Screening Benefit ***   
Hazard Ratio RT 0.63 LogNormal (-0.48, 0.17) 
Hazard Ratio RP 0.56 LogNormal (-0.60, 0.19) 
Cure parameter -0.22 Beta (60.18, 213.38) 
Baseline Survival &  
  
HR baseline survival 
correction 
0.82 LogNormal (-0.20, 0.03) 
Surv.ageDx 0.14 Normal (0.14, 0.006) 
Surv.ageDxG8 -0.16 Normal (-0.16, 0.002) 
Surv -4.31 Normal (-4.31, 0.004) 
Surv.FU 0.07 Normal (0.07, 0.001) 
Surv.FU2 -0.01 Normal (-0.01, 0.000) 
Surv M1 -2.06 Normal (-2.06, 0.004 
SurvM1.FU -0.06 Normal (-0.06, 0.001) 
SurvM1.FU2 -0.01 Normal (-0.01, 0.000) 
* This corresponds to the models used in (6,15).  
** The onset function consists of two components. 1) a probability of onset ; 2) the distribution 
of onset per age is given by a piecewise constant hazard function dependent on age group.  
*** The hazard ratios are relative to the baseline survival. Their value and corresponding 
distributions are based on the literature (4, 29). The cure parameter is applied on top of the 
benefit of treatment.  
# Some Parameters were excluded. 
& HR baseline survival correction (infl.hr) was calibrated to the observed prostate cancer 
mortality in the control group of the ERSPC trial. The Baseline Survival equation for non-
metastatic cases equals,   
Prostate Cancer Survival = exp( Surv + Surv.FU*(t-8)  + Surv.FU2*  (t -8)^2 ) * infl.hr, 
Where t, is the time since onset. By replacing all “Surv” parameters  with the set of “Surv.M1” 
parameters we obtain the survival for metastatic cases. The parameter Surv.ageDx denotes an 
age specific factor (at the time of clinical diagnosis) applied to the baseline survival.  
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Appendix Table 2: Parameters included in the Gaussian Process emulator.*# 
Parameter Name Coefficient               (β) Correlation Length (ψ)  
Probability of onset 0.51 9.45 
Hazard onset age 30-50 -6.73 6.16 
Hazard onset age 50-70 -3.46 20 
Duration  T1G6 2.67 2.51 
Duration  T2G6 5.19 4.73 
Clinical Diagnosis T1-Stage -4.2 2.31 
Clinical Diagnosis T2-Stage -4.15 1.4 
Clinical Diagnosis T3-Stage -3.84 1.74 
Biopsy Compliance 0.41 1.48 
PSA growth after onset 0.33 0.86 
* Contains all parameters included in the emulator. Correlation Length (Phi) 
parameters were estimated with maximum likelihood estimation.  The estimate for 
the σ2 parameter equals        4.55 e-05. 
# In the 5 parameter run the following parameters were included in the emulator: 
Probability of onset, Hazard onset age 30-50, Hazard onset age 50-70, Duration  
T1G6 and PSA growth after onset. 
 
 
Figure 1: Standardized Individual Prediction Errors for the overdiagnosis emulator.*  
  
*See Figure 2. 
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Figure 2: Standardized Individual Prediction Errors for the prostate cancer mortality 
emulator.  
 
 
* This figure uses data from the first 30 runs (See Appendix Table 4). Individual 
Prediction Error is based on (18). It equals the difference between the emulator 
prediction and MISCAN output divided by the standard error of the emulator. A 
value of the individual prediction error higher than 2 indicates a discrepancy 
between the emulator and the data, since the standardized prediction errors should 
be normally distributed. 
 
 
Appendix Table 3: Mahalanobis distance values for different sensitivity analyses* 
Scenario Mahalanobis Distance 
Basecase 9900 
Another random number seed 11736 
N=50 6509 
N=150 11373 
5 parameters in emulator > 1 million 
Randomly choosen parameters 2773 
True model contains 10 parameters 60 
Prostate Cancer Mortality Emulator 1269 
* Based on the test given in Bastos and O’Hagan (18). The test was calculated using 
data from the first 30 runs. Expected value of the Mahalanobis distance statistic is 
30. Basecase denotes 100 runs, using 123 as a random number seed and 10 carefully 
chosen parameters. In Another random number seed, seed number 124 is chosen.  
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General Discussion 
 
This Chapter begins with a description of the answers to research questions 
followed by the interpretation of the results, limitations and future directions.  
 
Answers to Research Questions 
 
Aim I: Screening 
 
Research Question 1: “Can we find a set of screening policies that 
significantly reduces the amount of overdiagnosis, while keeping 
most of the prostate cancer mortality reduction?”  
 
In this study, we estimated overdiagnosis and prostate cancer mortality for about 80 
different screening policies, differing by start and stop age, screening frequency, 
PSA threshold for biopsy referral and policies where screening frequency depends 
on PSA value. 
   
Using as basecase, yearly screening between ages 50 and 74, we find that we can 
reduce overdiagnosis by about 30%, just by stopping screening at age 70. This 
comes at a cost of a prostate cancer mortality increase of about 3%. We can reduce 
overdiagnosis even further by 60%, if we stop at age 66, but at a cost of about 7% 
increase in prostate cancer mortality (PCM). 
 
We studied a wide-range of possible ways to perform screening, but we found no 
evidence of improvement over yearly screening. Restricting screening up to age 70 
seems to be a reasonable way to keep the balance of harms and benefits, since 
increasing the stop age will result in a large amount of overdiagnosis, and the 
number of lives saved will be limited.   
 
Research Question 2: “Can prostate cancer screening be cost-
effective?” 
 
In this study we used ERSPC data and quality of life estimates based on the 
literature to predict costs and effects of screening for several screening strategies, 
differing by stop age and screening interval. We found that PSA-screening with 
intervals shorter or equal than 3 years between PSA-tests are more cost-effective 
than longer intervals. Using $100,000 as willingness to pay threshold for the 
incremental cost-effectiveness ratio, we found that screening can be cost-effective if 
restricted between ages 55 and 59 with a biannual screening interval.  
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Research Question 3: “What is the influence of comorbidity 
conditions in the harms and benefits of cancer screening?” 
 
In this study we estimated how the age of screening cessation will vary per 
comorbidity cohort and cancer site. We used lifetables corresponding to different 
degrees of comorbidity ranging from, no comorbidity to severe comorbidity, based 
on Medicare data. We determine the best age to stop screening, by comparing the 
ratio of number needed to screen per life year gained against a reference ratio of 
men aged 74 with average health.   
 
For every cancer site, we find that an increased level of comorbidity resulted in a 
decreased optimal age of cessation of screening. In particular for prostate cancer the 
cessation age ranged from 78, for people with no comorbidity, down to never screen 
for men with severe comorbidity.  
 
Research Question 4: “Why is the prostate cancer incidence higher 
in African-Americans than in the general US population?”  
 
In this chapter we try to ascertain which components of the natural history of 
prostate cancer explain the higher incidence of prostate cancer for blacks compared 
to the general US population. We used three independently developed models of 
prostate cancer natural history using PSA screening patterns by race, based on 
responses to the National Health Interview Survey in 2005.   
 
We find that African-Americans have a higher chance of developing prostate cancer, 
and progressing to metastatic disease. On the other hand, given onset of prostate 
cancer, the chance of detection is similar to the general US population. These 
findings suggest that PSA-screening should be done in a different way for African-
American men than for the general US population, namely with more frequent 
screening or/and an earlier starting age.  
 
Aim II: Active Surveillance 
 
Research Question 5: “ What is the prostate cancer mortality 
increase and overdiagnosis reduction associated with Active 
Surveillance, in comparison with Immediate Radical Treatment? ” 
 
For this study, we first built a module in MISCAN to simulate Active Surveillance 
(AS). We estimated probabilities of referral to treatment, given progression of the 
disease during AS, based on Johns Hopkins cohort data. We projected the lifetime 
risk of overdiagnosis and prostate cancer mortality of screening combined with 
different Active Surveillance protocols.  
 
We found that the increase in prostate cancer mortality due to AS (i.e., due to 
delayed radical treatment) is modest, about 1%. The corresponding overdiagnosis 
reduction is about 18%. However, by decreasing the frequency of biopsies to 3 
years after the first year the overdiagnosis reduction becomes about 30%, with only 
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a 2% prostate cancer mortality increase. These results show that Active Surveillance 
is relatively safe and will significantly reduce overtreatment among low-risk men.   
 
 
Research Question 6: “Do personal characteristics matter when 
choosing between immediate radical treatment and active 
surveillance in an older age group (65+)?” 
 
In this study we use comorbidity-specific lifetables, based on MEDICARE data.  
We estimated the probability of overtreatment and prostate cancer mortality, for 
men who were screen-detected, by age of screen-detection, disease-stage at 
detection, comorbidity status and screening history.   
 
We found that disease stage at screen-detection is a critical factor for overtreatment 
and prostate cancer mortality. While men in the low-risk group have a high 
probability of being overtreated, and should seriously consider Active Surveillance, 
men in the high risk group will likely benefit from immediate treatment, unless they 
have severe comorbidities. For intermediate risk men, age and comorbidity also 
play an important role, as someone younger and without comorbidity has a risk 
profile which is similar to high risk men. 
 
Research Question 7: “Is Active Surveillance more cost-effective 
than Immediate Radical Treatment?” 
 
In this study we used the same model as in Research Questions 5 and 6 to quantify 
the associated cost and effects of choosing Active Surveillance (AS) instead of 
immediate radical treatment. We projected the costs and effects of three screening 
policies, differing by stop age and frequency, combined with three AS protocols 
with different inclusion criteria and biopsy intervals.  
 
All screening and treatment protocols where immediate treatment was offered for 
all men were dominated (more costly and resulting in less QALYs gained) or 
weakly dominated (less QALYs gained but with a higher cost-effectiveness ratio 
than the next most expensive policy). The same holds true if we refer low and 
intermediate risk men to AS. Including only low-risk men in AS was cost-effective, 
when combined with quadrennial screening. It resulted in an incremental cost-
effectiveness ratio (ICER) lower than $100,000 per QALY gained. For yearly 
screening (55-69), the ICER was above $200,000 per QALY gained.  
 
We conclude that AS is more cost-effective than immediate treatment, and that 
performing AS for low-risk men with triannual biopsies after the first year of 
follow-up seems to be more efficient. On the other hand, we note that the 
differences in costs and effects between the different AS protocols are relatively 
small.  
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Research Question 8: “When should Active Surveillance for 
prostate cancer stop if no progression is detected?” 
 
In this study we use the same model as in Research Questions 5, 6 and 7, and the 
same costs and utility estimates as in Research Question 7, to address a gap in the 
literature relative to the timing of AS cessation, if no progression is detected. We 
project the costs and effects of AS protocols differing by the number of follow-up 
biopsy rounds compared to Conservative Management, where patients can only be 
treated, if and at the time, when they would be clinically diagnosed in absence of 
screening.  
 
We conclude that AS is cost-effective compared to Conservative Management for 
up to 7 biopsy rounds, but only for the age group 55-65. For these men an intensive 
follow-up biopsy schedule is recommended. For men older than 65, AS is not 
effective after taking into account quality of life outcomes. For these men there is 
no need to stay for many years on AS. 
 
Aim III: Parameter Uncertainty in MISCAN  
 
Research Question 9: “Can we evaluate parameter uncertainty in 
MISCAN in a more efficient manner?” 
 
In this chapter we analysed the effect of parameter uncertainty on overdiagnosis 
estimates. This is usually performed within the probabilistic sensitivity analyses 
framework. There are several obstacles which prevent us from using a probabilistic 
sensitivity analysis as a routine tool with MISCAN. The method used to estimate 
MISCAN parameters (Nelder-Mead algorithm) does not produce confidence 
intervals. Additionally MISCAN has more than 50 model parameters, and its 
running time is somewhat slow. Most parameters in MISCAN are calibrated and 
they are not observed or there is not much information in the literature about them.  
 
Our solution to evaluate uncertainty is:  (1) we use the distance between observed 
and predicted data, to obtain approximate confidence intervals for model 
parameters; (2) in order to reduce the model running time, we used an emulator, that 
is, a statistical model based on data of model inputs and outcomes that mimics the 
behaviour of MISCAN. This approach resulted in a predicted confidence interval of 
37%-48%, for overdiagnosis, and upon validation we verify that the prediction 
error, due to the usage of the emulator instead of MISCAN, is modest (on average 
smaller than 2%).  
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Interpretation of the findings 
 
Towards more effective PSA-based Screening  
 
PSA-based screening saves lives, however it also causes significant harm. The 
major focus of the screening aim was to study multiple avenues to make PSA-based 
screening more effective. Current guidelines on how to do screening are 
contradictory. While the USPSTF issued a recommendation against PSA-based 
prostate cancer screening other organizations recommend shared-decision making 
between ages 55 and 69 (1, 2).  
 
The impact of the negative USPSTF recommendation seems to have resulted in a 
decrease of the incidence among all age groups (3, 4), however, it is difficult to 
move away from inefficient opportunistic screening, since there is no clear “best” 
screening protocol. The screening protocol in the ERSPC consisted of a PSA test 
every 4 years for men aged between 50 and 74 (with a core age group between 55 
an 69), while the PLCO screened men aged between 55-74 with PSA every year 
during 6 years (5, 6). It is unlikely that any of these screening protocols constitute 
the best balance of harms and benefits of PSA-based screening given the multitude 
of ways in which screening can be performed.  
 
Modelling is likely the only way through which we can find the best set of 
protocols, given that it would be impracticable to run a trial with a large enough 
power to detect an effect of screening between several competing screening 
protocols. In Research Questions 1-3 we use a microsimulation model validated to 
ERSPC data (for projecting effects of policies in Europe) and /or SEER incidence 
data (for the US population), to project the effects of multiple ways of doing 
screening, differing by age of start and cessation, frequency, PSA threshold and 
where the frequency of screening depends on PSA value.  
 
In general we find that overdiagnosis increases strongly with age, and in particular 
strategies where screening age cessation is beyond age 70 are likely to result in a 
large amount of overdiagnosis. Consequently, this will result in a large reduction in 
life years gained, when adjusting for quality of life outcomes. Therefore, screening 
programmes that focus only on younger age groups are more likely to be cost-
effective. 
 
For instance, in Chapter 2, overdiagnosis decreased by 30% when we reduced stop 
age from 74 to age 70, and by 60% when stop age would reduce to age 66.  In 
Chapter 3, we found the average cost per QALY of yearly screening between 55 and 
75 was about $320,000. By contrast, screening between 55 and 59, with 2 year 
interval resulted in an average cost per QALY of $45,615.  
 
The trade-off between prostate cancer mortality and overdiagnosis and the cost per 
QALY found in Chapters 2 and 3 may not be applicable for African-Americans. As 
we showed in chapter 5, there is a higher probability of onset and progression of 
prostate cancer, for African-Americans. Potential implications for these findings 
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would be to recommend more frequent screening and/or an earlier start age for 
African-Americans. On the other hand, it is unclear what would be the effect of 
recommending such policies on the harms and cost-effectiveness.  
 
There are some limitations associated with these results. First, we used a biopsy 
compliance of 90% in the base case of chapter 1. Biopsy compliance in the US is 
much lower, about 40% (7), and our sensitivity analyses showed that using such a 
low biopsy compliance will decrease the efficiency of screening, that is for the same 
level of overdiagnosis, there will be less lives saved. In chapters 1-4, we use a cure 
rate based on Wever et al (8). This cure rate is dependent on the disease stage 
(Gleason ≤ 7 and Gleason > 7) and can only take two values (in Chapter 3, 3 
values). By contrast, in chapters 6-9 we use a continuous cure rate which 
exponentially decreases with lead-time, which is likely to be more realistic (See 
Model Appendix Table 1 for an overview).   
 
Reducing the harms of screening with Active Surveillance 
 
The main focus of the Active Surveillance (AS) aim is to find a set of screening and 
AS protocols that will minimize the amount of overtreatment, and the risk of 
prostate cancer mortality.  
 
Current evidence from clinical cohorts seems to suggest that AS is safe, with a low 
number of prostate cancer related death events (9). Recent evidence from a 
randomized control trial comes from the ProtecT trial (10). Their main finding is 
that there is no significant difference in prostate cancer mortality between treatment 
and AS arms, after 10 years. However, the way in which AS should be carried out, 
in order to minimize overtreatment and guarantee safety is still unclear (9, 11-12).  
Namely, there is no consensus on what the definition of clinically insignificant 
cancer is, and this results in different selection criteria and/or triggers for 
intervention while in AS (12). In the US, AS rate of utilization has moved from a 
mere 10% of low-risk men up to 40% (13) and in some cohorts to 50% (14).   
 
Based on current clinical evidence on the benefit of screening, we only screen men 
in the 55-69 age group in the model (15). There is considerable uncertainty 
regarding the best possible AS protocol, therefore, we considered three protocols: 
including low-risk men with yearly biopsies, low-risk men with a biopsy every 
three years after the first year and low and intermediate risk-men with yearly 
biopsies.  
 
Our main results show that the protocol including low-risk men, with triannual 
biopsies after the first year substantially reduces overdiagnosis (about 30%) with a 
relatively low increase in prostate cancer mortality (2.3%). It appears this is more 
efficient, than including intermediate risk men, however, some caution is advised 
when interpreting results about intermediate risk men in AS, since the probabilities 
of referral to treatment are based on the Johns Hopkins cohort, which did not 
include any intermediate risk men. To model this we assume that given progression 
(which is determined by our natural history model), the probability of referral to 
treatment is similar to low-risk men.  
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In chapter 7, we estimated the cost-effectiveness of screening and AS, compared 
with screening and immediate treatment. In addition to screening yearly between 55 
and 69, we studied less intensive screening protocols (given the results in Chapter 
3) either by an earlier screening cessation age or with the same stop age but a longer 
screening interval.  Our results show that AS is more cost-effective than immediate 
treatment after taking into account several combinations of screening and AS 
protocols. As in chapter 5, it seems that an AS protocol with triannual biopsies after 
the first year is to be preferred, however, the differences between the different AS 
protocols are small. Importantly, we found, for a willingness to pay threshold of 
$100,000 that limited screening (55-69, quadrennial) combined with AS can be 
cost-effective.    
 
While in Chapters 5-7 we simply assumed that for every man, AS stops at age 75, if 
no progression is detected, in chapter 8, we studied when AS should be stopped. As 
far as we know, there is not yet an explicit guideline on this. In practice, this will 
likely depend on age of screen-detection, and personal characteristics like 
comorbidity level. We studied this by comparing the lifetime outcomes of a patient, 
under Conservative Management and Active Surveillance regimens, using the cost-
effectiveness analysis framework. Our findings show that, for men younger than 65, 
AS is cost-effective up to 7 yearly biopsy rounds. For these men, a stricter biopsy 
schedule is needed, and immediate treatment should be considered. On the other 
hand, for men older than 65, AS is not effective. Therefore, for these men, there is 
no need to perform many repeat biopsies.  
 
The main limitation of the AS model is the fact that the probabilities of referral to 
treatment while in AS given progression, are based solely on the Johns Hopkins 
cohort treatment-free survival (15). Other cohorts have slightly different inclusion 
criteria, likely less strict than Johns Hopkins cohort, and different intervals between 
biopsies (9).   
 
Our model assumes 100% of low-risk men choose AS, while in the US, this number 
is likely to be under 50% (13, 14). We also did not consider men who progress and 
choose not to be treated (16). It is likely, that this happens due to considerations 
which are not fully explicit in the data, like the level of comorbidity.  
 
In chapters 5 and 6, we did not include data on biopsy compliance, since there were 
no data available in the literature. We assumed this was 90%. Based on PRIAS data 
(17) we observe that the biopsy compliance is somewhat lower, and decreases with 
time spent on AS. Our findings in Chapter 8 suggest that our initial assumption on 
Chapter 5 of stopping AS for every man at age 75 is likely far from optimal. 
Together, these two limitations will likely result in underestimation of the 
overtreatment decrease and prostate cancer mortality increase, in Chapter 5.  
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How to advice a patient given current evidence? 
 
Prostate cancer screening is a controversial subject, given the PLCO and ERSPC 
debate. Even if we assume that prostate cancer screening saves lives, as shown in 
ERSPC trial, the probability that a patient may benefit from screening may vary 
widely from patient to patient.  
 
On the other hand, there is much that we know now: (1) an overwhelming majority 
of overdiagnosis cases is concentrated in men older than 60, and in men older than 
70, screening may be hard to justify (Chapters 2, 3 refs. 18-20). (2) Active 
Surveillance should be the default option for screen-detected low-risk men   
(Chapter 5-8, refs 9, 21, 22). (3) Screening could be cost-effective if limited to the 
age group 55-59 (Chapter 3).  
 
While these findings may give some certainty to doctors and patients, there may be 
substantial discrepancies on the probability of overtreatment, even within the same 
age group. For instance, Wever et al (20) found that for men screen-detected 
between 65 and 69 the probability of overdiagnosis ranged from 9% to 50%, 
depending on disease stage at detection. 
 
In this thesis, we look at life expectancy as a way to personalize advice on 
screening. In chapter 4, we find that comorbidity has a strong effect on the age of 
screening cessation. Namely, assuming that the harms-benefit relation for a 
reference screening policy for men with average comorbidity at age 74 is the 
decision-rule for when to screen, men with severe comorbidity should not be 
screened and men without comorbidities could be screened beyond age 75.   
 
In Chapter 6, we used the AS model together with the comorbidity lifetables, to 
inform the decision between immediate treatment and AS for men older than 65, 
which is the group where overdiagnosis has more impact. We find that for low risk 
men, AS seems to significantly reduce overtreatment at a cost of a modest increase 
in prostate cancer mortality. For intermediate risk men, the decision between 
immediate treatment or AS may depend on age and comorbidity status. While some 
of these men have a profile of a low risk man, especially if older and/or with 
comorbidities, others have a risk of prostate cancer death closer to the high risk 
group. Men screen-detected in a high risk disease stage may benefit from immediate 
treatment even beyond age 70. 
 
A limitation in these studies is that the comorbidity lifetables used are based on 
MEDICARE data, thus they only start at age 65. Additionally, they are not relative 
to a specific disease, but to a comorbidity score (23).   
 
The AUA guidelines recommend shared-decision making between age groups 55-69 
(15). The burden of screening could be reduced, by screening men with lower PSA’s 
less frequently after age 60, perhaps with only one additional screen after 8 years 
(24, 25). Men screen-detected in a low-risk stage (Gleason 6, T-stage < T2b, PSA 
<10) should be referred to AS, until progression occurs (Chapter 6-8), though 
patients preferences regarding treatment should also be taken into account.  
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This policy may need to be fine-tuned, for men with family history or African 
ancestry, which could start screening earlier and more frequently (Chapter 5), and 
men with significant comorbidities, which could have an earlier age of cessation 
(Chapter 4, 6). 
 
It is crucial to prevent opportunistic screening from occurring in later ages (>75)  
(Chapters 2, 3 and 7, refs. 3, 18-20), and if men decide to be tested, to ensure that 
only those who need treatment (Gleason 7 or higher, stage T2 or higher, no or mild 
comorbidities) are radically treated.  
 
Uncertainty in Simulation Models 
 
Results of microsimulation models are subject to uncertainty. We usually 
distinguish between three types of uncertainty. Simulation uncertainty, which is due 
to random errors, can be minimized by simulating a large enough cohort. Parametric 
uncertainty is the uncertainty in the model outcomes due to model parameters and 
structural or model uncertainty is the uncertainty in the outcomes due to the 
uncertainty in assumptions used to build the model.  
 
In Chapter 9, we analysed the effect of parametric uncertainty on the overdiagnosis 
estimates. This is usually performed within the probabilistic sensitivity analyses 
framework. Given the fact that this procedure is computationally expensive, we 
used an emulator for the model, based on Gaussian Process Regression.  With this 
we showed it becomes feasible to obtain a confidence interval for model outcomes. 
There is also uncertainty associated to assumptions used to build the model. We 
routinely collaborate with other prostate cancer screening modelling groups under 
the CISNET framework, where independently developed models using common 
data sources are compared in a systematic way (26).  
 
For instance, a study including three models (including MISCAN) found a range for 
overdiagnosis between 23% and 42% for screen-detected men (27). In chapter 5, we 
estimated that the lifetime probability of onset for African-Americans is between 
31% and 45%, across three independently developed models. In a comparable study 
to chapter 2, by Gulati et al (28), where prostate cancer mortality and overdiagnosis 
were projected for different screening policies, it seems that for the same level of 
overdiagnosis, there is less prostate cancer mortality. Previous MISCAN studies 
have also looked at the effects of changing several model assumptions (20, 29).  
 
The utilities used for studies where QALYs are the primary outcome, are subject to 
substantial uncertainty. In our experience, one of the critical parameters is the utility 
of the post-recovery period, after radical treatment (Model Appendix Table 11).  
This utility determines how much harm the treatments cause, and we assume a 
relatively long duration (the utility decrement holds on for 9 years after treatment). 
One source of uncertainty comes from the quality of life of patients treated in low 
and high volume medical centres, since men treated in high volume centres are 
likely to have less complications and side-effects (30). 
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There is also uncertainty about the discounting rate used. There are several 
guidelines on which discount rate to use and these may differ substantially across 
countries. For instance, UK guidelines recommend discount rate of 3.5% for cost 
and effects (31), while The Netherlands recommends a 1.5% discount rate for 
effects and 4% for costs (32). Therefore some caution is advised when translating 
cost-effectiveness results between countries.    
 
Future Directions 
 
Risk Stratification   
 
PSA-screening can be made more effective, with better risk-stratification. Risk 
stratification based on the value of PSA at age 60 (studied in Chapter 1) seems to be 
a promising avenue to decrease the burden of screening (24, 26). This way, about 
50% of men could have a less intensive screening schedule or even stop after age 
60.  Still, this would not solve the “conundrum”, as few men with PSA lower than 1, 
would have a PSA higher than 3 at a later point, that is, not many biopsies would be 
avoided (See Model Appendix Table 4). 
 
A limitation of the PSA test is that it is not prostate cancer specific (33). Elevated 
PSA could be caused by other benign conditions. This results in many unnecessary 
biopsies that need to be performed, decreasing the quality of life of the men who 
undergo PSA-screening. Therefore, many efforts have been devoted to find better 
biomarkers (34, 35), genetic markers (35, 36), risk calculators (37), or a better 
combination of biomarkers clinical variables and genetic markers (38). Other 
significant efforts are being made with novel imaging technologies like MRI (39, 
40). Each of these markers or technologies could be applied at different stages of 
screening, namely, before or together with PSA test, after the PSA and before 
biopsy and finally to select patients with lower likelihood of developing advanced 
disease for Active Surveillance.  
 
Examples of two biomarkers are PHI and PCA3. PHI is a combination of three PSA 
derivatives. It was shown that PHI has a higher AUC and could reduce the number 
of biopsies by about 16% (33). PCA3 (prostate antigen 3) is a marker which is 
overexpressed in prostate cancer tissue, which also has shown some predictive 
value (34). As of 2013, more than 70 prostate cancer susceptibility loci have been 
identified. These explain about 30% of family history risk, and for the top 1% the 
risk distribution, there is a 4.7-times higher risk of prostate cancer than for the 
average men (35, 36). This type of information could be used to develop a 
personalized screening schedule. There seems to be more value in combining 
several biomarkers and other clinical variables of interest, than by using a single 
one. In Poyet et al (37) the usage of risk calculators increased AUC from 0.58 (with 
PSA only) to 0.65-0.66 and performed even better for clinically significant prostate 
cancer. The Stockholm-3 trial (38) studied a test which combined PSA, other 
biomarkers, genetic markers and clinical variables, and found that the AUC 
improved from 0.56 to 0.74. This resulted in about 32% less biopsies needed. MRI-
targeted biopsy seems to be more sensitive for high risk cancers, with substantially 
C h a p t e r  1 1  | 211 
 
 
more high risk cancers detected compared to standard biopsy, while at the same it 
diagnosis less low-risk cancers (39, 40).   
 
Questions about how much overdiagnosis or prostate biopsies will be reduced, and 
the cost-effectiveness of MRI, biomarkers or combinations of markers, could 
potentially be answered by MISCAN in the future by modulating the overall test 
and biopsy sensitivity and specificity. 
 
However, there are some methodological issues relative to the performance of 
biomarkers, due to uncertainty in the sampling of the prostate tissue at biopsy. If the 
biopsy found no cancer, it could be a false negative as its sensitivity is not perfect 
(39), and therefore evaluation of biomarker performance is difficult. Regarding 
MRI, its performance may also depend on the operator (39). It is also uncertain how 
to best combine all these variables, and which threshold scores for biopsy referral 
should be used.  
 
Following the results of Chapter 4, on the racial differences between black and 
white men on the prostate cancer natural history, it seems that management of 
prostate cancer care should be done in a different way for the African-American 
population. MISCAN could be used to project the harms and benefits of different 
screening and AS protocols for black men. The main obstacle for this is to obtain 
high quality data on prostate cancer survival for black men. For instance, the benefit 
of treatment in MISCAN is based on a Swedish cohort (41), and the benefit of 
screening is based on ERSPC trial (6), which are both unlikely to contain a 
significant African population.  
 
Active Surveillance  
 
While there is an emerging consensus on the referral of low-risk men to AS, there is 
substantial uncertainty regarding its application (9-12). A significant proportion of 
men in AS are eventually referred to treatment. There are several reasons for this, 
for example, the fact that biopsy of the prostate is not sensitive enough, namely 
many Gleason 6 cancers could actually be Gleason 7 cancers which were 
misidentified. Some patients also leave AS, without a protocol based reason, due to 
anxiety (17). AS could become more cost-effective, by employing stricter selection 
with the help of MRI and/or biomarkers and risk calculators.  If clinical cohorts 
keep showing low rates of prostate cancer related death events, it is likely that the 
uptake of AS will continue to increase.  
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General Conclusions 
 
In this thesis, my aim was to quantify the harms and benefits 
of prostate cancer screening and treatment. My findings can be 
summarized as follows, 
 
(1) PSA-based prostate cancer screening can be made 
more efficient by focusing on younger age groups. Almost all 
overdiagnosed cases of prostate cancer occur in men older than 
60. After age 70, though a few lives are saved, the amount of 
overdiagnosis added with each screening round becomes 
overwhelming. Screening may be cost-effective if restricted to 
men younger than 60.   
 
(2) Active Surveillance for prostate cancer should be the 
default option for low-risk men older than 60. Additionally, we 
find that doing triannual biopsies seems better at reducing 
overtreatment and more cost-effective, than doing annual 
biopsies, though the differences between AS protocols are 
small. For intermediate risk men, the choice between 
immediate treatment and AS, may depend on personal 
characteristics like age and level of comorbidity. Men older 
than 65 don’t need to stay many years on AS, if no progression 
is detected. 
 
(3) Personalized screening strategies are needed to 
improve the current balance of harms and benefits of 
screening. For instance, we found that Black men have a 
higher risk of onset than Caucasians, which may indicate a 
need to start screening earlier. Men with significant 
comorbidities have a significantly higher probability of not 
benefitting from screening and treatment, which may indicate 
an earlier stopping age for screening than for the general 
population.  
 
(4) Uncertainty in the results of simulation models can be 
analysed with probabilistic sensitivity analyses, even for large 
models like MISCAN, by using statistical techniques to 
emulate the model, like Gaussian Process Regression. 
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Recommendations 
 
(a) Start PSA-screening pilot studies, including men aged 
between 55 and 60.  
 
(b) Avoid PSA testing in men older than 70.  
 
(c) Present Active Surveillance low-risk men older than 
60 as the default treatment approach. 
 
(d) Increase the role of risk stratification at every stage of 
the screening process. 
 
(e) Build a web-based tool, including MISCAN model 
estimates, for clinicians and patients.  
 
(f) Publish future model estimates including an 
uncertainty interval. If this is a computationally 
expensive task, then use an emulator (like Gaussian 
process regression). 
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Overview of Model Characteristics per Chapter 
 
Table 1: Model characteristics per Chapter. 
 
 Topic Data Detection Survival & AS Other 
Aim Screening      
Ch. 2 Screening policies 
for prostate 
cancer. 
US Separate PSA 
growth, biopsy 
compliance and 
sensitivity. 
 
Two cure rates 
for,  Gleason ≤ 7 
and Gleason > 7 
Not 
modelled. 
- 
Ch. 3 Cost-Effectiveness 
of Screening 
Policies. 
Europe A single joint 
sensitivity 
parameter per 
health state. 
 
Three cure rates 
for,   Gleason  < 
7, Gleason 7 and  
and Gleason > 7.  
30% of men 
on AS 
receive 
Radical 
Treatment 
within 7 
years. 
 
- 
Ch.4 Screening 
Cessation based 
on comorbidity.  
US A single joint 
sensitivity 
parameter per 
health state. 
 
Two cure rates 
for,  Gleason ≤ 7 
and Gleason > 7  
Not 
modelled. 
Uses 
comorbidity
-specific 
lifetables. 
Ch. 5 Prostate Cancer in 
black man. 
US  
(by 
race) 
A single joint 
sensitivity 
parameter per 
health state. 
Two cure rates 
for,  ≤ Gleason 7 
and Gleason 8 or 
higher 
Not 
modelled. 
Race-
specific 
Natural 
History 
Parameters 
Aim Active 
Surveillance 
     
Ch. 6 Risks and Benefits 
of AS protocols 
US Separate PSA 
growth, biopsy 
compliance and 
sensitivity 
Exponentially 
decreasing with 
time to clinical 
diagnosis. 
 
See Tables 
8-9   
 
Ch. 7 Individual benefit 
of AS 
US Separate PSA 
growth, biopsy 
compliance and 
sensitivity. 
 
Exponentially 
decreasing with 
time to clinical 
diagnosis. 
See Tables 
8-9   
Uses 
comorbidity
-specific 
lifetables. 
Ch. 8 Cost-Effectiveness 
AS 
US Separate PSA 
growth, biopsy 
compliance and 
sensitivity. 
 
Exponentially 
decreasing with 
time to clinical 
diagnosis. 
See Tables 
8-10 
Biopsy 
Compliance 
based on 
PRIAS 
Ch. 9 When to Stop AS? US Separate PSA 
growth, biopsy 
compliance and 
sensitivity. 
 
Exponentially 
decreasing with 
time to clinical 
diagnosis. 
See Tables 
8-10  
Biopsy 
Compliance 
based on 
PRIAS  
 Uncertainty in 
MISCAN 
     
Ch.10 Evaluating 
uncertainty with 
emulators 
US Separate PSA 
growth, biopsy 
compliance and 
sensitivity 
Exponentially 
decreasing with 
time to clinical 
diagnosis. 
Not 
Relevant 
Uses an R 
build 
programme 
to emulate 
MISCAN 
*AS denotes Active Surveillance.  
& Mainly, the differences regarding modelling of survival for screen-detected men. 
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MISCAN: Model Description 
 
Microsimulation Screening Analysis (MISCAN) is a microsimulation model, which 
simulates individual life histories including the natural history of prostate cancer. Its 
main purpose is to simulate prostate cancer screening and treatment policies (for 
more details see http://cisnet.cancer.gov/prostate/profiles.html). 
 
Natural History 
The natural history part is divided into several health states.  We model 18 
detectable disease stages, consisting of the combination of 3 stages (T1, T2, T3), 3 
grades (which correspond to Gleason Score 2-6, 7 and 8-10) and whether or not the 
cancer is metastasized. In each of these disease stages, an individual can progress to 
a higher disease state, be clinically or screen detected, become metastasized or can 
die. Progression is defined by a matrix of odds of moving between states 
(depending on the particular disease state) and dwelling time distributions for the 
time spent in each state. The dwelling times are determined by Weibull distributions 
(1, 2). 
 
Given the probability of onset of prostate cancer in the general population, the age 
distribution of the onset of prostate cancer is given by a piecewise constant hazard 
function which increases with age and is defined as,  
 
 λo(t) = exp (ψt), 
 
where t equals ages 30, 50 and 70.  
 
Detection 
 
At each disease state (See Figure 1), a person can be clinical or screen-detected.  
The durations and hazards of clinical diagnosis depend on the disease state.  In 
absence of screening, metastasis and death other causes, the individual will 
transition to a clinical diagnosed state if the generated random number is smaller 
than the probability of clinical diagnosis, 
 
 p(ccurrstate) = 1  -  p(ncurrstate), 
 
Where p(.) denotes probability, currstate denotes the current disease state (See 
table 1) c denotes clinical diagnosis event and n the event of moving to a higher 
disease state than currstate. The exact p(ccurrstate) is more complex as it depends 
also on, the hazard of metastasis (if metastasis occurs then there is a higher 
probability of clinical diagnosis), the screening schedule and other cause survival. 
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Figure 1:  The MISCAN model* 
 
* Reproduced from Heijnsdijk et al (3), Prostate cancer develops from no prostate cancer via 
one or more screen-detectable preclinical stages to a clinically diagnosed cancer or screen 
detected cancer. The arrows indicate the possible transitions. Each state can be local or 
metastatic, but for simplicity this is not illustrated. 
 
The screening part contains several parameters. Conditional on the individual’s 
current prostate cancer disease stage, the probability of screen-detection (dcurrstate) 
given the current disease state is a function of the probability of attendance (a) ,  
biopsy compliance (b) and the joint PSA and biopsy sensitivity (scurrstate), 
 
p(dcurrstate) = a* b * scurrstate . 
 
The screening schedules in the US are generated based on Mariotto et al (4). The 
estimation  of scurrstate parameters is described on Wever et al (5). The parameter 
scurrstate was later changed, and we now model PSA growth explicitly, see section 
on modelling PSA growth. 
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Cure Rate and benefit of treatment 
 
The probability of cure is dependent on Gleason Score and the presence or absence 
of metastasis (this was changed to a lead-time dependent cure see section on Lead-
Time Dependent Cure). The estimation process is extensively described in Wever et 
al (1). In the case where the patient is referred to radical treatment, there is an 
additional hazard ratio of cure, which depends on the type of treatment. A detailed 
description of the assumed hazard ratios of cure is described on Etzioni et al (6). 
 
Estimation 
 
Typically, model parameters for the natural history component and the screening 
tests are estimated as follows: A model is constructed for a specific case, such as 
prostate cancer incidence in the US or both arms of the ERSPC trial Rotterdam. 
Parameters are calibrated by minimizing the distance between observed numbers of 
cases and the cases predicted by the model. This distance is calculated assuming a 
Poisson deviance function for incidence data. For the minimization an adapted 
version of the simplex optimization method of Nelder and Mead is used. 
Optimization is initiated with small sample sizes and repeated with larger sample 
sizes, until it is not possible to decrease the deviance. (See 
http://cisnet.cancer.gov/prostate/profiles.html) 
 
The MISCAN-model was primarily validated to the ERSPC trial data.  
Subsequently it was adjusted for the US situation by adapting the population and 
the PSA testing practice, namely by inserting US lifetables and screening 
dissemination patterns based on Mariotto et al (4). Additionally, we included an 
extra stage-specific hazard of clinical diagnosis, which implies an earlier diagnosis 
of prostate cancer in the absence of screening in the US population compared to the 
ERSPC trial. The model is calibrated to the SEER incidence from 1975 to 2000, as 
well as stage distribution data. The probability of cure was calibrated based on the 
observed 29% mortality reduction in the ERSPCtrial (Wever et al (1) and Schroder 
et al (7)).   
 
Modelling PSA growth 
 
We generate a new PSA measurement j for an individual i as,  
 
𝑝𝑠𝑎𝑖𝑗 = 𝑒𝑥𝑝 {𝑏0 + 𝑏1𝑖  (𝑎𝑔𝑒 − 40) + 𝑏2𝑖 (𝑎𝑔𝑒 − 𝑜𝑛𝑠𝑒𝑡𝑎𝑔𝑒) +
𝑎𝑔𝑒𝑓𝑎𝑐𝑡𝑜𝑟 (62 − 𝑎𝑔𝑒) + 𝑏3𝑖𝑗 } ,  
Where 𝑏0 is the constant term , 𝑏1𝑖 and  𝑏2𝑖 are truncated normal distributed and  
𝑏3𝑖𝑗  is a normally distributed error term.  
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Table 2:  Parameters of the PSA growth equation and biopsy sensitivities 
 
Parameter Value Note 
b0  (Constant Term) 
-0.47 Exp(-0.47) matches  the average PSA at age 
40.* 
Age factor 
0.07 Centred at age 62. Makes PSA grow slower for 
older men. 
b1i  (Age - 40) 0.02**  
b2i (Age – Onset Age) 
0.33** It becomes non-zero, at the time of onset of 
prostate cancer. 
error term (b3ij) variance 
0.35 Matches the interquartile PSA distribution  at 
age 40.* 
correlation between PSA 
measurements *** 
0.75 Has an effect in individual PSA dynamics. See 
Table 2. 
Biopsy Sensitivity Value  
T1GS6,T1GS7 0.85 Stage T1 and GS ≤ 7 
T2GS6, T2GS7 0.95 Stage T2 and GS ≤ 7 
T1GS8, T2GS8 0.97 Stage ≤ T2 and GS  ≥  8 
T3GS6, T3GS7 0.97 Stage T3 and GS ≤ 7 
T3GS8 0.99 Stage T3, GS ≥ 8 
M1T1 0.97 Metastasis, Stage T1 
M1T2 0.98 Metastasis, Stage T2 
M1T3 0.99 Metastasis, Stage T3 
* Based on Vickers et al. (8)  
** This value corresponds to the mean of the distribution. 
*** Correlation between the errors (b3ij in the PSA growth generator). 
 
 
Table 3: Cumulative PSA distribution at 1st Screen (%) 
PSA Observed (ERSPC) 
Predicted 
(MISCAN) 
0.5 14.9 12.1 
1 40.2 40.3 
1.5 57.4 60.8 
2 68.5 73.5 
2.5 75.4 81.5 
3 80.3 86.8 
4 87.0 92.4 
5 91.1 95.2 
7 95.3 97.7 
10 97.8 99.0 
100 99.9 100.0 
* ERSPC stands for European Randomized Screening for Prostate Cancer Trial. 
 Data corresponding to the first round of screening was used. 
 
 
226 | M o d e l  A p p e n d i x  
 
 
 
Table 4:  PSA within individual dynamic 
 
 ERSPC Correlation between PSA measurements 
 
 
0 0.7 0.75 0.8 1 
Events   Probabilities  
PSA < 1 at age 60 and PSA > 
3 at age 68 
2.2 9.5 3.6 2.3 1.6 1.4 
PSA < 1 at age 60 and PSA < 
3 at age 68 
97.8 90.5 96.4 97.7 98.4 98.6 
PSA > 1 at age 60 and PSA > 
3 at age 68 
35.5 24.1 27.6 28.2 28.8 29.6 
PSA > 1 at age 60 and PSA < 
3 at age 68 
65.5 75.9 72.4 71.8 71.2 70.4 
* This validation is necessary for the screening policies where stop age and frequency 
depend on PSA value at a certain age.  In the ERSPC data (7), men were selected that 
participated in the first/second screening round about age 60 and that two screening 
rounds later were still screened around age 68.   
 
 
 
 
Figure 2: Incidence of PC in the US population, between 1975 and 2009, for age 
group 50-85. (Between the vertical dots is the calibration period, 1990-2002). 
   
*Observed denotes  the observed prostate cancer incidence rate in age group 50-84, in the US 
population based on SEER 1975-2009 data.  Predicted denotes the predicted incidence by 
MISCAN, based on a sample of 10 million men  representative of the US age distribution across 
time. The data used for calibration of PSA growth parameters were 1990-2002 SEER data. 
Before 1990, the model is similar to Wever et al (1).   
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Figure 3: Observed and Predicted Incidence in the US population, 1975-2005 per age 
group.* 
 
* Based on de Carvalho et al (9). Observed denotes  the observed prostate cancer incidence rate 
in age group 50-84, in the US population based on SEER 1975-2005 data. Predicted denotes the 
predicted incidence by MISCAN, based on a sample of 10 million men representative of the US 
age distribution across time. 
 
 
 
Lead-Time Dependent Cure 
 
Table 5:  Observed and Predicted cumulative prostate cancer deaths in the ERSPC* 
 Observed MISCAN 
ERPSC-Control 415 415 
ERSPC-Screening 265 266 
*Using data at 11 years of follow-up (7). The survival in absence of treatment (based 
on pre-PSA era data) was corrected with a hazard ratio calibrated to the observed 
prostate cancer mortality in the control group of the ERSPC trial, which equals 0.82. 
The effect of screening is calibrated to the observed prostate cancer mortality 
reduction after 11 years of follow-up in the ERSPC trial. 
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Table 6:  Observed and Predicted cumulative prostate cancer deaths in the ERSPC 
(13-year follow-up) by age at randomization.* 
 ERSPC-Control ERSPC-Screening 
 Observed Predicted Observed Predicted 
55-59 114 113 174 187 
60-64 121 123 159 192 
65-69 120 128 212 206 
Total 355 364 545 585 
* Using data at 13 years of follow-up (10). In the ERSPC the follow-up is not complete, but it is 
complete in MISCAN. For this reason we calibrated the cure parameter to the observed prostate 
cancer mortality reduction after 11 years of follow-up in the ERSPC trial. The survival in 
absence of treatment (based on pre-PSA era data) was corrected with a hazard ratio calibrated 
to the observed prostate cancer mortality in the control group of the ERSPC trial, which equals 
0.82.  
 
Table 7: Sensitivity Analyses, Observed and Predicted cumulative prostate cancer 
deaths in the ERSPC & 
Trial Arm Observed Linear Fit 20% less 
cure 
5% higher 
HR 
Control 415 415 415 439 
Screening 265 308 276 276 
& “Linear Fit” corresponds to the best linear fit (parameter value equal to -0.071), “20% less 
cure” uses  a 20% lower value for the cure rate, and “5% higher HR” corresponds to a 20% 
higher value for the hazard ratio for baseline survival. Percentage of variation was chosen as the 
approximate minimum that increases/decreases prostate cancer mortality by 5%, relative to the 
original model fit.  
 
 
Figure 4:  Relationship between Cure Probability and lead-time.* 
 
* Cure probability denotes the effect of screening. It is given by the expression, Cure probability 
=  exp(cure parameter * lead-time).  Cure parameter equals -0.22. Each point in the plot 
denotes a year.  
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Modelling Active Surveillance 
 
Table 8: Modelling referral to treatment in AS* 
\ Event Modelling Parameter(s) 
Volume 
Progression 
Indirectly Modelled, may occur  if in 
absence of screening there would be 
an  increase in T-stage.  
Probability of volume progression, 
given an increase in T-stage. 
Gleason Upgrade Directly modelled, may occur  if in 
absence of screening Gleason would 
increase. 
Sensitivity for Gleason upgrade 
Clinical Diagnosis 
$ 
Time of clinical detection in absence 
of screening. 
  
Hazard of clinical diagnosis per 
stage.  
Treatment in 
absence of  
progression 
Randomly selected from all men in 
AS.  
Probability of treatment in absence 
of evidence of progression or 
clinical diagnosis.  
* The parameters of the natural history model are calibrated to ERSPC data (7). The parameters 
related to referral to treatment in AS are calibrated to JH-AS (11) cohort data, including the 
number of men experiencing volume progression or gleason upgrade, men treated without 
evidence of progression and the 5 year treatment free survival. 
 
$ For the clinical diagnosis event, all the related parameters are calibrated to SEER data and 
denote an additional hazard of clinical detection in the US, relative to the European situation. 
 
Table 9: Comparison of observed treatment free survival (TFS) and progression in 
JH-AS cohort with predicted by MISCAN.* 
  Detection Probabilities at each AS round 
Detection Probabilities 
(Gleason/>T2a /≤T2a) Observed 0/0/0 1/1/1 0.5/0.5/0.5 0.5/0.4/0.1 0.5/0.4/0.1 
Time in AS (a)  (b)  (c) (d)  (e)     (f) 
1 
 
0.99 0.99 0.99 0.99 0.99 
2 0.81 0.97 0.56 0.77 0.88 0.86 
3 
 
0.95 0.36 0.58 0.77 0.74 
4 
 
0.92 0.24 0.43 0.67 0.64 
5 0.59 0.90 0.17 0.31 0.58 0.55 
Grade Progression 
 
106 0 127 105 111 109 
Volume Progression 
 
129 0 334 264 129 125 
Treatment without 
Progression 
67 69 34 41 44 66 
* The 2011 follow-up report of the JH cohort (11) showed there were no prostate cancer deaths 
in the AS cohort. The latest update (5) showed a prostate cancer survival of 99.9% at 10 years. 
MISCAN predicted 2 prostate cancer deaths in against the observed 0 in (11).    
a: As in Tosoian et al (11).  This was updated in (12), where the TFS at 5 years was 61%.  
b: if a  man has volume or gleason progression it is not detected. Only clinically detected men 
are treated. 
c: if a man has volume or gleason progression it is detected with 100% probability.  
d: if a man has volume or gleason progression it is detected with 50% probability. 
e: if a man has gleason progression it can be detected with 50% probability.  If a man is in 
T2aGS6 stage or in > T2aGS6 , then the probability of detecting volume progression, is, 
respectively, 10% or 40%.  
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f: Similar to (d), but with a probability of leaving AS without progression equal to 0.04 at every 
AS round.  
 
 
Table 10: Biopsy Compliance during Active Surveillance § 
Year of Follow-up Biopsy Compliance 
1 81%* 
2 73% 
3 66% 
4 60%* 
5 58% 
6 55% 
7 53%* 
8 45% 
9 39% 
10 33%* 
>10 33%  
§ All numbers marked with “ * “ are the observed biopsy compliances in the PRIAS cohort (13). 
The numbers in between are extrapolated using the compound annual growth rate formula. 
After 10 years in AS, we assume the biopsy compliance remains 33%.  
 
Quality of Life: Calculation of Post-Treatment Utility 
 
 
Table 11: Adverse symptom proportions and their utilities by treatment modality.*§ 
 
Symptom Baseline 24 
Months* 
Baseline 24 
Months* 
Utility 
Urinary 
Problem 
(Incontinence) 
2 8 2 5 0.83 
Bowel Problem 
 
1 1 3 11 0.71 
Sexual Problem 
 
12 43 18 37 0.89 
“No Problem” 
& 
100 63 100 70 1 
* All utilities come from (14), and the estimates of the proportion of symptoms at baseline and 
24 months are based on (15). 
 
& We assume that utility at baseline (that is, before cancer diagnosis) equals 1. The utility 
decrements are thus applied to the extra adverse events caused by radical treatment.   
 
§ Average post-recovery treatment utility is calculated as the utility decrement due to 
symptoms times the approximate proportion of men who experience symptoms. For radical 
prostatectomy this is equal to,  
 
(0.08-0.02)* 0.83 + (0.01-0.01)*0.71 + (0.43-0.12)*0.89 + 0.63*1 = 0.956, 
 
And using a similar calculation for radiation therapy this equals 0.951.  Since for simplification 
we assume there is an equal chance of getting either treatment, the average post-recovery 
treatment utility is 0.95.  
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Summary   
 
Introduction 
 
Prostate cancer is the second most diagnosed cancer and the fifth deadliest cancer 
worldwide. The number of prostate cancer cases substantially increased in the US 
and Western Europe since the introduction of the PSA (prostate-specific antigen) 
test in the 90’s. On the other hand, prostate cancer related mortality is experiencing 
a downward trend, which is attributed to improvements in treatment and early 
detection. 
 
Two major randomized clinical trials evaluated whether prostate cancer screening 
reduces prostate cancer mortality.  While one found no effect of screening on 
prostate cancer mortality (PLCO, in the US), the other found a 21% prostate cancer 
mortality reduction due to screening (ERSPC, in several European countries).  Due 
to this, prostate cancer screening is considered to be controversial. Several reasons 
may explain this discrepancy in the outcomes between the two trials. Likely the 
most important explanation is the high proportion of men who were PSA tested in 
the control arm of the PLCO trial.  
 
In general screening may cause both positive and negative effects. On the positive 
side, we consider prostate cancer mortality reduction and reduction in advanced 
disease. On the negative side, we consider overdiagnosis and overtreatment. 
Overdiagnosis consists on the diagnosis of disease through early detection, that 
would never become symptomatic. In case treatment is offered, this person is 
overtreated.  In prostate cancer, this has a severe effect on the quality of life of men. 
First, an unnecessary diagnosis of cancer may cause major psychological harm. 
Secondly, treatment of prostate cancer may cause major side effects, like impotence, 
incontinence or bowel problems.  
 
The goal of this thesis is, with the help of a simulation model, to predict the harms 
and benefits of several screening and treatment policies.  We aim to find a policy 
which maximizes prostate cancer mortality reduction while keeping the harms of 
screening as low as possible.    
 
Aim I: Screening 
 
In this part, we aim to find the best possible prostate cancer screening policy.  In 
chapter 2, we projected the results of more than 80 different screening policies, and 
we found that every screen above age 70 adds a substantial layer of overdiagnosis. 
236 | S u m m a r y ,  A c k n o w l e d g e m e n t s ,  A u t h o r  
 
 
We can reduce overdiagnosis by 30% by stopping screening at age 70, and by more 
than 60% if we stop at age 66, compared to stopping screening at age 74. In chapter 
3, we added costs and utilities, to each procedure associated with screening and 
treatment and we studied whether prostate cancer screening can be cost-effective.  
We found that using a cost-effectiveness threshold of 100,000 euros per quality-
adjusted life year gained, a limited screening program (55-59, biannual) can be cost-
effective.  
 
In chapters 4 and 5, we moved away from a one-size-fits-all screening policy. In 
chapter 4 we used lifetables which differ per level of comorbidity to estimate the 
harms and benefits of screening. In chapter 5 we used lifetables and estimated 
screening patters for the African-American in order to find what causes the higher 
incidence of prostate cancer, among African-Americans, relative to the  general US 
population. In both chapters 4 and 5, we found that cohort specific screening 
policies may be more efficient given the differential patterns of life expectancy and 
disease incidence of the different sub-populations.  
 
Aim II: Active surveillance 
 
In this aim, screen-detected low-risk men (and in some cases intermediate risk men) 
are referred to Active Surveillance, instead of immediate treatment. Active 
Surveillance for prostate cancer consists of the carefully monitoring of newly 
screen-detected men with, with PSA tests and/or repeat biopsies, resulting in 
referral to treatment if progression of the disease is observed. The aim of Active 
Surveillance is to keep the quality of life of men diagnosed with cancer, while 
avoiding the danger of missing the cure window, by progressing to advanced 
disease. As in Aim I, we projected the harms and benefits of screening combined 
with Active Surveillance. Two key questions that were evaluated throughout are:            
1) Should intermediate risk men be included in AS? ; 2) How many biopsies should 
we do during AS?  
 
In Chapter 6, we studied the effects of different Active Surveillance protocols, 
differing by biopsy frequency and whether or not we admit intermediate risk men 
on AS, on overtreatment and prostate cancer mortality. We found that including 
more patients in AS (from very low-risk, to low risk and intermediate risk), resulted 
in a higher reduction of overdiagnosis, though at a cost of a slightly increased 
prostate cancer mortality risk. On the other hand, it seems to be more effective to 
include only low-risk men and have a reduced number of biopsies (triannual) than 
to include low and intermediate risk men with annual biopsies.  In Chapter 7 we 
stratified men by level of comorbidity at screen-detection (as in Chapter 3). While 
for people with high risk disease, there could be benefit in treatment even for men 
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with significant comorbidities, for men with low risk disease and no comorbidity, 
Active Surveillance should be the primary treatment option.  For men with 
intermediate risk disease, level of comorbidity may be important, since younger 
men without comorbidity have a profile similar to high risk men.  
 
In Chapter 8 we added quality of life and costs, and studied whether screening 
combined with AS is cost-effective. We found as in Chapter 3, that only limited 
screening, i.e. low frequency or early stopping age can be cost-effective. 
Additionally, we found that AS is more cost-effective than immediate treatment, 
independently of the intensity of screening. In Chapter 9 we studied when men 
should stop AS if no progression is detected. We compared Active Surveillance with 
Conservative Management, an approach where men are not treated unless the 
cancer becomes symptomatic.  We found that for men older than 65, the benefit of 
AS compared to Conservative Management is limited. On the other hand, for men 
younger than 65, a relatively intensive biopsy protocol is recommended, with at 
least 7 biopsy rounds.  
 
Aim III: Uncertainty in simulation models 
 
All results in this thesis are subject to different forms of uncertainty, namely 
uncertainty due to simulation error, uncertainty around the parameter estimates and 
uncertainty due to assumptions used to build the simulation model. In this aim we 
investigate what is the effect of parameter uncertainty on the model outcomes. Our 
main goal is to obtain a distribution and confidence interval for model outcomes. 
This is a difficult task to perform with MISCAN, since many model runs are needed 
in order to build confidence interval.  In order to make this task feasible we use a 
statistical technique called Gaussian process regression. We run MISCAN at a few 
selected input parameter configurations and collect the corresponding outcomes. 
Based on this data, we fitted a Gaussian process regression model that we used to 
obtain an estimate of the values of the outcomes for other parameter configurations 
of interest. We found an empirical confidence interval for overdiagnosis between 
37% and 48%, with a 42% as the point estimate.  
 
 
Conclusion  
 
Screening is more effective when applied to younger age groups. Though some 
lives will be saved for older men, this comes at a cost of a large amount of 
overdiagnosis, and loss in quality of life.  Active Surveillance is an effective way to 
reduce overtreatment. It should become the default option for low-risk men older 
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than 60. The differences in outcomes between the different AS protocols are small. 
Our findings support a less frequent biopsy schedule (triannual instead of annual), 
and inclusion of low-risk men only.  Personalized screening and treatment strategies 
are needed in order to improve the harms and benefits trade-off of prostate cancer 
care, namely, besides age group, also race and comorbidity should be taken into 
account, and in the future, biomarkers, genetic markers and MRI-imaging may help 
to improve screening and treatment decisions.  
 
 
 
Samenvatting   
 
Introductie 
 
Prostaatkanker is de tweede meest gediagnosticeerde kanker en de vijfde meest 
dodelijke kanker wereldwijd. Het aantal gevallen van prostaatkanker is aanzienlijk 
toegenomen in de VS en West-Europa sinds de invoering van de PSA (prostaat-
specifiek antigeen) test in de jaren '90. Anderzijds is er een dalende trend te zien in  
prostaatkankersterfte, die wordt toegeschreven aan verbeteringen in de behandeling 
en aan vroege opsporing. 
 
Twee grote gerandomiseerde studies hebben geëvalueerd of vroeg opsporing  van 
prostaatkanker de prostaatkankersterfte vermindert. Terwijl de ene studie geen 
effect van screening op prostaatkankersterfte (PLCO, in de VS) heeft gevonden,  
vond de andere studie een 21% daling van prostaatkankersterfte als gevolg van 
screening (ERSPC, in verschillende Europese landen). Hierdoor wordt vroege 
opsporing van prostaat kanker als controversieel gezien. Verschillende redenen 
kunnen dit verschil in de resultaten verklaren. De belangrijkste verklaring is 
waarschijnlijk het hoge aandeel mannen in de controle-arm van de PLCO trial die  
een PSA test hebben ondergaan. 
 
In het algemeen kan screening zowel positieve als negatieve effecten veroorzaken. 
Aan de positieve kant, prostaatkankersterfte reductie en een vermindering van 
vergevorderde ziekte. Aan de negatieve kant, overdiagnose en overbehandeling. 
Overdiagnose is een door vroege opsporing  veroorzaakte diagnose van ziekte, die 
zonder de vroege opsporing nooit symptomatisch zou zijn geworden. In het geval 
dat de behandeling wordt aangeboden, wordt deze persoon overbehandeld. Bij 
prostaatkanker, heeft dit ernstige gevolgen op de kwaliteit van leven van mannen. 
Ten eerste, kan een onnodige diagnose van kanker grote psychische schade 
veroorzaken. Ten tweede, kan de behandeling van prostaatkanker ernstige 
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bijwerkingen, zoals impotentie, incontinentie of darmproblemen veroorzaken. 
 
Het doel van dit proefschrift is, met de hulp van een simulatiemodel, de voor- en 
nadelen van verschillende screening en behandeling strategieën te voorspellen. Wij 
streven naar een beleid dat prostaatkankersterfte vermindert terwijl de nadelen van 
screening zo laag mogelijk blijven. 
 
Deel I: Vroege Opsporing 
 
In dit deel willen we de beste mogelijke vroege opsporingsbeleid vinden. In 
hoofdstuk 2, hebben we de resultaten van meer dan 80 verschillende strategieën 
geprojecteerd, en we vonden dat elke extra screen ronde boven de leeftijd van 70 
een aanzienlijke  hoeveelheid overdiagnose toevoegt. We kunnen overdiagnose 
verminderen met 30% door het stoppen  met screening op leeftijd 70, en met meer 
dan 60% als we stoppen op leeftijd 66, in vergelijking met het stoppen van 
screening op  leeftijd 74. In hoofdstuk 3 hebben we kosten en utiliteiten aan elke 
fase in het proces van  screening en behandeling toegevoegd en we hebben 
onderzocht of vroege opsporing voor prostaatkanker kan kost-effectief zijn. Als we 
een drempel van  € 100.000 per gewonnen  voor kwaliteit van leven gecorrigeerde 
levensjaar gebruiken, vinden we dat een beperkt screeningsprogramma (55-59, 
tweejaarlijks)  kosteneffectief kan zijn.  
 
In hoofdstuk 4 gebruikten we lifetables die verschillen per comorbiditeit niveau, en 
we hebben onderzocht hoe de voor- en nadelen van screening ermee veranderen. In 
hoofdstuk 5 hebben we gebruik gemaakt van Afro-Amerikaanse specifieke 
lifetables en screening patronen om uit te vinden wat de oorzaak van de hogere 
incidentie van prostaatkanker, onder Afro-Amerikanen is, in verhouding tot de 
algemene Amerikaanse bevolking. In beide hoofdstukken 4 en 5, hebben we  
gevonden dat subpopulatie specifieke screening strategieën efficiënter kunnen zijn, 
gezien de verschillende  patronen van levensverwachting en incidentie. 
 
Deel II: Active Surveillance 
 
In Deel II worden screen-gedetecteerde laag risico mannen (en in sommige gevallen 
intermediair risico mannen) verwezen  naar Active Surveillance (AS), in plaats van 
onmiddellijke actieve behandeling. Active Surveillance voor prostaatkanker bestaat 
uit het zorgvuldig bewaken van de  screen-gedetecteerde mannen met PSA testen en 
/ of herhaalde biopten. Pas als progressie van de ziekte wordt bewezen volgt een 
verwijzing naar behandeling. Het doel van Active Surveillance is om de kwaliteit 
van  leven van de gediagnosticeerd mannen te houden, terwijl ze het gevaar van 
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ongeneeslijk worden en/of ontwikkelen van gevorderde ziekte vermijden. Net als in 
Deel I, hebben we de voor- en nadelen van screening in combinatie met Active 
Surveillance gekwantificeerd. Twee belangrijke algemene vragen, in deze gedeelte 
zijn: 1) Kunnen intermediair risico mannen naar AS worden verwezen? ; 2) Hoeveel 
biopsieën moeten we doen tijdens AS? 
 
 
In Hoofdstuk 6 onderzochten we de effecten van verschillende Active Surveillance 
protocollen, per biopsie frequentie en met en zonder inclusie van intermediair risico 
mannen, op overbehandeling en prostaatkanker sterfte. We vonden dat het verwijzen 
van meer patiënten naar AS (van zeer laag risico, laag risico en tot intermediair 
risico), resulteerde in een hogere reductie van overdiagnose, maar tegen een prijs 
van een licht verhoogd prostaatkankersterfterisico. Aan de andere kant lijkt 
efficiënter slechts lage risico mannen te includeren met een beperkt aantal biopsieën 
(driejaarlijkse) dan laag en gemiddeld risico mannen met jaarlijkse biopten te 
includeren. In hoofdstuk 7 stratificeren wij mannen per comorbiditeit niveau op de 
tijd van screen-detectie (zoals in hoofdstuk 3). Terwijl voor mensen met een hoog 
risico het voordelig is om te kiezen voor  behandeling, zelfs voor mannen met 
comorbiditeiten, moet voor mannen met een laag risico ziekte en geen 
comorbiditeit, Active Surveillance de primaire behandelingsoptie zijn. 
Voor patiënten met een intermediair risico, kan het niveau van comorbiditeit van 
belang zijn, omdat jongere mannen zonder comorbiditeit  een profiel vergelijkbaar 
hebben als hoog risico mannen.  
 
In Hoofdstuk 8 hebben we kwaliteit van leven en kosten toegevoegd, en hebben we 
onderzocht of screening in combinatie met AS kost-effectief kan zijn. Vergelijkbaar 
met hoofdstuk 3 hebben we gevonden dat een beperkte screeningsprogramma, dat is 
een programma met een lage screenfrequentie of vroege stop leeftijd, doelmatig kan 
zijn. Bovendien vonden we dat AS kosten-effectiever is dan onmiddellijke 
behandeling, onafhankelijk van de intensiteit van screening. In hoofdstuk 9 
onderzochten we wanneer moeten mannen stoppen met AS als er geen voortgang in 
de ziekte wordt gedetecteerd. We vergeleken Active Surveillance met conservatieve 
behandeling, een aanpak waar mannen niet worden behandeld, tenzij de kanker 
symptomatisch wordt. We hebben gevonden dat bij mannen ouder dan 65, AS in 
weinig winst resulteert in vergelijking met conservatieve behandeling. Anderzijds 
kunnen we voor mannen jonger dan 65, een relatief intensieve biopsie protocol  
aanbevelen, inclusief ten minste 7 biopsie rondes. 
 
 
 
 
T h e  E n d  | 241 
 
 
Deel III: Onzekerheid in simulatie modellen 
 
Alle resultaten in dit proefschrift zijn onderhevig aan verschillende vormen van 
onzekerheid, namelijk de onzekerheid als gevolg van simulatie error, de 
onzekerheid rond de parameter schattingen en de onzekerheid als gevolg van de 
aannames die gebruikt zijn om het simulatie model te ontwikkelen. In Deel III 
onderzoeken we wat het effect van de parameter onzekerheid  is op de 
modeluitkomsten. Ons belangrijkste doel is om een  verdeling en een 
betrouwbaarheidsinterval voor modeluitkomsten te schatten. Dit is een moeilijke 
taak om met MISCAN uit te voeren, aangezien veel model runs nodig zijn om het 
betrouwbaarheidsinterval te schatten. Om deze taak mogelijk te maken, gebruiken  
we een statistische techniek genaamd Gaussian Process Regression. We hebben 
MISCAN gerund bij een aantal geselecteerde input parameter configuraties en de 
bijbehorende resultaten verzameld. Op basis van deze gegevens, hebben we een 
Gaussian Process Regression model gebouwd en een schatting gemaakt van de 
waarden van de uitkomsten voor andere input parameter configuraties. We hebben 
een empirische betrouwbaarheidsinterval voor overdiagnose gevonden tussen 37% 
en 48%, met 42% als puntschatting. 
 
Conclusie 
 
Screening is effectiever wanneer het toegepast wordt op jongere leeftijdsgroepen. 
Hoewel ook bij  oudere mannen sommige levens zullen worden gered, zal screening 
bij hen gepaard gaan met  een grote hoeveelheid overdiagnose en verlies in kwaliteit 
van leven. Active Surveillance is een effectieve manier om overbehandeling te 
verminderen. Het moet de standaard behandelingsoptie worden voor laag-risico 
mannen ouder dan 60. We vinden dat de verschillen in uitkomsten tussen de 
verschillende AS protocollen klein zijn. Onze bevindingen ondersteunen een minder 
frequent biopsie schema (driejaarlijkse in plaats van jaarlijks), en AS aan te bieden 
aan mannen met een laag risico. Gepersonaliseerde screening en 
behandelingsstrategieën zijn nodig om de afweging tussen voor- en nadelen van 
prostaatkanker te verbeteren. Met name moet er naast de leeftijdsgroep, ook met  
ethniciteit en comorbiditeit rekening gehouden worden. In de toekomst kunnen 
biomarkers, genetische markers en MRI -Imaging helpen om beslissingen over 
screening en behandeling te verbeteren. 
 
 
 
 
242 | S u m m a r y ,  A c k n o w l e d g e m e n t s ,  A u t h o r  
 
 
Acknowledgements  
 
Many people contributed directly and/or indirectly to this book. In first 
place, I would like to thank my promotor, Prof. Harry de Koning for 
giving me this opportunity. Your critical eye and experience was 
essential, especially when writing my first paper.  Eveline, as my daily 
supervisor, you always had an open door, for advice and support, it was 
a pleasure to work with you during this 4.5 years. Additionally, I would 
like to thank all members of the thesis commission, for taking their time 
to evaluate this thesis.  
 
I would like to thank all fellow members or collaborators of CISNET-
Prostate, namely, Ruth Etzioni, Roman Gulati, Alex Tsodikov and Sigrid 
Carlsson, among others: the CISNET meetings were always an 
outstanding source of new ideas and inspiration and greatly contributed 
to this book and my development as a researcher. I would also like to 
thank all participant members of the ERSPC meetings, and from the 
Urology department at Erasmus MC, for their helpful comments.  
 
In my first months at Erasmus, I was fortunate to have Elizabeth as my 
own “MISCAN” guru. Your help was essential! During my final months 
at Erasmus I also took great pleasure in guiding Katerina, hope you 
enjoy your time at Erasmus MC!  Additionally, Luc and Katerina: I am 
very thankful for your comments on the Gaussian Process article.  
 
I was very lucky, to share my office room and corridor with very friendly 
and helpful colleagues (too many to name them all! :  Frank, Else, Lea, 
Kevin, Suzette, Reinier, Amir, Maggie, Karen, Frederik, Ivana, Adi, 
David, Luc, Sandra, Carlijn, Branko, Esther, … ), and I hope to keep in 
touch with some of you in the near future.    
 
I would like to thank my mom, for all the support, and the multiple 
people that I met through Couchsurfing, in Rotterdam, in Lisbon and 
around the world which made these 4.5 years truly memorable! 
 
     
 
 
T h e  E n d  | 243 
 
 
About the author 
 
Tiago Marques was born on the 15th February 1988, in Lisbon, 
Portugal. He completed his secondary school education at Escola 
Secundaria Antonio Gedeao, Almada. Afterwards he decided to 
study Economics at ISEG, University of Lisbon. During the last 
year of his studies he decided that it was time to go abroad, and 
switch to a more quantitative study.   
 
In September 2008 he started to study Econometrics and 
Operations Research at the University of Groningen, first as a 
pre-Master, and then as a Master Student.  In 2011, he moved to 
Rotterdam, for a job at the consulting company Pharmerit, where 
he also did his Master thesis.   
 
In April 2012, he started at the Department of Public Health, 
Erasmus Medical Center as a Junior Researcher. During his time 
at the department he worked with a microsimulation model of 
prostate cancer screening. Most of his research was performed 
within the CISNET (Cancer Intervention and Surveillance 
Modelling Network) network, which is a National Cancer 
Institute (US) sponsored international consortium of modelling 
groups, for different cancer sites. Since December 2016, he works 
at the Department of Applied Health Research, University 
College London, continuing his research on prostate cancer 
screening. 
 
The research findings on the harms and benefits of prostate 
cancer screening and Active Surveillance are presented in this 
thesis.   
 
 
 
 
 
244 | S u m m a r y ,  A c k n o w l e d g e m e n t s ,  A u t h o r  
 
 
Publications and Working Papers 
 
Published  
 
1. de Carvalho TM, Heijnsdijk EA, de Koning HJ. When should 
Active Surveillance for prostate cancer stop if no progression is 
detected?. Prostate. 2017;77(9):962-969. 
 
2. Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EA, 
Hunter-Merrill RA, Mariotto AB et al. Is prostate cancer different 
in black men? Answers from three natural history models. 
Cancer. 2017. doi: 10.1002/cncr.30687 
 
3. de Carvalho TM, Heijnsdijk EA, de Koning HJ. Estimating 
the risks and benefits of Active Surveillance protocols for Prostate 
Cancer: A microsimulation study. BJU Int 2016. 
doi: 10.1111/bju.13542. 
 
4. de Carvalho TM, Heijnsdijk EA, de Koning HJ. Estimating 
the individual benefit of immediate treatment or active 
surveillance for prostate cancer after screen-detection in older 
(65+) men. Int J Cancer 2016;138(10):2522-8. 
 
5. Carlsson SV, de Carvalho TM, Roobol MJ, Hugosson J, 
Auvinen A, Kwiatkowski M, et al. Estimating the harms and 
benefits of prostate cancer screening as used in common practice 
versus recommended good practice: A microsimulation screening 
analysis. Cancer 2016. doi: 10.1002/cncr.30192. 
 
6. de Carvalho TM, Heijnsdijk EA, de Koning HJ. Screening for 
prostate cancer in the US? Reduce the harms and keep the 
benefit. Int J Cancer 2015;136(7):1600-7. 
 
7. Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen 
V, Kwiatkowski M., et al. Cost-effectiveness of prostate cancer 
screening: a simulation study based on ERSPC data. J Natl 
Cancer Inst 2014;107(1):366. 
 
T h e  E n d  | 245 
 
 
 
8. Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de 
Carvalho TM, Knudsen AB, et al. Personalizing age of cancer 
screening cessation based on comorbid conditions: model 
estimates of harms and benefits. Ann Intern Med 
2014;161(2):104-12. 
 
 
Working Papers  
 
1. de Carvalho TM, Heijnsdijk EA, de Koning HJ. Cost-
Effectiveness of Active Surveillance compared to Immediate 
Treatment: A modelling study. Submitted.  
 
2. de Carvalho TM, Heijnsdijk EA, Coffeng L, de Koning HJ. 
Evaluating parameter uncertainty in a simulation model of cancer 
using emulators. Submitted.  
 
3. de Carvalho TM, Heijnsdijk EA, de Koning HJ. Using a 
Gaussian process emulator to model many screening policies. 
Work in Progress. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
246 | S u m m a r y ,  A c k n o w l e d g e m e n t s ,  A u t h o r  
 
 
PhD Portfolio 
 
Activity Period ECTS 
General Courses 
 
  
Survival Analyses Summer 2012 1.9 
Computational Econometrics  Fall 2012 0.7  
Planning and Evaluation of Screening Spring 2013 1.4 
Introduction to Joint Modelling of Longitudinal and Survival 
Outcomes 
Spring 2013 0.7 
Principles of Genetic Epidemiology Summer 2015 0.7 
Case-Control Studies Summer 2015 0.7 
Causal Mediation Analyses Summer 2015 0.7 
Seminars and Workshops 
 
  
Seminars at the Department of Public Health, Erasmus MC 
Rotterdam 
2012-2016 6.0 
Methodology Club, Department of Public Health, Erasmus MC 
Rotterdam 
2012-2016 1.0 
Seminars at the Department of Biostatistics, Erasmus MC, 
Rotterdam 
2012-2014 0.6 
Seminars at the Department of Epidemiology, Erasmus MC, 
Rotterdam 
2012-2016 0.6 
Presentations 
 
  
Cancer Intervention and Surveillance Modelling Network 
(CISNET) meetings, National Cancer Institute, USA. 
2012-2016 6.0 
Methodology Club, Department of Public Health, Erasmus MC, 
Rotterdam. 
2012-2016 1.8 
Screen-Section Meeting, Department of Public Health, Erasmus 
MC, Rotterdam 
2012-2016 1.8 
European Randomized study of Screening for Prostate Cancer 
Meeting, Antwerpen and Gothemburg.   
2013-2014 1.2 
Cancer Control Joint Action (CanCon), Rotterdam 2016 0.6 
International Conferences 
 
  
Active Surveillance for low-risk prostate cancer conference, 
European School of Oncology, Amsterdam, Milan.  
2014, 2016 0.6 
International Microsimulation Association (IMA) Conference , 
Esch/Belval, Luxembourg. 
2015 0.6 
Society for Medical Decision Making, Biennial European 
Conference, London. 
2016 0.6 
Teaching 
 
  
Biostatistics I Practicum, NIHES program, Erasmus Medical 
Center 
Fall 2015 0.6 
Review 
 
  
Reviewer for the Journal of the National Cancer Institute (JNCI) 2015 0.6 
Reviewer for the British Journal of Cancer (Brit J Cancer) 2016 0.6 
Total 2012-2016 30.0 
T h e  E n d  | 247 
 
 
 
 
